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1 INTRODUCTION 
 
1.1 Basic tumor biology and biological role of oncogenes in cancer   
 
     The cell is the fundamental unit, which is capable of performing all of the processes that 
define life. Each of the organs in the body consists of specialized cells that carry out the 
organ’s functions. To assure the proper performance of each organ, worn out or injured cells 
must be replaced and particular types of cells must proliferate in response to environmental 
changes. Reproduction of normal cells is a process of cell division, which is highly regulated.  
If anything goes wrong during this complicated process, a cell may become cancerous.  
 
     Tumor growth is often a multi-step process that starts with the loss of control of cell 
proliferation, which is thought to originate via the oncogenic transformation of a single cell. 
The cancerous cell then begins to divide rapidly, resulting in a microscopically small, 
spheroid tumor [1]. In order to progress to a clinically significant (macroscopic) tumor the 
transformed cells must be able to avoid the immune system. In some cases, the ability to 
cause angiogenesis (i.e. to stimulate the growth of blood vessels) is also important in 
progression to a clinically significant tumor. Relatively late in their existence some tumors 
gain the ability to escape from the site of their initial location and invade other areas of the 
body (metastasis). Each of these processes, i.e. oncogenic transformation, ability to escape 
recognition by the immune system, angiogenesis and development of metastasic potential, 
are associated with genetic changes. 
  
     Oncogenic transformation arises from a series of environmentally induced changes to 
critical genes. Genes responsible for the cancer phenotype have been termed as oncogenes or 
cancer-causing genes. They are derived from proto-oncogenes, cellular genes that promote 
normal growth and differentiation. Proto-oncogenes may become oncogenic by influences 
that alter their behavior in situ, including not only point mutations rendering a signaling 
molecule constitutively active, but also amplification, as seen for HER-2 in adenocarcinomas 
such as breast, ovary, lung, stomach and pancreatic cancer [2,3] and N-myc in neuroblastoma 
[4], and chromosomal translocations [5].  
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     Detailed analysis of the diverse functions of the known oncogenes shows that they code 
for components of the signal transduction cascade, i.e. growth factors, growth factor 
receptors, adaptor molecules, protein kinases, G-proteins, nuclear transcription factors, as 
well as molecules that repair DNA, regulate the cell cycle and various check points, or 
mediate apoptosis, metastasis and invasion. As described by Hanahan and Weinberg [6], this 
catalogue of genes manifest six essential alterations in physiology that collectively dictate 
malignant growth, i.e. self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, resistance to programmed cell death (apoptosis), limitless replicative potential, 
sustained angiogenesis, tissue invasion and metastasis. These six capabilities are shared in 
common by most and perhaps all types of human tumors.  
 
1.2 Angiogenesis in tumor growth 
 
     Angiogenesis is the process of generating new capillary blood vessels. In the adult, the 
proliferation rate of endothelial cells is very low compared with many other cell types in the 
body. Physiological exceptions in which under tight regulation angiogenesis occurs are found 
in the female reproductive system and during wound healing [7]. Unregulated angiogenesis 
may result in different pathologies [1]. Tumor growth and metastasis are angiogenesis-
dependent [8].  
 
     As the tumor mass grows, the cells will find themselves further and further away from the 
nearest capillary. Finally, the tumor stops growing and reaches a steady state, in which the 
number of proliferating cells counterbalances the number of dying cells. The restriction in 
size is caused by the lack of nutrients and oxygen [9]. In situ carcinomas may remain 
dormant and undetected for many years, and metastases are rarely associated with these small 
avascular tumors. Several months or years later, an in situ tumor may switch to the 
angiogenic phenotype, induce the formation of new capillaries, and start to invade the 
surrounding tissue. The “angiogenic switch” depends on a net balance of positive and 
negative angiogenic factors in the tumor. Thus, the angiogenic phenotype may result from 
the production of growth factors, including acidic fibroblast growth factor (aFGF, FGF-1), 
basic fibroblast growth factor-2 (bFGF, FGF-2) [10], vascular endothelial growth factor 
(VEGF) [11], hepatocyte growth factor (HGF) [12], epidermal growth factor (EGF), 
transforming growth factor-α (TGF-α) [13] and pleiotrophin (PTN) [14], by tumor cells 
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and/or the downregulation of negative modulators, like angiostatin [15,16], endostatin [17] 
and thrombospondin-1 (TSP-1) in tissues with a quiescent vasculature [18].  
 
     In both normal and pathological angiogenesis, hypoxia is the main force initiating the 
angiogenic process. In a tumor, the angiogenic phenotype can be triggered by hypoxia 
resulting from increasing distance of the growing tumor cells to the capillaries or from the 
inefficiency of the newly formed vessels. Also, several oncogenes such as v-ras, k-ras, v-raf, 
src, fos and v-yes [19-22] induce the up-regulation of angiogenic factors like VEGF and 
increase the production of cytokines and proteolytic enzymes [23]. Moreover, oncogene 
products may act directly as angiogenic factors [24]. 
 
     Neovascularization of the primary tumor increases the possibility that cancer cells will 
enter the blood stream and spread to other organs, and is also necessary for the growth of 
metastases in distant organs [25]. Most of the micrometastases have a high death rate and are 
not vascularized until they switch to the angiogenic phenotype [1]. 
 
1.3 Fibroblast growth factors and the fibroblast growth factor-binding 
     protein 
 
1.3.1 Fibroblast growth factors (FGFs) 
 
     The FGF family consists of a group of structurally related polypeptide growth factors. To 
date, 23 different FGFs have been discovered. Defining features of this family are a strong 
affinity for heparin and heparan-like glycosaminoglycans (HLGAGs) [26], as well as a 
central core of 140 amino acids that is highly homologous between different family 
members. Although all FGFs are categorized by their structure, the historical nomenclature 
refers to the fact that the first members of FGF family, isolated from bovine pituitary 
extracts, stimulated fibroblast proliferation [27]. In fact, the designation “FGF” is misleading 
since several FGFs have a broad mitogenic spectrum. They stimulate proliferation of a 
variety of cells of mesodermal, ectodermal and also of endodermal origin [28,29]. The only 
known exception is FGF-7, which is only mitogenic for epithelial cells and not for fibroblasts 
or endothelial cells [30].  
 
Introduction                                                                           4 
     FGFs have been shown to interact with three different types of binding partners: heparan 
sulphate proteoglycans (HSPGs) [31], FGF-binding proteins (FGF-BPs) [32,33] and high 
affinity transmembrane FGF receptors (FGFRs) of the tyrosine kinase family which are 
responsible for signal transduction [34-38]. The binding of FGFs to heparin or heparan 
sulphate proteoglycans (HSPGs) may serve three physiologically relevant goals: first, their 
protection from degradation, e.g. protection of FGF-1 from proteolysis by thrombin [39] and 
FGF-2 from trypsin [40] or plasmin [41], secondly, the creation of a local reservoir of growth 
factors and thirdly, control of the release and hence of the bioactivity of FGFs. The role of 
FGF-BP and its binding to FGFs is discussed in detail in section 1.3.7.  
 
     Cellular responses mediated by FGFs include angiogenesis, embryonic development, cell 
migration, proliferation, and differentiation [42-45]. In general, formation and sprouting of 
new capillaries involves endothelial cell proliferation and cell migration, as well as 
breakdown of surrounding extracellular matrix (ECM) components. Together with vascular 
endothelial growth factor (VEGF), FGFs are the most important regulators of these 
processes. During embryonic development, FGFs play a role in organogenesis, particularly in 
the nervous system and the limbs [46-48]. By means of knockout studies in mice, it has been 
demonstrated that several FGFs including FGF-4 (Kaposi-FGF, k-FGF), FGF-8 (androgen 
induced factor) and FGF-10 are essential for mouse development and for lung formation. For 
example, FGF-4-/- [49] and FGF-8-/- [50] mutations are embryonically lethal, while FGF-
10-/- mice die at birth due to insufficient lung formation [51]. On the other hand, FGF-2-/- 
and FGF-6-/- mice are not only viable, but are phenotypically indistinguishable from wild-
type animals by gross examination [52,53]. This observation is probably due to partly 
substitution of FGF-2 and FGF-6 functions by other family members [54,55]. Furthermore, 
FGFs play a role in the final phase of wound healing and regeneration of the proximal renal 
tubule following chemically induced damage [56]. In different cell systems basic fibroblast 
growth factor (bFGF, FGF-2) participates in the regulation of apoptosis [57-59]. Moreover, 
in prostate cancer cells, FGF-2 has been shown to confer resistance to anticancer drugs [60]. 
 
     FGFs may promote tumor growth by three different mechanisms: as angiogenic inducers, 
as mitogens for the tumor cells themselves, and as inhibitors of apoptosis. Since there are no 
documented activating mutations in FGFs themselves, the biological activities of FGFs in 
tumor growth are based on overexpression or increased availability of FGFs due to release of  
intracellular  and mobilization of extracellular FGFs. 
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     On the basis of the interplay between tumor cells and the surrounding stromal cells, 
overexpression of secreted FGFs may result from three possibilities: first, secretion of FGFs 
by tumor cells themselves without external signal as autocrine and paracrine growth factor, 
which has been shown to occur in the case of FGF-2 in human gliomas [61], secondly, 
secretion by stromal cells in response to a signal from the tumor cells, which is found for 
FGF-5 in pancreatic cancer [62] and thirdly, secretion of FGFs by the tumor in response to a 
signal from non-transformed cells, as in the case of FGF-2 in Kaposi’s sarcoma [63]. 
 
     Basic fibroblast growth factor (bFGF, FGF-2) is especially relevant in this thesis with 
regard to the fibroblast growth factor-binding protein (FGF-BP). For this reason it is 
described in more detail below. 
 
     Fibroblast growth factor-2 (FGF-2) was initially purified as an 15 kDa heparin-binding 
protein from bovine pituitary extracts [64], that was later found to represent a proteolytic 
product of the primary 18 kDa form [65]. FGF-2 occurs in several isoforms resulting from 
alternative initiations of translation: an 18 kDa isoform and four larger molecular weight 
isoforms (22, 22.5, 24 and 34 kDa), which are initiated at different in-frame CUG codons 
upstream from the conventional AUG codon (reviewed in [66]). The main structural feature 
of the four high molecular weight forms of FGF-2 is the presence of a nuclear localizing 
sequence (NLS) which directs the growth factor to the nucleus, whereas the 18 kDa FGF-2 
form initiated from AUG is essentially cytosolic [67,68]. The biological significance of the 
different subcellular localization of the FGF-2 isoforms is still unclear. 
 
     None of the FGF-2 isoforms have a signal sequence; however, it has been demonstrated in 
various cell types expressing the 18 kDa FGF-2 that this growth factor can be secreted into 
the extracellular medium by a still unknown mechanism [69,70] and thereby can act as a 
paracrine or autocrine growth factor by activating specific cell surface receptors. One view of 
how FGF-2 is released from cells is through passive processes such as cell death, wounding, 
or chemical injury [71]. Haimovitz-Friedman et al. [72] reported that FGF-2 can be released 
into the medium after irradiation. Factors such as fibrin-split products also induce FGF-2 
release [73]. A second view is that a nonclassic pathway exists for the release of proteins 
such as FGF-2 that lack secretion signals. It has been demonstrated that migration of an 
isolated single cell expressing FGF-2 can be inhibited by FGF-2-neutralizing antibodies [69]. 
Thus, a mechanism other than cell death can lead to FGF-2 release. Because FGF-2-
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dependent cell migration was not inhibited by drugs affecting the classic secretion pathway, 
FGF-2 release may occur via a novel mechanism [74]. 
 
     As other members of FGF family, FGF-2 binds to heparin or heparan sulphate 
proteoglycans (HSPGs). While the functional domain of FGF-1 for heparin-binding is 
dependent on residues at the carboxy terminus, probably between amino acids 122-137 
[75,76], the data for binding sites of FGF-2 are contradictory. Baired et al. [77] characterized 
two functional heparin-binding domains in the FGF-2 molecule through the use of blocking 
peptides and localized these domains to amino acids 24-68 and 106-115. Another two sites of 
interaction have been identified [78], in which the amino acids involved were not arranged 
consecutively in the primary structure of the polypeptide chain, in contrast to the peptide 
blocking studies of Baired. Instead, the binding sites were composed of groups of basic 
amino acids brought together by the secondary structure of the folded polypeptide.  
 
     There are currently two different known mechanisms to explain how FGFs are released 
from the extracellular matrix (ECM) reservoir: the first one is based on the enzymatic 
cleavage of heparan sulphate proteoglycans (HSPGs) by heparanase, which has been 
investigated in numerous studies [79-81]. Interestingly, the expression of heparanase, which 
has been cloned and expressed in metastasic carcinoma cell lines independently by 
Vlodavsky et al. [82] and Hulett et al. [83], seems to correlate with invasive phenotype of 
several human breast cancer cell lines. 
 
     An alternative mechanism for the regulation of FGF release from ECM involves the 
fibroblast growth factor-binding protein (FGF-BP) that may act as a carrier protein for FGF-1 
and FGF-2. 
 
1.3.2 The fibroblast growth factor-binding protein (FGF-BP) 
 
     The FGF-binding protein (FGF-BP) was originally identified as a heparin-binding protein 
and designated HBp17 (heparin-binding protein 17 kDa) [32]. Through heparin affinity 
chromatography, gel filtration and reverse-phase HPLC, FGF-BP was isolated from 
serumfree culture medium conditioned by human epidermoid carcinoma A431 cells. The 
1163 bp cDNA was cloned and the primary structure of 234 amino acids long protein was 
determined. In contrast to α2-macroglobulin [84], the detection of a non covalent, reversible 
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binding of FGF-BP to FGF-1 or FGF-2 suggested a physiological role for FGF-BP as a 
carrier protein. Most recently, it has been demonstrated that FGF-BP is also able to interact 
with FGF-7, FGF-10 and FGF-22 [85]. 
 
     Furthermore, a human cDNA clone containing an open reading frame (ORF) for a protein, 
which has amino acid sequence similarity of 21% to FGF-BP and a homology of 41% was 
discovered by a gene data bank blast search. No further significant homology was found with 
other known proteins. Data on the protein derived from this gene, which is referred to as 
“killer-specific secretory protein of 37 kDa” (Ksp37), were published in a single study by 
Ogawa et al. [86]. They suggest that like FGF-BP, this protein could bind to proteins to 
regulate their activity and thereby mediate unknown functions. Consequently, in a further 
study this Ksp37 was also named FGF-BP2 [87] suggesting the existence of an FGF-BP 
family. 
 
1.3.3 FGF-BP expression in neoplastic tissues and its regulation in skin and colon  
         carcinogenesis 
 
     The expression pattern of FGF-BP in neoplastic cells has revealed that the expression of 
this protein is highly regulated and tissue-specific. A screening of different human tumor cell 
lines and normal human keratinocytes showed that FGF-BP mRNA was positive in most 
squamous cell carcinoma (SCC) cell lines derived from different origins including lung, 
bladder, skin, and cervix, and in normal human keratinocytes [88]. A high level of expression 
FGF-BP mRNA expression has also been reported in tumor tissues from patients with SCC 
of the head and neck [88]. Recently, in situ hybridization demonstrated similar results [89]. 
Interestingly, the highest density of microvessels was observed exclusively in FGF-BP-
positive SCC, suggesting that FGF-BP may be an angiogenic factor in SCC [89]. 
Furthermore, high expression of FGF-BP has been demonstrated in invasive human breast 
cancer [90]; in some human colon cancer cell lines and tissues [91], as well as in prostate 
carcinoma cell lines [92].  
     
     Transfection of FGF-BP into the non-tumorigenic adrenal carcinoma cell line SW-13, 
which expresses constitutively high levels of FGF-2 but no FGF-BP [88], results in the 
release of biologically active FGF-2, formation of colonies in soft agar assay and 
vascularized tumors in nude mice. In further studies, the role of FGF-BP for FGF function 
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mainly during the early phase of tumor growth has been elucidated by means of a 
tetracycline-regulated expression system in SW-13 cells [93]. SW-13/tetBP cells were 
generated, in which the expression of FGF-BP can be regulated in xenografted tumors in vivo 
by tetracycline treatment of athymic nude mice. It was demonstrated that growth of the SW-
13/tetBP xenografts is dependent on FGF-BP expression during the early stages of tumor 
formation and does not appear to contribute significantly to the further expansion of tumors. 
Furthermore, when human cervical (ME-180) and colon carcinoma (LS174T) cell lines were 
depleted of endogenous FGF-BP by ribozyme targeting, the release of biologically active 
FGF-2 from cells in culture was reduced and a decrease in the growth and angiogenesis of 
xenograft tumors in mice was observed, indicating that FGF-BP can serve as an angiogenic 
switch molecule [91]. Similarly, ribozyme-mediated reduction of FGF-BP levels decreased 
the proliferation of PC-3 prostate carcinoma cells in vitro and completely abolished the 
ability of highly metastatic PC-3 cells to grow s.c. tumors in athymic nude mice [92]. 
 
     Due to the fact that FGF-BP is expressed in a variety of SCCs, in normal human 
keratinocytes, and in the mouse embryonic skin [32,88,94], the role of FGF-BP during skin 
carcinogenesis was further explored. Kurtz et al. [94] used a mouse model of skin 
carcinogenesis, which upon DMBA/TPA treatment describes a predictable multistage 
process of tumor formation from the clonal expansion of a normal epidermal cell into a 
benign sequamous papilloma that progresses into a malignant squamous cell carcinoma 
(reviewed by [95]), to investigate the role of FGF-BP expression during tumor progression. 
In DMBA/TPA-induced papillomas, levels of FGF-BP mRNA were 4-5 folds higher than in 
untreated skin and remained up-regulated after malignant conversion into SCC. Moreover, 
FGF-BP mRNA was up-regulated in cell lines derived from DMBA/TPA-induced papillomas 
and a cell line derived from DMBA-initiated skin and selected for resistance to Ca2+-induced 
terminal differentiation [94]. 
 
     Similarly, the role of FGF-BP in the formation of human skin SCC was examined using a 
human skin/SCID mouse model, where human skin (upper eyelid skin) was xenografted onto 
SCID mice and treated with the DMBA/TPA carcinogen protocol [96]. While upon 
carcinogen treatment the human skin grafts displayed no obvious macroscopic alterations, in 
murine skin induction of papillomas was visible within 6 weeks. Immunohistochemical 
analysis of the treated human skin, however, showed p53-positive keratinocytes in the 
epidermis, increased angiogenesis in the treated skin, enhanced proliferation of the 
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keratinocytes in the basal layer, and an increase of FGF-BP protein and mRNA [96]. In 
conclusion, these two reports demonstrate the association of mouse as well as human FGF-
BP with the early neoplastic stages of skin SCC, where angiogenesis is thought to play a 
critical role. 
 
     Because of the high expression of FGF-BP in human colon cancer cell lines and tissues 
[91], the regulation of FGF-BP during colon carcinogenesis was further evaluated [97]. Up-
regulation of FGF-BP expression, which coincides with a significant increase in blood vessel 
density, was demonstrated during early stages of human colon epithelial malignant 
progression. In contrast with this, in a very small portion of normal human colon biopsy 
samples FGF-BP expression was detectable [97]. 
 
1.3.4 FGF-BP expression in normal tissues and its regulation during embryonic 
         development and tissue repair 
 
     In contrast to neoplastic tissues, normal human adult tissues, like brain, heart, muscle, 
kidney, skin, liver, spleen, larynx, tongue, lymph node, lung and breast do not appear to 
express FGF-BP mRNA as demonstrated by Northern blotting or in situ hybridization [88-
90]. In the adult mouse FGF-BP mRNA was barely detectable in intestine, skin and ovaries 
and below detection in heart, muscle, kidney, liver, spleen, stomach, thymus and brain [94]. 
In contrast to the normal human tissues, high expression of FGF-BP was observed in lungs of 
adult mouse.  
 
     However, during embryonic development, tissue repair, wound healing, and renal diseases 
in children, changes in FGF-BP expression were observed. The available data of the 
regulation of FGF-BP during these processes is discussed below. 
     
     In immunohistochemical studies in mice, the distribution of FGF-BP protein expression 
was shown in a broad spectrum of tissues at various stages between day 8 and 16 of 
embryonic development [98]. FGF-BP is found in the digestive system, skin, hair follicles 
and the dental germ, in the respiratory tract, various glandular tissues, kidney, liver, and 
certain areas of the CNS. Immunoreactivity is detected predominantly in cells of primitive 
epithelia in various tissues including lung bronchi, GI tract, nasal cavity, and tongue. The 
comparison between different organs and tissues reveals different intensities of 
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immunostaining indicating heterogeneous levels of FGF-BP expression. Particularly strong 
staining is observed in thymus, skin, kidney, respiratory tract, GI tract, and the oral cavity. 
The comparison of different stages of embryonic development also reveals that in some 
tissues FGF-BP expression is related to the stage of differentiation. This is found in the liver, 
various tissues of the CNS including spinal cord and midbrain and in the heart where 
immunopositivity decreases with development. In contrast, the epithelia of the oral cavity 
show increasing FGF-BP levels during mouse embryogenesis. These data indicated that 
FGF-BP expression is tightly regulated during development. This study is in agreement with, 
but significantly extends the results of Kurtz et al. [94] on FGF-BP expression in mouse 
embryos. 
 
     Interestingly, the comparison of the protein levels of FGF-2 and FGF-BP during mouse 
embryo development reveals broad similarities as well as some marked differences in 
localization [98]. In general, strong FGF-2 expression overlaps with strong FGF-BP 
immunreactivity in the digestive tract, in skin, lung, kidney, pancreas, and various glands. 
This is true for skeletal and heart muscle where weak expression is seen for both molecules. 
In contrast to these tissues, in liver the staining patterns for FGF-2 and FGF-BP are different. 
While FGF-2 was relatively weak, strong FGF-BP immunopositivity was detected [98]. 
 
     Recently, the effect of human FGF-BP transgene expression in chicken embryos has been 
explored. The expression of human FGF-BP dose-dependently induced vascular 
permeability, hemorrhage and embryonic lethality, which resulted from compromised 
microvascular structure as indicated by light and electron microscopic studies [99].      
 
     In nonmalignant diseases that include tissue repair, changes in FGF-BP expression were 
also observed. A strong up-regulation of FGF-BP expression was found in the kidney stroma 
of children with renal damage due to diverse causes that include HIV infection as well as 
bacterial toxins causing hemolytic uremia syndrome (HUS) [100]. In support of a role of 
increased FGF-BP expression during kidney repair, an enhancement of FGF-induced kidney 
epithelial proliferation by FGF-BP was observed [100]. Furthermore, the FGF-BP expression 
was found up-regulated in blood vessels of mice that succumb to premature atherogenesis 
[101]. In contrast to this long-term up-regulation of FGF-BP, wound healing studies in 
murine and human tissues showed only a transient up-regulation of FGF-BP that upon wound 
closure returned to baseline [96]. Recently, it was shown that FGF-BP interacts with FGF-7 
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and FGF-10, which have important functions for repair of injured epithelia, as well as with 
the recently identified FGF-22 enhancing the activities of low concentrations of these ligands 
[85]. The interaction of FGF-BP with FGF-7 and FGF-10 suggests that up-regulation of 
FGF-BP expression after epithelia injury stimulates FGF activity at the site of wound, thus 
enhancing the process of epithelial repair. 
 
1.3.5 Regulation of FGF-BP expression by TPA, EGF, fetal bovine serum and retinoids 
 
     The regulation of cellular FGF-BP expression as well as the FGF-BP promoter has been 
extensively analyzed in the ME-180 SCC cells. Several studies have shown that FGF-BP 
expression is significantly up-regulated by 12-O-tetradecanoylphorbol-13-acetate (TPA), 
mitogens such as epidermal growth factor (EGF) and fetal bovine serum (FBS), and that it is 
downregulated by retinoids in vitro and in vivo. 
 
     Phorbol esters, such as TPA (12-O-tetradecanoylphorbol-13-acetate), are potent tumor 
promoters as pharmacological activators of the protein kinase C (PKC) pathway [102]. 
Recent studies demonstrated that FGF-BP is up-regulated during TPA promotion of skin 
cancer [94,96]. In the ME-180 cells, TPA increased FGF-BP mRNA levels in a time- and 
dose-dependent manner mediated via the protein kinase C signal transduction pathway [103]. 
The deletion or mutational analysis of the FGF-BP promoter indicated that TPA effects on 
FGF-BP gene transcription are tightly controlled by a complex interplay of positive elements 
and a novel regulatory element, which contains sequences recognized by E-box element 
factors [103]. The significance of these regulatory elements has also been shown by EGF-
mediated FGF-BP up-regulation in ME-180 cells as well as in the breast cancer cell line 
MDA-MB-468 [90,104]. Although the C/EBP site in the FGF-BP promoter is a necessary 
element for EGF-induced FGF-BP promoter activity in both cell lines, it is noteworthy that 
the deletion of this site in MDA-MB-468 cells resulted in a significant increase in basal 
activity [90], whereas the deletion of the same site in ME-180 cells did not result in any 
change in the basal activity [104], suggesting  a unique dual role of C/EBP site in the 
regulation of promoter activity specific to breast cancer cells. 
 
     Similarly, treatment of serum-starved ME-180 cells with fetal bovine serum results in a 
rapid increase in FGF-BP mRNA levels and in the rate of FGF-BP gene transcription [105]. 
Promoter analysis showed that C/EBP is the main promoter element required for the serum 
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response. Unlike EGF-activation of FGF-BP, transcriptional induction by serum is not 
significantly regulated through the AP-1 or E-box sites in the promoter [105]. These results 
illustrate a strict control of FGF-BP expression by various mechanisms and promoter 
elements, which in part depend on the stimulus.  
 
     Retinoids, a group of naturally occurring or synthetic analogues of vitamin A, are potent 
regulators of normal epithelial differentiation and growth and affect many neoplastic cell 
systems including several squamous cell carcinoma (SCC) cell lines [106-109]. Moreover, 
retinoids have been shown to suppress carcinogenesis in various epithelial tissues in animal 
model systems [110-114] and also to have clinical efficacy as chemotherapeutic agents 
against selected malignancies including SCCs [115-119].  
   
     FGF-BP has been found to be a target for downregulation by retinoids. Oral all-trans 
retinoic acid (tRA) treatment induced a significant decrease of FGF-BP protein levels in 
stomach, eye and lung tissues of rats as demonstrated by immunohistochemical analysis 
[120]. Similarly, it was demonstrated that in different squamous cell carcinoma (SCC) cell 
lines tRA downregulates FGF-BP mRNA in a time- and dose-dependent manner and that 
downregulation occurs both at the transcriptional and post-transcriptional levels [121]. 
Furthermore, in vivo tRA treatment of SCC xenografts in athymic nude mice has been shown 
to reduce the FGF-BP expression, correlating with inhibition of tumor angiogenesis, 
induction of apoptosis and a decrease in tumor growth [122]. In further studies, the relative 
roles of the retinoid receptor subtypes (RXR and RAR) in the transcriptional and post-
transcriptional repression of FGF-BP gene expression have been investigated. It was shown 
that post-transcriptional degradation of FGF-BP mRNA is the predominant mechanism for 
reducing of FGF-BP and that RAR receptors are major regulators at this level [123].  
 
     Recently, other regulators of FGF-BP expression have been demonstrated. In prostate 
carcinoma PC-3 cells transfected with human full-length androgen receptor, androgen 
stimulation induces an increase in FGF-BP mRNA and protein, suggesting the production of 
FGF-BP under androgen control [124]. A subsequent study reported the up-regulation of 
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1.3.6 Structural characterization of FGF-BP 
 
     Lametsch et al. [125] described the purification and characterization of FGF-BP from 
bovine prepartum mammary gland secretions. Inspection of the cDNA sequence predicted 
that the unprocessed bovine FGF-BP is 234 residues long and the amino acid sequence 
showed a significant similarity with that of human (60%) and mouse (53%) FGF-BP. By 
means of matrix assisted laser desorption ionization-time of flight-mass spectrometry 
(MALDI-TOF-MS), it was determined that all 10 cysteines, which are positionally conserved 
in human, mouse and bovine FGF-BP, participate in disulfide bonds, and the pattern was 
identified as Cys71-Cys88, Cys97-Cys130, Cys106-Cys142, Cys198-Cys234 and Cys214-
Cys222. N- and O-glycosylation of Asn155 and Ser172, respectively, was demonstrated in 
bovine FGF-BP. While the bovine N-linked glycosylation site has no counterpart in the 
predicted amino acid sequences of human and mouse FGF-BP, the O-glycosylated residues 
in bovine protein are conserved in other FGF-BPs.  Lametsch et al. [125] found that the 
purified bovine FGF-BP started at Gly32 and Ser52, respectively, whereas the human FGF-
BP starts with Lys34 [32]. The enzyme responsible for cleavage of the removed peptides 
from unprocessed bovine FGF-BP during secretion process remains to be identified. It is 
noteworthy, that the C-terminus of removed peptide in bovine FGF-BP contains a dibasic 
sequence (Arg30-Arg31 and Lys48-X-X-Arg51), which is not found in the sequence of 
human FGF-BP. The presence of this sequence suggests that one or more subtilisin-like 
endopeptidases may be responsible for the processing [126]. 
  
     While data on the FGF-binding site of FGF-BP are still lacking, data on heparin-binding 
sites are available. The principle heparin-binding site of human FGF-BP purified from A431-
conditioned medium has been localized to residues Arg110-Phe143 characterized by the high 
content of basic amino acid clusters and may contribute to the binding specificity [127]. In 
addition to this highly basic region, there are two partial heparin-binding consensus 
sequences (Lys25-His32 or Lys163-Ser169), which were determined by comparison of the 
proposed consensus sequences of protein-heparin interactions [128,129]. It is noteworthy that 
the first partial heparin-binding consensus sequence (Lys25-His32) is included in the N-




Introduction                                                                           14 
1.3.7 The mechanism of FGF-BP action 
 
     The role of FGF-BP in the extracellular activation of FGF-2 is still somewhat unclear, 
since previous studies provide only indirect conclusions on the mechanism of action of FGF-
BP or lead to partly contradictory and still incomplete results. It has been demonstrated that 
the transfection of FGF-BP in the non-tumorigenic FGF-BP negative human adrenal 
carcinoma cell line SW-13 resulted in a tumorigenic and angiogenic phenotype when these 
cells were injected into nude mice [88]. It was also shown that these FGF-BP transfectants 
form colonies in the soft agar assay and release FGF-BP into their media together with FGF-
2 in a non-covalently bound form. As expected, colony formation of FGF-BP-transfected 
SW-13 cells can be blocked by a specific antibody against FGF-2, demonstrating that the 
tumorgenic potential of FGF-BP is FGF-2-dependent [88]. 
 
     As an alternative approach, the effects of depletion of endogenous levels of FGF-BP on 
angiogenesis and tumor growth were also investigated [91]. Endogenous FGF-BP mRNA in 
human squamous cell carcinoma ME-180 and in human colon carcinoma LS174T cells was 
reduced by means of ribozyme-targeting. The reduction in FGF-BP expression resulted in 
decreased levels of biologically active FGF-2 released from the cells in culture. In addition, 
the growth and angiogenesis of xenografted ME-180 and LS174T tumors in mice was 
decreased in parallel to the ribozyme-mediated reduction of FGF-BP. 
 
     In further studies, it was found that FGF-BP binds to FGF-2 in a dose-dependent and 
specific manner and that binding is inhibited by FGF-1, heparan sulphate, and heparinoids 
[33]. Furthermore, in chicken chorioallantoic membrane (CAM) assays, a significant FGF-
BP-dependent increase of FGF-2-mediated angiogenesis was demonstrated. Additionally, 
FGF-BP enhanced FGF-1- and FGF-2-dependent proliferation of NIH-3T3 fibroblasts. These 
results suggest a positive modulation of the biochemical and biological activity of FGF-2 by 
FGF-BP in multiple models. Finally, further evidence of a role of FGF-BP in the 
extracellular activation of FGF-2 comes from findings that FGF-BP alters the binding affinity 
of FGF-2 to heparin without additional cofactors, which directly proves the mechanism of 
FGF-2 release from the extracellular matrix [130]. Moreover, exogenously administered 
FGF-BP stimulates the growth of different tumor cells as well as the growth and chemotaxis 
of endothelial cells and, this effect is FGF-2-dependent [130]. 
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     Taken together, these data are consistent with the concept that the secreted FGF-BP can 
recover FGF-2 from its immobilized state on the cell surface and thus serve as an 
extracellular carrier molecule to its receptor (Fig. 1). As such, FGF-BP can bolster autocrine 





Fig. 1 Model of mechanism of action of FGF-BP. 
In some tumors, FGF-BP expression is up-regulated and FGF-BP is secreted into extracellular environment. 
FGF-BP binds to immobilized FGF-2, which is stored in the extracellular matrix. FGF-2 is then released in a 
soluble and bioactive form, allowing it to reach its target cell receptor and exert its effects (from [132]).  
 
 
On the other hand, various lines of evidence suggest that FGF-BP expression is 
downregulated in SSCs and has no obvious role in the release of FGF-2. By Northern and 
Western blotting, Sauter et al. [131] demonstrated that FGF-BP expression is decreased with 
progression to carcinoma. In clinical specimens, FGF-BP protein expression in normal 
human epithelium is relatively uniform and shows moderate to high intensity, whereas 
carcinomas demonstrate more focal, less intense and more heterogenous staining. Moreover, 
ex vivo transduction of FGF-BP into a transformed keratinocyte cell line (HaCaT) and 
tumorgenic human SSC cell lines (Det 562, FaDu) did not lead to tumor formation or 
increased vascularity of the tumors upon injection of the cells into SCID mice. 
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     It was also reported that the binding of FGF-BP to FGF-1 and FGF-2 inhibits their 
biological activities at least in the absence of heparin and this effect is due to reduction of 
ligand binding [32]. Furthermore, it was shown that FGF-BP purified from conditioned 
medium of human epidermal carcinoma cells A431-AJC inhibits at high medium 
concentrations DNA synthesis and cell growth in mouse fibroblast 3T3 cells [133]. These 
effects are probably due to the formation of FGF-BP/FGF complexes leading to the reduction 
of free FGF-1 and FGF-2 concentrations and hence leading to insufficient stimulation of 
DNA synthesis and cell growth in these cells. When FGF-1 and FGF-2 were added back at 
very low concentration to medium, they reversed this inhibition by FGF-BP and cellular 
DNA synthesis and growth were recovered, indicating that FGF-BP interacts with both FGFs 
in reversible manner. The degree of specificity of FGF-BP interaction with FGF-1 and FGF-2 
was shown by the fact that EGF did not reverse the inhibition of DNA synthesis and cell 
growth mediated by high concentrations of FGF-BP. In contrast to high concentrations of 
FGF-BP in conditioned medium, low concentrations induced DNA synthesis and cell growth 
of 3T3 cells. This biphasic action of FGF-BP on DNA synthesis in 3T3 cells suggests 
specific physiological roles in addition to the function as carrier protein. It is noteworthy that 
the biphasic action of FGF-BP was seen in normal cell lines (HUVEC: Human umbilical vein 
endothelial cells and 3T3: mouse fibroblast cell line), while it had no effect on human 
epidermal carcinoma cells A431-AJC [133]. 
    
     Furthermore, FGF-BP has been postulated to exist as a dimer [134]. This and other data 
(Achim Aigner, unpublished data) indicated the existence of stable, covalent multimers of 
FGF-BP. Moreover, although the purified bovine FGF-BP from prepartum mammary gland 
secretion has not been shown to form multimers, discrepancies between the calculated and 
observed molecular weights could not be fully explained [125]. Clearly, the mechanism of 
FGF-BP action and the relevance of the apparent formation of the stable homo- or 
heterocomplexes mentioned above remain to be elucidated.  
 
1.4 The HER-2 Receptor 
 
     The HER-2 proto-oncogene (also known as neu, NGL, or c-erbB-2) encodes a 185-kDa 
transmembrane glycoprotein, with extensive sequence homology to the epidermal growth 
factor receptor (EGF-R) [135-137]. It was originally identified as a transforming oncogene in 
chemically induced rat neuroglioblastomas, where a single point mutation in the 
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transmembrane domain of the molecule is sufficient to confer oncogenic activity [136,138]. 
Indeed, this and other HER-2 point mutations have only rarely been found in human cancers. 
 
     HER-2 is a member of the membrane-spanning type I receptor tyrosine kinase (RTK) 
family, which is also called human epidermal growth factor receptor HER or ErbB family 
and comprises four homologous receptors: (a) HER-1, also termed epidermal growth factor 
receptor (EGF-R) or erbB-1 and the first to be cloned [139]; (b) HER-2, c-erbB-2; (c) HER-
3, erbB-3; and (d) HER-4, erbB-4 [140,141]. In response to growth factor ligands, members 
of the HER family induces a variety of cellular responses, including proliferation, 
differentiation, cell motility, and survival.  
 
1.4.1 Structure of HER receptors 
     
     All HER receptors share a similar structure, comprising an extracellular ligand binding 
domain with four subdomains including two cysteine rich domains (I-IV), a transmembrane 
lipophilic segment, and an intracellular domain (Fig. 2) [142]. The intracellular portion of 
HER receptors consists of a tyrosine kinase domain, a juxtamembrane region, and a carboxyl 
tail harboring the autophosphorylation site. The highest degree of sequence homology 
(approximatly 80% amino acid identity) between HER-1, HER-2 and HER-4 lies in the 
tyrosine kinase domain, suggesting that this region is essential for the signaling function of 
these molecules [143]. HER-3, by contrast, contains substitutions of critical amino acids 
within this domain and lacks kinase activity [144,145]. 
 
     The activation of HER receptors, which exist as monomers in the plasma membrane, is 
usually dependent on the presence of ligands [147,148] and other receptors of the HER 
family [149]. Ligand binding induces the homo- or heterodimerization of HER receptors. 
Some intriguing questions concerning the process of ligand-induced receptor dimerization 
have been clarified by publications describing the crystal structure of HER-1, HER-2 and 
HER-3 ectodomains (reviewed in [150]). As mentioned above, the extracellular region of 
each HER receptor consists of four domains (I-IV; Fig. 3). Determination of the structure of 
ligand-bound HER-1 has confirmed earlier studies (reviewed in [150]) that show the 
importance of domains I and III in peptide binding. Moreover, these studies also revealed 
that there is a direct receptor-receptor interaction promoted by the domain II dimerization 
arm [151,152]. In unliganded HER-3 [153] or ligand-bound inactive HER-1 [154] the 
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receptors assume the so-called tethered structure, in which the domain II dimerization 
interface is blocked by intramolecular interactions between domains II-IV. 
 
 
                                                HER-1   HER-2   HER-3   HER-4        
                             
                      
Fig.2  Structure of HER receptors. 
HER receptors are located at the cell membrane and have in common an extracellular ligand binding domain, a 
single hydrophobic transmembrane domain, and an intracellular domain. The extracellular domains comprise 2 
cysteine-rich domains (represented by loops), which mediate ligand-induced dimerization. In addition, the 
ectodomains include 2 cysteine-free regions, each capable of binding a distinct portion of the bivalent growth 
factor ligand (shown as a dark structure). The highly homologous cytoplasmic regions contain a tyrosine kinase 
domain, a juxtamembrane region, and a carboxyl tail harboring the autophosphorylation site. HER-3 contains 
substitutions of critical amino acids within this domain and lacks kinase activity (from [146]). 
       
 
     The structure of the HER-2 extracellular region is radically different from the others. 
HER-2 has a fixed conformation that resembles the ligand activated state: the domain II-IV 
interaction is absent and the dimerization loop in domain II is exposed [155,156]. This 
structure is consistent with the data that indicate that HER-2 is the preferred partner for other 
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Fig.3  Structures of HER extracellular domain. 
The extracellular region of each HER receptor consists of four domains (I-IV). It has been suggested that in the 
absence of ligand, HER-3 and HER-1 (not shown) assume a tethered structure. (a) Domains I and III are 
involved in the neuregulin (NRG) binding and, following this, the dimerization arm in domain II is exposed (b) 
and promotes receptor-receptor interaction (c). HER-2 has a fixed conformation that resembles the ligand-
activated state of HER-1 and HER-3 (modified from [157]). 
 
 
     Both ligand-mediated homo- and heterodimerization of HER receptors lead to receptor 
transphosphorylation on tyrosine residues within the activation loop, which significantly 
enhances kinase activity [158,159]. Subsequent tyrosine phosphorylation on residues within 
the carboxyl terminal tail of the receptors enables the recruitment and activation of signaling 
effectors containing Src homology 2 (SH2) domains and phosphotyrosine binding (PTB) 
domains. Subsequently, intracellular proteins involved in the signaling pathway are 
phosophorylated and activated, resulting in the modulation of gene transcription [160]. 
     
1.4.2 Ligands of HER receptors 
 
     There are ten characterized human ligand genes encoding HER-specific ligands, each of 
which containing an EGF-like domain that confers binding specificity, allowing them to be 
divided into three groups (Fig. 4). The first group includes EGF, amphiregulin (AR), and 
transforming growth factor-α (TGF-α), which bind specifically to HER-1; the second group 
consists of betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), 
which exhibit dual specificity in that they bind HER-1 and HER-4. The third group is 
composed of the neuregulins (NRG) and forms two subgroups based upon their capacity to 
bind HER-3 and HER-4 (NRG-1 and NRG-2) or only HER-4 (NRG-3 and NRG-4). 
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       Interestingly, HER-2 is a unique member of the HER family in that it does not bind 
directly any of the known ligands with high affinity. Though HER-2 is thought to be an 
orphan receptor, it is a co-receptor for many different ligands and the preferred heterodimeric 
partner for other HER receptors. Neuregulins can induce the formation of HER-2/HER-3 and 
HER-2/HER-4 heterodimers [161,162].  
 
                      
 
Fig.4 The HER growth factor ligands. 
The family of the HER-specific ligands consists of ten members. They can be divided into groups depending 
upon binding specificity toward the HER receptors. No known direct ligand binds HER-2. Hence, it needs a 
heterodimerization partner to acquire signaling potential (indicated by phospho residues). Since HER-3 lacks a 
functional tyrosine kinase domain, HER-3/HER-3 homodimers do not signal. However, interestingly, the NRG-
mediated HER-2/HER-3 heterodimers provide the most potent mitogenic signal (from [172]).  
 
   
     Although both ligand-mediated homo- and heterodimerization result in the activation of 
the HER network, heterodimers are more potent and mitogenic. Heterodimerization can 
provide additional phosphotyrosine residues for the recruitment of binding partners, as well 
as induce distinct patterns of the receptor phosphorylation and downstream signaling. In 
addition, the attenuation of signaling through receptor endocytosis and subsequent lysosomal 
degradation differs between receptor dimers [163,164]. Interestingly, heterodimers 
containing HER-2 have particularly high ligand binding and signaling potency as compared 
to heterodimers without HER-2 [165,166]. The increased potency of HER-2-containing 
heterodimers is attributable to several reasons, including increased ligand affinity through a 
decelerated rate of ligand dissociation, efficient coupling to signaling pathways, and 
decreased rate of receptor downregulation [165,167-169]. Furthermore, signaling through the 
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kinase-deficient HER-3 requires heterodimerization with a kinase-active partner. Through 
heterodimerization, the ligandless HER-2 and the kinase-inactive HER-3 provide the most 
potent mitogenic [161,170] and angiogenic signal [171]. 
 
1.4.3 HER-2-induced signaling pathways 
 
     HER signaling can not be considered as a linear pathway because of the high level of 
interaction that occurs between the different HER receptors. Instead, HER signaling is a very 
interactive system in which the ligand can lead to the formation of different homodimers or 
heterodimers that interact to stimulate a variety of signaling pathways. This process has been 
described as network signaling. The HER network play important roles in cell growth and 
differentiation and is implicated in signaling downstream of cellular stimuli, including cell 
adhesion, lymphokines, or stress signals [173]. 
 
     The HER signal-transduction network consists of a stromal input layer (ligands or growth 
factors), a cellular information processing layer (receptors, SH2-proteins, transcription 
factors), and an output layer (cell growth, differentiation or migration). Receptor 
dimerization is important here, allowing a signaling network with an enormous potential for 
diversification of biological messages instead of four receptors with only four linear 
pathways. The coordination of the whole network, according to this model, is performed by 
HER-2. Furthermore, it is believed that the absence of a HER-2-specific ligand facilitates the 
HER-2-mediated regulation of the entire HER signaling network.  
 
     The three best characterized signaling pathways induced through HER receptors are Ras-
mitogen-activated protein kinase (Ras-MAPK), Phophatidylinositol 3-kinase-protein kinase 
B (PI3k-PKB/Akt), and phospholipase C-protein kinase C (PLC/PKC) pathways (reviewed 
by [160,174,175]). 
 
     The Ras-MAPK cascade is a critical pathway for a number of signals transduced inside 
the cell, many of which being growth-regulating signals. Moreover, Ras genes, which encode 
small proteins with intrinsic GTPase activity, are the most frequently mutated oncogenes in 
human cancers [176], leading to the concept that this pathway is a common target for many 
transforming and/or carcinogenic agents. Stimulation of the Ras pathway ultimately leads to 
the activation of mitogen-activated protein (MAP) kinase, an enzyme with a number of 
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intracellular targets including nuclear transcription factors [177]. All HER ligands and 
receptors couple to activation of the Ras-MAPK pathway, either directly through SH2 
domain-mediated recruitment of Grb-2 or indirectly through PTB domain-mediated binding 
of the Shc adaptor.  
 
1.4.4 The relevance of the HER-2 network in cancer 
 
     The HER network is implicated in multiple human cancers, and deregulation of many 
signaling pathways induced through HER receptors can promote multiple properties of 
neoplastic cells, including proliferation, migration, angiogenesis, stromal invasion, and 
resistance to apoptosis. Hyperactivation of the HER network can occur via an autocrine 
secretory loop involving overproduction of ligands and receptors by the tumor cells, or 
paracrine growth, which is dependent on HER ligands produced by adjacent stromal cells 
[178]. Alternatively, aberrant growth can ensue from constitutive receptor activation [179]. 
      
     The oncogenic effect of HER-2 may relate to its high basal autophosphorylation [179]. 
High levels of HER-2 expression may result in its constitutive homodimerization and 
promote transformation in tissue culture models [180,181]. In addition, ligand-independent 
homodimerization was observed in rats treated with carcinogen, in which a single point 
mutation within the transmembrane domain of the HER-2 receptor (called NeuT) results in 
constitutive receptor activation and the formation of neuroglioblastomas [136,137,182]. 
Although not naturally occuring, a comparable mutation in human HER-2 leads to increased 
dimerization and transforming ability [182]. Alternatively, overexpressed HER-2 may 
promote tumor formation as a result of spontaneous or ligand induced heterodimerization 
with other HER receptors [183] leading to signal potentiation. Indeed, coexpression of an 
additional HER receptor is required for NeuT-mediated transformation [184,185]. 
Furthermore, many HER-2-expressing tumors also exhibit an autocrine loop involving the 
expression of both HER-1 and one of its ligands, and loss of HER-2 function inhibits the 
proliferation of these tumor cells. Most breast, skin, lung, ovary, and gastrointestinal tract 
tumors express HER-3 and/or HER-4, and heteromerization of these receptors with HER-2 
may be involved in some cancers, such as oral squamous cell cancer and childhood 
medulloblastoma [186,187]. 
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     Amplification and/or overexpression of HER-2 is relevant in human cancer, as it has been 
observed in 20-30 % of adenocarcinomas such as breast, ovary, lung, stomach and pancreatic 
cancer [2,3] and in 100 % of stage III/IV ovarian carcinoma cell lines [188]. Furthermore, 
HER-2 overexpression has been linked to an unfavorable prognosis and more aggressive 
malignant behavior of tumors in patients with breast and ovarian  cancer [189]. Hence, HER-
2 is a prognostic and an excellent target for novel therapeutic approaches in HER-2-
overexpressing cancers. 
 
 1.4.5 Effects of HER-2 overexpression on chemotherapeutic drug sensitivity in tumor  
         cells 
 
     The consequences of HER-2 overexpression are mainly hyperactivation of different 
components of the cell cycle apparatus, increased proliferation and survival rate of cells, 
increased metastasis (presumably through up-regulation of basement membrane degradative  
enzymes, such as the matrix metalloproteases (MMPs) [190]), as well as in many cases 
increased resistance towards cytokines, hormone therapy, certain chemotherapeutic agents 
[191,192] and radiation therapy [193,194] (Fig. 5). 
 
                                
 
 Fig. 5 Consequences of HER-2 overexpression in cancer cells (according to [190]). 
 
     The relationship between HER-2 overexpression and drug sensitivity is of considerable 
interest, as this may allow to better predict response to chemotherapy. Several in vitro studies 
demonstrated the association of overexpression of HER-2 receptor with chemoresistance to 
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several anticancer drugs in cancer cells. HER-2 overexpression can cause chemoresistance in 
some non-small-cell lung cancer cell lines [195]. Moreover, using a panel of established 
human breast cancer cell lines that express different levels of HER-2, higher levels of HER-2 
expression in these cell lines were correlated with increased resistance to two 
chemotherapeutic drugs, paclitaxel (taxol) and docetaxel (taxotere) [196]. The analysis of 
molecular mechanisms underlying HER-2-mediated taxol resistance in HER-2-transfected 
MDA-MB-435 breast cancer cells indicated that overproduction of HER-2 up-regulates 
p21Cip1, which in turn inhibits taxol-mediated activation of p34Cdc2 kinase and thereby 
impedes taxol-induced apoptosis [197]. 
 
     An important method for demonstrating the involvement of the HER-2 gene in drug 
sensitivity is the suppression of the HER-2 oncoprotein by treatment with antisense HER-2 
oligonucleotides [198] or treatment with an anti-HER-2 antibody. Trastuzumab (Herceptin) 
is a humanized monoclonal antibody which interferes with HER-2-mediated signaling by 
binding to the extracellular domain of HER-2 and downregulating HER-2 receptor density. 
In vitro studies indicate that co-treatment with trastuzumab and anticancer drugs such as 
anthracyclines and taxanes increases drug sensitivity in an additive and synergistic manner 
[199-201]. Subsequent clinical studies of combination treatments with trastuzumab and 
doxorubicin or paclitaxel indicated an increased response rate and prolonged survival 
compared to treatment with either anticancer drug alone [202].     
 
     Several clinical studies confirmed the above-described relationship between HER-2 
overexpression and drug sensitivity in breast tumors. A clinical study conducted in 1992 
found that HER-2-overexpressing breast tumors are less responsive to adjuvant 
chemotherapy regimens consisting of cyclophosphamide, methotrexate and 5-fluorouracil 
(CMF) than are tumors that express normal amounts of HER-2 [203]. Interestingly, patients 
with node-positive early-stage breast tumors that overexpressed HER-2 benefitted from 
higher doses of chemotherapy, whereas patients with early-stage disease not exhibiting HER-
2 overexpression did not [204]. Meanwhile, another study showed that the status of HER-2 
expression was useful for predicting survival time only in patients receiving adjuvant 
therapy, further suggesting that HER-2 may be a marker of drug resistance [205]. In addition, 
several studies have shown that the serum level of the HER-2 protein can also predict the 
responsiveness of breast cancers to adjuvant treatment [206,207]. 
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     For ovarian carcinoma cells, conflicting data have been obtained. On the one hand, in the 
HER-2 overexpressing SKOV-3 cell subtype SKOV-3.ip1 HER-2 reduction through stable 
expression of adenovirus type 5 E1A protein was coincident with increased sensitivity to 
paclitaxel  [208,209]. On the other hand, it was found that reversal of HER-2 overexpression 
in SKOV-3 cells led to increased rather than decreased cellular resistance towards paclitaxel 
[210] and, concomitantly, in another study paclitaxel-resistant SKOV-3 ovarian carcinoma 
cells displayed lower HER-2 levels as compared to the corresponding paclitaxel-sensitive 
wildtype cells [211]. Finally, Pegram et al. [192] reported that overexpression of HER-2 was 
not sufficient to induce intrinsic paclitaxel resistance in ovarian and breast cancer cells and 
concluded that HER-2 levels are not sufficient to predict changes in chemosensitivity 
profiles.  
 
1.4.6 HER-2-targeting strategies  
 
     As a result of the observations to the role of HER-2 overexpression in tumor cells, HER-2 
proves to be an excellent target for novel therapeutic approaches specific to HER-2-
overexpressing. In the past ten years, several targeting strategies have been developed.  
 
     In the context of this thesis, different and independent HER-2 targeting strategies were 
employed, including treatment with the HER-2 inhibitory antibody trastuzumab (Herceptin), 
downregulation of HER-2 expression by ribozyme-targeting, and treatment with tyrosine 
kinase inhibitors. All these strategies are described in detail below.  
 
Development of anti-HER-2 receptor antibody 
     The cancer-inhibitory potential of antibodies to HER-2 was realized as far back as 1984, 
when mice bearing tumors with an active form of rodent HER-2 were treated with specific 
antibodies [212]. On the basis of these observations, the exact mechanism by which anti-
HER-2 antibodies inhibit cell growth has been examined. Mechanistically, the antibodies 
appear to act by removing HER-2 from the cell surface. It has previously been shown that the 
oncogenic activity of HER-2 necessitates its localization in the plasma membrane [213]. In 
line with blocking HER-2 action by preventing its interaction with other surface-localized 
HER receptors, the tumor-inhibitory potential of certain combinations of anti-HER-2 
antibodies [214] correlates with the efficiency of antibody-induced downregulation of HER-
2. This downregulation of cell-surface HER-2 has been observed by treating HER-2-
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overexpressing tumor cells with the humanized monoclonal mouse antibody trastuzumab 
[215] that is known as Herceptin. In preclinical studies and Phase II and Phase III trials 
Herceptin has demonstrated tumor inhibitory and chemosensitizing effects for taxol and 
several chemotherapeutic agents [199,216-219]. Furthermore, Herceptin has been approved 
for the adjuvant treatment of advanced breast and ovarian cancer (for review, [220,221]). 
 
Suppression of HER-2 expression through riboyzme targeting 
     Ribozymes (ribozymes ═ ribonucleic acid-derived enzymes) are one kind of catalytic 
RNAs with site-specific binding and cleavage activities. Hammerhead ribozymes are the best 
characterized ribozymes and were discovered in plant RNA viruses, which contain a single 
circular RNA molecule as their genetic material. These viruses replicate using a so-called 
‘rolling circle mechanism’, in which the replication machinery constantly travels around the 
circular RNAs and produces a linear chain containing many copies of the RNA genome. The 
hammerhead ribozyme is the ‘pair of scissors’ in this process, snipping the linear chain into 
single-genome length pieces. It does this by attaching itself to the RNA genome via specific 
sequences at the region between its two ‘hammer heads’. The minimal sequence of the 
hammerhead ribozyme required for catalysis comprises around 40 nucleotides folded into 
three stems which are connected by single-stranded regions (Fig. 6) [222,223] for review see 
[224]). The properties of hammerhead ribozymes, i.e. site specific mRNA binding and 
cleavage activity, have been applied to destruct target gene expression by artificially 
designed and synthesized hammerhead ribozymes [92,225-227]. Hence, Hammerhead 
ribozymes have long been considered a potentially useful tool for gene silencing, have 
demonstrated their utility in attenuating eukaryotic gene expression and have been examined 
in preclinical gene therapy models [228].  
 
     Ribozyme-targeting of cancer-relevant genes has attracted great attention due to the 
simple structure of ribozyme as well as their easy designation, site specific mRNA cleavage 
activity, and catalytic potential [229-234]. Furthermore, ribozyme-targeting is a very 
attractive and generally applicable method, which has the advantage of allowing the stable 
and selective reduction of an isolated gene product without interference in other cellular 
processes, providing a tool for the isolated functional study of the gene of interest. Ribozyme 
targeting of HER-2 gene expression has been recently examined by numerous studies [235-
238]. In two studies, an adenovirus encoding a ribozyme targeting of HER-2 was shown to 
deplete HER-2 mRNA in ovarian carcinoma and in breast cancer cells. Moreover, Suzuki et 
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al. [235] demonstrated the repression of the tumor cell growth by ribozyme-containing 
adenovirus. Finally, the effects of anti-HER-2 ribozymes transfected as ribozyme-expression 
plasmids into ovarian carcinoma cells were investigated [236,238]. 
 
                                              
Fig.6 Structure of a hammerhead riboyzme. 
The hammerhead motif consists of three base-paired stems connected by single-stranded regions. The arrows 
indicate the cleavage site on the riboyzme. 
 
 
Inhibition of the tyrosine kinase activity of the HER-2 receptor through tyrosine kinase 
inhibitors 
     Tyrosine kinase inhibitors (TKIs) are small molecules that inhibit the activity of tyrosine 
kinases in the intracellular domain of the HER receptors, thus preventing receptor 
auotophosphorylation and subsequent activation [239]. They compete at the binding site for 
adenosine triphosphate. Gefitinib (ZD1839, Iressa), one of the most widely studied, 
demonstrates remarkable selectivity for HER-1 compared to other receptor tyrosine kinases. 
In contrast, there are some dual TKIs of HER-1 and HER-2, which are currently in clinical 
trials, including Lapatinib (phase III) or AEE788 (phase I) [157]. In response to ligand 
activation, HER-2 and HER-1 heterodimerize. This makes dual tyrosine kinase inhibition of 
HER-1 and HER-2 an attractive therapeutic strategy for epithelial tumors.  
 
     Early work with TKIs assessed their potential as primary chemotherapeutic 
chemosensitizing and radiosensitizing agents. They have been shown to inhibit the growth of 
cancer cell lines in vitro, e.g. ovarian, colon, and breast cancer cells [240] as well as  in vivo 
in human tumor xenografts [241]. Furthermore, growth inhibition has been shown to be 
enhanced when gefitinib is combined with structurally and functionally different drugs in 
vitro and in vivo, such as cisplatin, paclitaxel, and topoptecan [242].  
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     D-69491 and D-70166 represent two newly developed low molecular weight HER 
tyrosine kinase inhibitors (Baxter Oncology GmbH, Frankfurt/Main, Germany). The 
inhibitory effects of these two HER tyrosine kinase inhibitors on the HER-2 phosphorylation 
were first shown in HER-2 overexpressing NIH3T3 cells [243]. The cells were treated with 
D-69491 or D-70166 for 8 h at different concentrations the phosphorylation of HER-2 was 
analyzed by Western blotting. Both D-69491 and D-70166 inhibit dose-dependently HER-2 
phosphorylation. While at tyrosine kinase inhibitor concentrations of 3.16 or 10 µM band 
intensities of non-phosphorylated HER-2 are slightly decreased, phosphorylated HER-2 is 
almost completely or completely (10 µM D-69491) absent indicating inhibition after 8 hours 
treatment. 
 
Other HER-2-targeting strategies include: 
-    Blocking of HER-2 expression through antisense oligonucleotides and antisense RNA  
     [244,245] 
-    Suppression of HER-2 expression through siRNA [246,247] 
-    Downregulation of HER-2 mRNA and protein expression through Retinoic acids  
     [248,249] 
-    Transcriptional repression of HER-2 gene expression through Adenovirus type 5 E1A 
      proteins [250-252], as well as 
-    Development of anti-HER-2 intracellular single-chain antibodies, which eradicate HER-2 
      from the cell surface membrane by ectopic localization of the HER-2 protein  to the 
      endoplasmic reticulum [253,254] 
 
1.5 Antineoplastic agents 
 
1.5.1 Taxol  
     
     Taxol® (paclitaxel), a naturally occurring diterpenoid isolated from the bark of the Pacific 
yew tree (Taxus brevifolia), is currently considered one of the most important drugs in cancer 
chemotherapy. Paclitaxel has been approved by the Food and Drug Administration (FDA) for 
treatment of various human tumors such as advanced ovarian cancer, metastatic breast cancer 
and Kaposi’s sarcoma [255,256]. This anticancer drug is currently undergoing clinical trials 
worldwide for the treatment of other cancers (e.g. lung, head and neck, prostate, and cervical 
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cancers) as well as in combination with other anticancer agents. Paclitaxel and docetaxel, a 
semisynthetic analog of paclitaxel, are the first members of a new class of microtubule-
stabilizing anticancer agents. 
 
     Taxol differs from other anti-microtubule agents such as vinblastine and colchicines by 
causing microtubule polymerization rather than of depolymerization [257]. This stabilizing 
effect leads to blockade of the cell in the late G2/M phase of the cell cycle and inhibition of 
cell division [257]. Furthermore, it has been found that taxol stabilized the microtubule 
dynamics at relatively low concentrations [258]. Most of the anti-microtubule agents, 
including taxol, vinblastine, colchicines and estramustine, bind to β-tubulin. Taxol binding 
sites on β-tubulin were identified at the N-terminal 31 amino acids and at residues 217-231 of 
the protein [259]. These two binding sites are part of the colchicine binding site and are 
highly conserved among species. However, Combeu et al. [260] showed taxol binding sites 
on both α and β subunits of tubulin. Taxol does not bind to actin, intermediate filament 
proteins, or to DNA in vivo and in vitro [261]. 
 
     During the last years, additional activities of taxol have been described including the 
effect on cell signaling and gene expression, activation of mitogen-activated protein kinases 
(MAPKs), Raf-1 and protein tyrosine kinases (PTK) [262-264]. Treatment of a variety of 
tumor cells with taxol induces apoptosis in vivo and in vitro [265], and it has been shown that 
the expression of apoptosis-related proteins like bcl-2, bad, bcl-x, p21-waf, and tumor 
necrosis factor-α (TNF-α), are regulated by taxol [266-270]. However, the exact mechanism 




     Extract preparations from natural mistletoe (Viscum album) have been widely used for 
several decades as alternative therapy in the management of patients with malignant disease, 
based on presumed immunostimulatory and antineoplastic effects [271,272]. Viscumin 
(mistletoe lectin, ML I) is the main therapeutic principle of extracts from mistletoe [271,273]. 
The heterodimeric 65 kDa glycoprotein belongs to the type II ribosome-inactivating proteins 
(RIPs) and catalyses the selective hydrolysis of the N-glycosidic bond at the adenine-4324 in 
the eukaryotic 28S ribosomal RNA which inhibits the elongation step of protein biosynthesis 
[274]. Tumor cells often display altered, cancer-specific glycosylation patterns [275], which 
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seem to represent preferential binding sites for Viscumin [276] and may account for its 
particularly potent cytotoxic effect on cancer as compared to normal cells. In vitro, Viscumin 
is active in tissue culture in the femtomolar to the low picomolar range [277] and it induces 
apoptosis in several in vitro systems [275,277]. Furthermore, numerous studies have shown 
an activation and/or proliferation of cellular components of the immune system including TH 
cells, granulocytes, natural killer cells and haematopoietic stem cells as well as an increased 
release of various inflammatory cytokines [278-280]. 
 
     More recently, the ML 1 gene was sequenced and its intron-free gene was cloned [281], 
and in a coassociation process from the recombinant A-chain and B-chain the non-
glycosylated 57 kDa Viscumin heterodimer, rViscumin, was obtained [282]. While the A-
chain mediates the ribosome inactivation, the B-chain displays a carbohydrate binding 
activity which allows cellular uptake of the protein, and both activities of the molecule are 
needed for the observed cytotoxic effect of rViscumin on target cells [283]. The recombinant 
drug rViscumin was studied extensively in preclinical models. It was found to possess 
antineoplastic and immunomodulatory properties in vitro and in vivo and was tolerated well 
in animals [284-287]. Furthermore, the potential receptor involved in the binding of 
rViscumin has been identified [288,289]. In contrast to another well-known ribosome-
inactivating agent, ricin, rViscumin was therefore characterized as a sialic acid-specific type 
II ribosome-inactivating protein. Neolacto-series gangliosides with a Neu 5Acα2-6Galβ1-
4GlcNAc-terminus (CD 75s) were defined as the rViscumin receptors for the B-chain, 
leading to internalisation of the holoprotein [288].  
 
     rViscumin displays full cytotoxicity on tumor cells, inhibitory effects on experimental 
urothelial carcinogenesis, immunomodulatory effects and rRNA N-glycosidase activity in 
vitro and in vivo [281,282,284,290]. In animal models, rViscumin displays potent anti-tumor 
activity e.g. in HER-2-positive tumors like ovarian cancer [291] and urinary bladder 
carcinoma [290], or in sarcoma [286]. Clinical development of rViscumin as anticancer drug 
focuses on utilizing its immunomodulatory properties as well as its direct cytotoxicity. 
Clinical trials with local and systemic administration of rViscumin in cancer patients with 
solid tumors have been performed to monitor tolerability and biological effects [292].  
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1.5 Biology of ovarian cancer 
 
    Ovarian cancer is the fourth leading cause of cancer death in women and the second most 
commonly diagnosed gynecologic malignancy [293]. Unlike breast cancer, ovarian cancer 
has only few prognostic indicators of clinical outcome. The most important prognostic 
parameters for ovarian carcinomas are tumor stage, histologic subtype, degree of malignancy 
and residual tumor after surgical treatment [294].  
 
      Ovarian tumors display histological heterogeneity [295-297]. The histological 
classification of ovarian tumors by the World Health Organization (WHO) is based on the 
histogenesis of the normal ovary [295]. The histogenetic classification categorizes ovarian 
neoplasms with regard to their derviation from coelomic surface epithelium, germ cells, and 
mesenchyme (the stroma and the sex cord). Each category includes a number of subtypes. 
Combinations of different subtypes, either intimately intermixed or side-by-side within a 
single tumor, are found with some frequency. Tumors that combine two or more subtypes are 
designated as mixed.  
 
     Molecular genetic analyses have indicated that either activation of oncogenes or 
inactivation of tumor suppressor genes is involved in the tumorgenic mechanisms of various 
human tumors [298]. There are many oncogenes and tumor suppressor genes that have been 
hypothesized to be involved in the pathogenesis and progression of ovarian cancers. For 
example, mutations in both BRCA-1 [299] and BRCA-2 [300] increase susceptibility to 
ovarian cancer. BRCA-1 mutations occur in about 5% of patients younger than 70 years with 
ovarian cancer. The estimated risk of ovarian cancer in women bearing BRCA-1 and BRCA-2 
is 16% by age of 70 years [300]. Approximately 30% of ovarian adenocarcinomas express 
high levels of HER-2 oncogene, which correlates with a poor prognosis. Mutations in the 
host tumor suppressor gene p53 are found in 50% of ovarian carcinomas [301]. 
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2 OBJECTIVES AND STRUCTURE OF THIS THESIS 
 
      The aim of this thesis was to study two gene products in ovarian cancer: the fibroblast 
growth factor-binding protein (FGF-BP) and the human epidermal growth factor receptor-2 
(HER-2). In contrast to HER-2, the expression status of FGF-BP in ovarian carcinomas had 
not been examined so far and its mechanisms of action were poorly understood. Therefore, 
the following points were studied: 
 
1. Examination of the expression of FGF-BP in normal ovaries and ovarian carcinomas  
      by immunohistochemical analysis of tissue microarrays. 
2. Analysis of mechanisms of FGF-BP action using the following strategy: 
      a) Generation of full length FGF-BP-CFP and FGF-2-YFP constructs as well as C- 
          and N-terminal FGF-BP truncations.  
            b) Analysis of the subcellular localization of the fusion proteins by confocal 
                microscopy. 
            c) Analysis of the subcellular colocalization and interaction of FGF-BP constructs  
                with FGF-2 by confocal microscopy. 
            d) Analysis of the biological functions of full length FGF-BP. 
            e) Analysis of the biological significance of the interaction of various FGF-BP  
                truncated mutants with FGF-2 in soft agar assays. 
            f) Analysis of the cellular uptake of exogenous FGF-BP and its dependence on the 
                interaction with FGF-2. 
 
     Previously, conflicting data were obtained regarding the role of HER-2 overexpression in 
the chemoresistance towards anticancer drugs particularly in ovarian carcinomas and in 
ovarian carcinoma cell lines. Therefore, the following aspects were studied in this thesis: 
 
1. Downregulation or inhibition of the HER-2 activity in human SKOV-3 cells by 
different strategies. 
2. Analysis of the effects of HER-2 downregulation or inhibition on the cellular 
sensitivity towards 
a) Paclitaxel and other established cytotoxic agents (doxorubicin and cisplatin). 
b) The novel anticancer drug rViscumin. 
3. Analysis of the underlying cellular mechanisms of these effects. 
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Agarose, Electrophoreses Grade PEQLAB





Cell Proliferation Reagent WST-1 Roche
3,3’-Diaminobenzidine tetrahydochloride DAB SIGMA
Diethylpyrocarbonate DEPC SIGMA
DNA ladder (1 kb) Fermentas
Ethidium bromide ROTH
Fluorescent mounting medium DAKO
Harris hematoxylin solution SIGMA




NaI125  Amersham Pharmacia
Ni-NTA sepharose QIAGEN
Normal goat serum Vector
Normal horse serum Vector
N,N,N',N',-Tetramethylethylendiamine TEMED SIGMA
peqGOLD TriFastTM PEQLAB
Prestained protein ladder, 10-180 kDa Fermentas
RotiPhorese® Gel 40 ROTH
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Alexa Fluor 488-conjugated goat anti-rabbit Molecular Probes
Anti-β-actin, mouse monoclonal SIGMA
Anti-bcl-2, mouse monoclonal DAKO
Anti-caspase-7, rabbit polyclonal Cell Signaling 
Anti-caspase-3, rabbit polyclonal PharMingen International 
Anti-ERGIC, mouse monoclonal  H.-P. Hauri, Basel
Anti-FGF2, rabbit polyclonal Sigma
Anti-FGF-BP, mouse monoclonal  R&D
Anti-GFP, rabbit polyclonal Clontech
Anti-p38, rabbit polyclonal Cell Signaling 
Anti-p42/44, rabbit polyclonal Cell Signaling 
Anti-SAPK/JNK, rabbit polyclonal Cell Signaling 
 
Name Supplier
Paclitaxel Pharmacy, Philipps-University Medical Center, Marburg
Doxorubicin Pharmacy, Philipps-University Medical Center, Marburg





QIAprep Mini-prep Kit QIAGEN
LumiGLO HRP Western blot kit Cell Signaling 
NUCLEOBOND Midi-prep Kit Macherey-Nagel
10mM dNTP Mix Fermentas
Rediprime™ II random prime labeling system                                    Amersham Pharmacia 
Restriction enzymes: EcoRI, XhoI, NotI, HindIII, and XbaI Fermentas
Ribonuclease Inhibitor Fermentas
Taq Polymerase Fermentas
T4 DNA Ligase supplied with 10x Ligation Buffer Fermentas
Transcriptor Reverse Transcriptase supplied with 10x Reaction Buffer                       Roche 
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Anti-phospho p38, rabbit polyclonal Cell Signaling 
Anti-phospho p42/p44, rabbit polyclonal Cell Signaling 
Anti-phospho SAPK/JNK, rabbit polyclonal Cell Signaling 
Biotinylated horse anti-mouse IgG Vector
Horseradish peroxidase-conjugated donkey anti-mouse antibodies     Amersham Pharmacia 
Horseradish peroxidase-conjugated donkey anti-rabbit antibodies      Amersham Pharmacia 
Texas Red-conjugated horse anti-mouse Vector
 
 
3.1.5 Oligonucleotides and primers 
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Escherichia coli DH5α Gibco BRL
pRc/CMV expression plasmid Invitrogen
Derivative pcDNA 3.1-based plasmid 
containing CFP  
W. Chubanov (Department of Pharmacology and 
Toxicology, Philipps-University, Marburg)
Derivative pcDNA 3.1-based plasmid 
containing YFP 
W. Chubanov (Department of Pharmacology and 
Toxicology, Philipps-University, Marburg)
Name Supplier
Iscove’s Modified Eagle’s Medium (IMDM) supplemented with glutamine                  PAA 
SF 900 II  supplemented with glutamine Life Technologies
Fetal calf serum (FCS) PAA
Trypsin/EDTA PAA
Phosphate buffered saline (PBS) PAA
Geniticin® (G418 Sulphate) CALBIOCHEM
Cell line Type      Source 
COS7 Simian fibroblasts cells American type culture collection (ATCC)
SW-3 Adrenal carcinoma cell line American type culture collection (ATCC)
SKOV-3 Ovarian carcinoma cell line American type culture collection (ATCC)
HepG2 Hepatoblastoma cell line American type culture collection (ATCC)
SF-9 Insect cells American type culture collection (ATCC)
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3.1.10 Standard solutions, buffers and bacterial growth media 
 
Cell culture freezing medium 
DMSO 5% (w/v)
FCS 20% (v/v)
IMDM Ad 100% (v/v) 
Name Supplier
Adjustable air-displacement pipettes Pipetman® Gilson
Autoclave Varioklav®  H+P Labortechnik
Biomax MS films Kodak
Centricon-10 vials Amicon
Centrifuge Biofuge Heraeus
Centrifuge Megafuge 1.0 R Heraeus
Centrifuge Sorvall RC 5B Du Pont
CO2-incubator Hera Cell Heraeus
Confocal laser scanning inverted microscope LSM 510 META  Carl Zeiss
Digital Camera Digital Science DC 120 Zoom  Kodak
Dounce homogenizer B.Braun
ELISA reader BIO-TEK
Exposition chamber Hypercassette™ Amersham Pharmacia 
Hyperfilm ECL Amersham Pharmacia
Incubatior Function Line Heraeus
Laminar flow hood Hera Safe Heraeus
Light microscope Wilovert A Hund
Magnetmixer Variomag® H+P Labortechnik
Microspin column (gel filtration) BIO-RAD
Nitrocellulose membrane Schleicher & Schuell
Nylon membrane (HyBond N) Amersham Pharmacia
PCR machine T3 Thermal cycler Biometra
pH-meter Radiometer
Poly-Prep® Chromatography columns BIO-RAD
Orbital Shaker Forma Scientific
Refrigerator -86C Freezer Forma Scientific
Rotor SS-34  Sorvall
γ-Sintillation counter Packard
Ultracentrifuge L7-55 Beckman
UV-Bank UV Transilluminator 2000 Bio-Rad
Vortex Genie 2 Scientific Industries
XCell II Blot Module NOVEX
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Tween 20 0.5% (v/v)
 
Denaturating lysis buffer 
SDS 4 % (v/v) 
2-Mercaptoethanol 40 % (v/v) 
Glycerol 20 % (v/v) 
Bromphenol blue 0.01 % (w/v) 
 
10x SDS electrophoresis buffer 
Tris-HCl 2.9 % (w/v)
Glycine 14.4 % (w/v)
SDS 1 % (w/v)
 
10x Electrophoresis transfer buffer  
Tris-HCl 2.9 % (w/v)
Glycine 14.4 % (w/v)
pH adjusted to 8.5 
 
10x Western blot electrophoresis transfer buffer  
Tris-HCl 2.9 % (w/v)
Glycine 14.4 % (w/v)
pH adjusted to 8.5 
 
Stacking gel (4%) 
RotiPhorese® Gel 40 (38 % Acrylamid, 2 % Bisacrylamid) 10 % (v/v)
1 M Tris-HCl pH 6,8 12.5 % (v/v) 
10% SDS 1 % (v/v) 
ddH20 Add 100% (v/v)
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For 4 ml stacking gel (4%): 
10 % (w/v) APS 40 µl
TEMED 4 µl
 
Separating gel (12%) 
RotiPhorese® Gel 40 (38 % Acrylamid, 2 % Bisacrylamid) 30 % (v/v)
1 M Tris-HCl pH 8,9 37.5 % (v/v) 
10% SDS 1 % (v/v) 
ddH20 Add 100% (v/v)
 
For 12.5 ml separating gel (12%): 
10 % (w/v) APS 62.5 µl
TEMED 6.25 µl
 
Western blot stripping buffer 
2-Mercaptoethanol 100 mM
Tris-HCl pH 6.7 2.5 mM  
SDS 2% (w/v)
 
Coomassie blue staining solution 
Coomassie blue 0.125% (w/v)
Ethanol 25% (v/v) 
Glacial acetic acid 10% (v/v)
 
Destaining solution 
Glacial acetic acid 10% (v/v)







Guanidinehydrochloride  6 M
Sodium phosphate 0.1 M
Tris-HCl 0.01 M
pH adjusted to 8.0 
 
Elution buffer (Ni-NTA affinity chromatography) 
Urea 8 M
Sodium phosphate 0.1 M
Tris-HCl 0.01 M
pH adjusted to 8.0 
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10x TAE (Tris/acetate/EDTA) electrophoresis buffer 
Tris-HCl 2 M
Glacial acetic acid 1 M
EDTA (pH 8.0) 0.05 M
 




Bromophenol blue 0.05% (w/v)
Xylene cyanol FF 0.05% (w/v)
 





Southern blot neutralization solution 
NaCl 1.5 M





Sodium citrat 0.3 M
 
 
50x Denhardt’s reagent 
Ficoll 400 1% (w/v)
Polyvinylpyrrolidone 1% (w/v)
Bovine serum albumin (BSA) 1% (w/v)
 
 




Add 100µl denaturated salmon sperm (10 mg/ml)/10 ml solution 
 
 








Materials and Methods                                                                        41  
SOB medium 
Tryptone 2 % (w/v)





Medium was prepared and autoclaved without magnesium. Filter sterilized stock solutions 
of 1 M MgCl2 and 1 M MgSO4 were added directly before use.  
 
Transformation buffer 
PIPES  10 mM








Tryptone 1 % (w/v)
Yeast extract 0.5 % (w/v)
NaCl 1 % (w/v)
pH adjusted to 7.5 
 
 
LB Plates with ampicilline 
LB medium  
Bacto-Agar 1.5 % (w/v) 
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3.2 Methods 
 
3.2.1 Cell culture methods 
 
3.2.1.1 Handling of COS-7, SW-13, HepG2, SKOV-3 and SF-9 cells 
 
     Handling and propagation of all cell lines was performed under sterile conditions. All 
solutions were stored at 4oC and pre-warmed to 37oC in a water-bath before using. Cell 
culture media and FCS used for all cell lines were filter-sterilized. COS-7, SW-13, HepG2 
and SKOV-3 cells were grown under standard conditions (37oC, 5% CO2) in Iscove’s 
Modified Eagle’s Medium (IMDM) supplemented with glutamine and 10% heat-inactivated 
fetal bovine serum (FCS) unless indicated otherwise. Spodoptera frugiperda (SF-9) cells 
were grown in SF 900 II medium supplemented with L-glutamine and 10% FCS in a 27oC 
non-humidified incubator. 
  
3.2.1.2 Thawing of cultured cell lines 
  
     The cell line aliquots were stored in 1 ml freezing medium at –80oC or in liquid nitrogen. 
To grow up a cell line, the freeze down was thawed quickly in a 37oC water-bath then 
transferred into a 75 cm2 cell culture flask containing 10 ml medium. After 4 h incubation 
under standard conditions (5% CO2, 37oC for COS-7, HepG2, SW-13 and SKOV-3 cells, 
27oC for SF-9 cells) the medium was changed and the cells were further cultivated. 
 
 3.2.1.3 Maintenance of cells in culture 
 
     All cell lines were grown in a 37oC or 27oC incubator and split in certain ratios depending 
on the stage of confluency and the proliferation rate of each cell line. SF-9 cells were 
detached through gentle tapping and split in several flasks containing fresh medium. The 
amount of medium added to the flask was dependent on its size. For 75 cm2 flasks, 10 ml 
medium were added. The medium was changed every three days. To split COS-7, SW-13 
and SKOV-3 cells, the medium was completely aspirated from the flask and the cells were 
washed briefly with 5-10 ml of PBS to remove traces of FCS. After removing the PBS, 2 ml 
trypsin was added to the flasks and the flasks were then incubated at 37oC. The cells were 
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detached after about 1-2 min with occasional gentle tapping. The trypsin was then 
immediately inactivated by adding 8 ml of serum-containing medium to each flask. This 
suspension was transferred into a 15 ml tube and centrifuged at 1,000 x g for 5 min. The 
supernatant was aspirated and the cell pellet was resuspended in medium and split into 3 to 5 
new flasks.  
 
3.2.1.4 Preparation of freeze-stocks of cultured cell lines 
 
     To freeze cells for long term storage, cells were harvested (at least one 75 cm2 flask of 80 
% confluent cells) and centrifuged at 1,000 x g for 5 minutes. The media was then aspirated 
and cells were resuspended in 1 ml of cell culture freezing medium. The resuspended cell 
solution was transferred to Cryo-tubes and placed at –80oC in an isopropanol-containing cell 
freezing container, which guarantees a slow freezing process. After 24 hours, the tubes were 
transferred to a storage box at –80oC or in liquid nitrogen. 
 
3.2.1.5 Transient and stable transfection of COS-7 and SW-13 cells 
 
     Transfections were performed using JetPEI as tranfection reagents. Prior to transfection, 
cells were grown to 80% confluency in 6-well plates in 2 ml/well IMDM medium containing 
10 % FCS. For one well 3 µg DNA and 12 µl jetPEI (N/P ratio 10) were separately dissolved 
in 100 µl 150 mM NaCl then mixed together. After incubation at room temperature for 1 h, 
the DNA/jetPEI complexes were added to the cells. The medium was changed after 5 h. 
Analysis of transient expression was performed 48 h after transfections, or selection for 
stable integrants started at the same time point by addition of 500 µg/ml (SW-13) or 1000 
µg/ml (COS-7) G418  for 3-4 weeks. 
 
3.2.1.6 Growth assays 
 
3.2.1.6.1 WST-1 proliferation assay 
 
     Experiments to study anchorage-dependent proliferation of SKOV-3 wildtype and 
different clonal derivative cell lines were carried out in a humidified incubator under 
standard conditions. SKOV-3 wildtype cells and stable ribozyme-transfected clonal cell lines 
were plated in quadruplicates into 96 well plates at 200 cells/well and cultivated for at least 
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24 h prior to addition of paclitaxel, doxorubicin, cisplatin or HER-2 inhibitors D-69491 or D-
70166 at the concentrations indicated in the figures. In double-treatment experiments, cells 
were kept on D-69491 or D-70166 for 24 h before paclitaxel was added. Experiments were 
performed with cells grown in IMDM medium supplemented with 10% FCS unless indicated 
otherwise or, upon addition of D-69491 or D-70166, in IMDM / 2% FCS. For growth assays, 
culture media were changed every 24 h; treatment with paclitaxel, doxorubicin or cisplatin 
was performed for 3 - 5 days. Cell numbers were assessed using a colorimetric assay, which 
is based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in 
viable cells, according to the manufacturer’s protocol. The WST-1 reagent was added to a 
final dilution 1:10, and after 1 h incubation, the plate was measured with the ELISA reader at 
450 nm. For comparison of the cell lines, the highest absorbance was defined as 100 % and 
all other values were normalized accordingly. For determination of IC50 values, curve fitting 
was performed using SigmaPlot.  
 
3.2.1.6.2 Soft agar assay 
 
     To study of anchorage-independent growth of COS-7 and SW-13 cells, soft agar assay 
was performed.SW-13 and COS-7 cells, transfected with the empty vector were used as a 
control. Melted, pre-sterilized Bacto-agar (1.2 g in 50 ml dd H2O) was mixed with 150 ml 
IMEM containing 10% FCS, 5 ml 10x IMEM, and kept at 42-44oC. From this 0.6% agar, a 1 
ml bottom layer was poured in 35-mm dishes and allowed to solidify at room temperature. 
The cells were cultured, grown in IMEM medium supplemented with 10% FCS and 
harvested as previously described and suspended in a concentration of about 10,000–20,000 
cells in 0.5 ml culture medium. This cell suspension was mixed with an equal volume of 
culture medium and 1.5 ml of the agar stock solution. This suspension (0.36% agar) was 
layered onto the bottom layer (0.8 ml/dish), and allowed to solidify. The dishes were then 
incubated at 37oC for 14–28 days. Colonies more than 50 µm in diameter were counted 
independently by two blinded investigators. Experiments were carried out in triplicate sets of 
35-mm dishes.  
 
     To study the effects of recombinant FGF-2 and FGF-BP on the proliferation of COS-7 in 
soft agar assay, FGF-2 and FGF-BP were diluted in PBS and were filter-sterilized and 
directly applied onto the solidified top agar.  
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3.2.2 Biochemical and immunochemical methods 
 
3.2.2.1 Immunohistochemistry 
       
     Immunohistochemistry (IHC) studies were performed using a standard streptavidin biotin-
peroxidase complex method. Tissue sections were pretreated 5 min in a microwave oven and 
then deparaffinized in xylene and rehydrated in graded alcohols. After washing with PBST, 
tissue sections were treated in 10 mM citrate buffer, pH 6.0, at 90oC for 15 minutes, for 
antigen retrieval. The slides were then washed with PBST and endogenous peroxidase 
activity was blocked with 0.3% hydrogen peroxide for 30 minutes at 4oC. After washing 
again, nonspecific binding was blocked with 10% normal horse serum in PBST, 2% BSA for 
1 h. The tissue sections were then incubated with a monoclonal anti-FGF-BP antibody (1:100 
in PBST, 2% BSA) at 4oC overnight in humidified chamber. Subsequently, the slides were 
washed with PBST and incubated sequentially with biotinylated anti-mouse antibodies at a 
concentration of 1:150 in PBST, 2% BSA for 1 h at RT and with a streptavidin-peroxidase 
conjugate for 1 h at 37oC and 3,3’-diaminobenzidine as a chromogene substrate. The tissue 
sections were counterstained using hematoxylin and then mounted.  
 
      Tissue microarrays (TMAs) were obtained from G. Sauter (University Hospital 





      80,000 cells were grown on glass slides for at least 24 h under standard conditions prior 
to the experiment. Transient transfections were performed as described above with 1-3 µg 
DNA. The medium was aspirated and slides were washed three times with PBS and fixed in 
3% paraformaldehyde in PBS for 10 min at RT. Cells were washed twice with PBS prior to 
incubation in 10 mM ammonium chloride for 30 min to quench paraformaldehyde-mediated 
autofluorescence, washed in PBS and permeabilized with 0.1% Triton-X100 in PBS for 7 
min at RT. After washing with PBST, cells were blocked with 1% BSA in PBST for 30 min, 
and with 2.5% normal goat serum or normal horse serum in PBST for 5 min at RT. Cells 
were washed again in PBST, and the slides were incubated with rabbit polyclonal anti-FGF2 
(1:1000), mouse monoclonal anti-FGF-BP (1:100) or mouse monoclonal anti-ERGIC (kindly 
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provided by H.-P. Hauri, Basel; 1:1000) antibodies diluted in PBST containing 1% BSA for 
1 h at RT. After washing again, slides were incubated with the appropriate secondary 
antibody (Texas Red-labeled horse anti-mouse, 1:100 in 2.5% horse serum/PBST, or Alexa 
Fluor 488 labeled goat anti-rabbit, 1:100 in 2.5% goat serum/PBST) for 30 min at RT. After 
extensive washing, slides were mounted and analyzed by confocal microscopy. 
 
     To analyze the cellular uptake of exogenous FGF-BP in COS-7 cells, 3 µg recombinant 
FGF-BP was diluted in 300 µl medium and added to the cells at 48 h post transfection. After 
1 h incubation of the cells under standard conditions (37oC, 5% CO2), medium was aspirated 
and cells were washed and fixed using the same procedures. 
 
3.2.2.3 Purification of recombinant FGF-BP  
 
     Recombinant FGF-BP with N-terminal and C-terminal His6 tags was expressed as 
described previously [130] as non-secreted protein in SF-9 insect cells using the BAC-TO-
BAC baculovirus expression system (Life Technologies, Bethesda MD). In the context of 
this thesis, the recombinant FGF-BP was purified and used to study the cellular uptake of 
exogenous recombinant FGF-BP in COS-7 and SW-13 cells as well as the effects of 
recombinant FGF-BP on proliferation of COS-7 cells in soft agar. 
 
     SF-9 cells were infected with recombinant baculoviruses and harvested 4-6 days after 
infection through tapping and centrifugation at 1000 x g for 5 min. The supernatants were 
used for further infection cycles of newly cultivated SF-9 cells. The pellets were either used 
directly to purify FGF-BP or stored at -20oC. Purification of recombinant FGF-BP was 
performed under denaturating conditions. SF-9 cell pellets were resuspended in 15 ml lysis 
buffer and incubated at 4oC for 20 min prior to sonication (5 bursts, 10 sec each), treatment 
with a Dounce homogenizer and centrifugation at 10,000 x g for 15 min. The supernatant 
was loaded onto 0.5 ml Ni-NTA sepharose equilibrated with lysis buffer, and the loaded resin 
was washed with 5 ml lysis buffer and with 5 ml washing buffer at pH 8.0, 6.3 and 5.9, 
respectively. Elution was performed with 0.5 ml of the same buffer at pH 4.0, the eluate was 
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3.2.2.4 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting 
             
      Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is used to 
separate complex protein mixtures by their molecular size. The standard Laemmli method 
[302] is applied for discontinuous gel electrophoresis under denaturing conditions in the 
presence of SDS. Western blotting (immunoblotting) is applied to identify specific proteins 
(antigens) recognized by polyclonal or monoclonal antibodies. After separation by SDS-
PAGE, the proteins are electrically transferred onto nitrocellulose membranes. The 
transferred proteins are bound to the surface of the membrane providing access for 
immunodetection reagents. All remaining binding sites are blocked by immersing the 
membrane in a solution containing either a protein or a detergent-based blocking agent. After 
probing with the primary antibody, the membrane is washed and the antigen is identified by 
detection with a secondary horseradish peroxidase-conjugated anti-IgG antibodies. 
Visualization of the antigen/antibody complex is performed by enhanced chemiluminescence 
using sensitive light-films. Experimental details for the antibodies used are listed in Table 1. 
 
     To analyze the expression of FGF-BP-CFP fusion protein in COS-7 cells by Western 
blotting, 100,000 cells were grown in 6-wells for at least 24 h under standard conditions. 
Transient transfections were performed as described above with 3 µg DNA. At 48 h post 
transfection, cells were lysed by addition of 200 µl denaturating lysis buffer and boiled for 5 
min. After centrifugation at 13,000 rpm for 5 min, 20 µl supernatant was separated by SDS-
PAGE (200V, 35 min). Proteins were transferred onto nitrocellulose membranes for 45 min 
at 25 V. Membranes were blocked for 1 h in TBST containing 5% BSA or milk, washed and 
probed at 4oC overnight with dilutions of antibodies listed in table 1. The blots were then 
washed in TBST and incubated with a 1:2000 dilution of donkey anti-rabbit or anti-mouse 
secondary antibody coupled to horseradish peroxidase for 1 h at RT. After additional 
washing in TBST bound antibody was visualized using the enhanced chemiluminescence 
reagents system from Amersham.  
 
     To examine the expression of recombinant FGF-BP in SF-9 cells, 25µl of eluate was 
mixed with 8µl denaturating lysis buffer and denaturated at 100oC for 5 min. Western 
blotting was performed as described above. 
     For analysis of apoptosis-relevant proteins or of the phosphorylation of downstream signal 
transduction proteins, SKOV-3 wildtype and RzB-8 cells were grown in 6-wells over at least 
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48 h. At 40–50 % confluency, cells were treated with paclitaxel or rViscumin in normal 
media for 24 h or as indicated in the texts and in the figures. After removal of the media, 
cells were immediately lysed by addition of 200 µl denaturating lysis buffer, scraped, 
sonicated and boiled for 5 min. After centrifugation, 20µl supernatant was subjected to SDS-
PAGE and Western blotting using appropriate antibodies as described above. To control for 
the amounts of detected proteins, blots were stripped in stripping buffer for 2 h at 65°C and 
reprobed with antibodies recognizing the unphosphorylated proteins or β-actin. Films were 
scanned using the Kodak Electrophoresis and Documentation System 120 which quantifies 
intensities of bands in arbitrary units. 
 
Table 1: Antibodies, appropriate working dilutions and blocking solutions 
 




Anti-GFP 5% milk/TBST 5% milk/TBST 
1:100 
TBST 
Anti-FGF-BP 3% BSA/TBST 3%BSA/TBST 
1:100 
TBST 
Anti-phospho p38 5% milk/TBST 5% milk/TBST 
1:1000 
TBST 





5% milk/TBST 5% milk/TBST 
1:1000 
TBST 





5% milk/TBST 5% milk/TBST 
1:1000 
TBST 
Anti-SAPK/JNK 5% milk/TBST 5 % BSA/TBST 
1:1000 
TBST 








Anti-bcl-2 5% milk/TBST 5% milk/TBST 
1:400 
TBST 
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3.2.2.5 Dot blotting 
 
     0.2 µg FGF-2 or BSA were dotted onto a nitrocellulose membrane. The membrane was 
incubated in 5% dry milk solution in TBST for 1 h to block non-specific protein binding, 
washed 3×5 min in TBST and incubated with FGF-BP solution (0.2 µg/ml in TBST) at 4°C 
overnight. After washing with TBST, the membrane was incubated with incubated with the 
dilution of anti-FGF-BP antibody (1:100 in 3% BSA/TBST) for 2 h at RT. The membrane 
was then washed in TBST and incubated with a 1:2000 dilution of donkey anti-mouse 
secondary antibody coupled to horseradish peroxidase for 1 h at RT. After additional 
washing in TBST, bound antibody was visualized as described above in Western blotting 
procedures.  
 
3.2.2.6 Protein staining with Coomassie brillant blue 
 
     To stain with Coomassie immediately after completion of electrophoresis, gels were 
soaked in Coomasie blue solution for 30-60 min with shaking. Gels were destained with the 
destaining solution until bands became visible, then soaked in drying solution for 30 min and 
put in a drying frame between two pieces of cellophane for preservation. 
  
3.2.2.7 [125I]-labeling of FGF-BP and rViscumin 
 
         [125I]-labeling of FGF-BP and rViscumin was performed using N-chloro-p-
toluenesulfonamide (Chloramin T). 10 µg recombinant FGF-BP or 100 µg rViscumin  was 
diluted in 80 µl 200 mM Na-phosphate buffer (pH 8.2) prior to addition of 500 µCi 125I 
iodine and 40 µl Chloramin T (1 mg/ml). After 5 min incubation at room temperature, 12 µl 
200 mM DTT was added and labeled FGF-BP or rViscumin were purified by gel filtration. 
 
3.2.2.8 Analysis of cellular uptake of [125I]-FGF-BP in COS-7 and SW-13 cells through  
            subcellular fractionation  
 
     100,000 cells were grown in 6-wells for at least 24 h under standard conditions. COS-7 
cells were transiently transfected as described above with 3 µg DNA (pRC/CMV empty 
vector or FGF-2 expression vector). At 48 h post transfection, 30µl [125I]-FGF-BP (5,000 
cpm)/well was added to the cells. After 1 h incubation under standard conditions (5% CO2, 
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37oC), the medium were aspirated and cells were washed three times with PBS. The cells 
were then fractionated by differential centrifugation. 1 ml of 0.25 M sucrose/well was added 
to the cells and the cells were carefully scraped and homogenized. The resulting homogenate 
was transferred into tubes and centrifuged at 600 x g for 10 min at 4oC to yield the nuclear 
(NUC) fraction. The pellet was washed three times with PBS and measured in a γ-
scintillation counter. The supernatant was first measured in a γ-scintillation counter and then 
centrifuged at 100,000 x g for 2 h at 4oC to obtain mitochondrial and microsomal (MIT and 
MIC) fractions. The resulting pellet was washed once with PBS and measured in a γ-
scintillation counter. 
 
3.2.2.9 Analysis of cellular rViscumin binding/uptake 
 
     For rViscumin binding/uptake studies, 2 µg [125I]-rViscumin (550,000 cpm) in 300 µl 
medium was added to 20,000 cells/well prior to incubation at 37oC/5% CO2 for the time 
points indicated. Supernatants were aspirated, cells were washed three times with PBS and 
lysed in 200 µl 1 % SDS. Lysates were measured in a γ-scintillation counter or 25 µl was 
subjected to non-reducing SDS-PAGE and the gel was autoradiographed overnight using 
Biomax MS films. Films were scanned using the Kodak Electrophoresis and Documentation 
System 120 which quantitates intensities of bands in arbitrary units. In all experiments, wells 
without cells were treated in the same way and served as negative control for nonspecific 
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3.2.3 Molecular biological methods 
 
3.2.3.1 Polymerase chain reaction (PCR) 
 
    The fragments were amplified in a 100 µl total reaction volume using primers and 
template DNAs as listed in table 2. The mixtures were prepared on ice by addition of the 
reagents in the following order: 
 
Master-Mix 1 
DNA (template) ~0,5 µg 
10 mM dATP 2 µl
10 mM dTTP 2 µl
10 mM dCTP 2 µl
10 mM dGTP 2 µl
10 pmol/µl forward primer 3 µl
10 pmol/µl reverse primer 3 µl




10x reaction buffer with 50 mM MgCl2  10 µl
dd H2O 39 µl
Taq polymerase 1 µl
 
 
     To start the PCR, master mix 1 and 2 were combined, and PCR vial was immediately 
transferred into the thermocycler and PCR was performed under the following conditions:  
 
3 min 94oC 
 
30 sec 94oC 
                      30 sec 54oC    (35 cycles) 
90 sec 72oC 
 
6 min 72oC 
 
     PCR products were analysed on a 1% agarose gel and visualized by ethidium bromide 
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Table 2: Constructs, primers and templates 
  
Generation of the FGF-BP-CFP constructs 
Constructs Forward primer Reverse primer DNA (Template) 
FGF-BP-CFP full 
length (1- 234) 



































Full length FGF-BP 
    
Generation of FGF-BP deletion mutants 
FGF-BP full length FGF-BP_2_f FGF-BP_2_r Full length FGF-BP 
BP-N-215 (1-215) BP-N215_2_f BP-N215_2_r Full length FGF-BP 
BP-N-150 (1-150) BP-N150_2_f BP-N150_2_r Full length FGF-BP 
BP-N-99 (1-99) BP-N99_2_f BP-N99_2_r Full length FGF-BP 
BP-C-91 (91-234) BP-C91_2_f BP-C91_2_r BP-C-91-CFP 
BP-C-146(146-234) BP-C146_2_f BP-C146_2_r BP-C-146-CFP 
    
Generation of FGF-2-YFP construct 
FGF-2-YFP 
(18 kDa) 
FGF-2_1_f FGF-2_1_r pET15b FGF2 
    
Generation of FGF-2 (18 kDa) 
FGF-2 (18 kDa) FGF-2_2_f FGF-2_2_r pET15b FGF2 
 
 
3.2.3.2 Electrophoretic separation of DNA fragments in agarose gels 
 
     For the analysis and purification of DNA fragments of different sizes horizontal agarose 
gel electrophoresis was performed. For preparation of the gel, the appropriate amount of 
agarose dissolved in 200 ml 1x TAE buffer was boiled in the microwave oven and after 
cooling down to 60oC, ethidium bromide was added to reach an end concentration of 0.5 
µg/ml. Agarose solution was poured into a gel chamber and combs with appropriate pocket 
size were inserted. After solidification, the gel was transferred into an electrophoresis 
chamber filled with 1x TAE buffer. The samples were mixed with the appropriate volume of 
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DNA loading buffer and pipetted into gel pockets. The electrophoresis was performed at 90 
V. DNA fragments were visualized by ethidium bromide intercalation under UV light. 
 
3.2.3.3 Phenol-chloroform extraction of DNA 
 
     The extraction of DNA with a mixture of phenol/chloroform/isoamylalcohol (25:24:1) 
and chlorophorm/isoamylalcohol (24:1) is a standard method for the removal of proteins 
from nucleic acid preparations. The purification was performed as follows:  
 
     An equal volume of phenol mixture was added to the DNA solution, mixed well and 
centrifuged for 5 min at 13,000 rpm. The upper DNA containing phase was carefully pipetted 
into a new vial. In order to remove the rest of phenol, it was mixed with the same volume of 
chlorophorm/isoamylalcohol mixture. After mixing and centrifugation at 13,000 rpm for 5 
min the upper phase was again pipetted in a new vial. 
     
      Precipitation of DNA was performed by adding 2-2.5 volumes ethanol and 1/10 volume 3 
M potassium acetate pH 5.0 to the extracted DNA solution. Samples were incubated for 5 
min at RT. After centrifugation at 13,000 rpm for 10 min at 4oC, the DNA pellet was washed 
with 70% ethanol and the precipitate was dried in the air at RT. The dried pellet was 
dissolved in sterile water. Purity and concentration of DNA was determined by measuring the 
absorbance at 260 and 280 nm against water.  
 
3.2.3.4 Linearization of the expression vectors and restriction digest of PCR products 
 
 
     For cloning of the FGF-BP-CFP fusion proteins, plasmids and PCR products were 
digested using restriction endonucleases listed in the table 3 The restriction was carried out in 
a total volume of 20 µl, containing the plasmid DNA or PCR products, and 5-10 U of every 
restriction endonuclease. To start the reaction, the components were mixed with the 
restriction endonucleases being added last and the reaction was incubated at 37oC for 1 hour 
to allow the enzymes to work at optimal conditions. Then, 1µl of the sample was loaded on a 
DNA gel for electrophoresis. Samples were run on the gel with a 1 kb DNA marker at 90 V 
for 30 min. The gel was checked under an UV light for a correct, complete digest.  
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Table 3: Restriction endnucleases used to digest plasmids and PCR products 
 
FGF-BP-CFP fusion proteins 
PCR products/Vector Restriction endonucleases 
FGF-BP-CFP EcoRI and XhoI 
BP-N-215-CFP EcoRI and XhoI 
BP-N-150-CFP EcoRI and XhoI 
BP-N-99-CFP EcoRI and XhoI 
BP-C-91-CFP NotI and XhoI 
BP-C-146-CFP NotI and XhoI 
A derivative pcDNA 3.1-based plasmid containing CFP EcoRI and XhoI 
A derivative pcDNA 3.1-based plasmid containing CFP 
and the N-terminal signal peptide of FGF-BP  
NotI and XhoI 
  
FGF-BP deletion mutants 
PCR products/Vector Restriction endonucleases 
FGF-BP HindIII and XbaI 
BP-N-215 HindIII and XbaI 
BP-N-150 HindIII and XbaI 
BP-N-99 HindIII and XbaI 
BP-C-91 HindIII and XbaI 
BP-C-146 HindIII and XbaI 
pRC/CMV expression plasmid HindIII and XbaI 
  
FGF-2-YFP fusion protein 
PCR products/Vector Restriction endonucleases 
FGF-2-YFP HindIII / EcoRI 
A derivative pcDNA 3.1-based plasmid containing YFP HindIII / EcoRI 
  
FGF-2 without fusion protein 
PCR products/Vector Restriction endonucleases 
FGF-2 HindIII / XbaI 
pRC/CMV expression plasmid HindIII / XbaI 
 
 
3.2.3.5 Dephosphorylation of digested DNA 
 
     After the digestion with restriction enzymes, the vector was dephosphorylated by Shrimp 
alkaline phosphatase (SAP) to remove the phosphate group at 5’-end and thus to prevent self 
ligation of the vector. 2 Units SAP were mixed with 4µl 10x SAP buffer and 35µl sterile 
water. The mixture was added to the 20µl sample after digestion and incubated 10 min at 
37ºC.  Then, to inactivate SAP, the sample was incubated at 65oC for 5 min.  
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3.2.3.6 DNA isolation from agarose gel 
 
     For isolation of DNA fragments from agarose gels, the DNA was separated by gel 
electrophoresis in 0.7% agarose gels at 90 V and visualized by ethidium bromide staining 
under UV light. The appropriate DNA bands were excised under UV light and transferred 
into an eppendorf vial with a very small opening created with a scalpel. The vial was inserted 
in another larger tube and centrifuged at 13,000 rpm, until sufficient liquid was collected in 




     The typical ligation reaction was carried out in a total volume of 10 µl containing vector 
and insert DNA (molar ratio vector : insert was approx. 1:5), 1/10 volume of 10x T4 ligase 
buffer and 3 U of T4 Ligase. The ligation was performed at room temperature for 4 h or at 
16°C overnight. 
 
3.2.3.8 Preparation of chemically competent Escherichia coli cells 
 
     To prepare chemically competent E.coli cells, the DH5α strain was used. Cells were 
plated on an LB-agar plate and incubated overnight at 37°C. Next day, a single colony of 
approximately 2 mm in diameter was transferred into 250 ml SOB medium and the flask was 
incubated at 18°C with 180 rpm shaking for 2-3 days until the as cell density of ~0.6 OD600nm 
was reached. The flask was kept on ice for 10 min and then, to harvest the cells, a 
centrifugation at 2500 x g and 4°C for 10 min was performed. The pelleted cells were 
resuspended in 80 ml ice-cold transformation buffer and incubated for another 10 min on ice. 
A second centrifugation was carried out as described above. The pellet was then resuspended 
in 18.6 ml ice-cold transformation buffer and 1.4 ml DMSO was added slowly with gentle 
stirring to the final concentration of 7% (v/v). After 10 min incubation on ice, cells were 
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3.2.3.9 Transformation of chemically competent Escherichia coli cells 
 
      An eppendorf vial containing 100 µl frozen chemically competent E.coli in 
transformation buffer was thawed on ice, 1 µl of a typical ligation reaction or 50 ng plasmid 
DNA (up to 10 µl) was added and the vial was kept on ice for other 30 min. After “heat 
shock” at 42°C for 90 seconds, the vial was placed on ice for 2 min and then 300 µl LB 
medium were added. The cells were incubated at 37°C with shaking for 1 h and then spread 
on an LB-agar plate containing 100 µg/ml ampicilline prior to incubation at 37°C overnight. 
The next day, positive colonies were analyzed and propagated.  
 
3.2.3.10 Bacterial culture 
 
     E.coli cells were cultivated in LB liquid medium at 37oC with shaking with 240 rpm. For 
selection and cultivation of transformed cells, 100 µg/ml ampicilline was added to the 
medium. To start a new culture, cells from glycerol stocks were used. 
 
3.2.3.11 Preparation of the glycerol stocks 
 
     Exponentially growing cultures from E.coli cells were mixed with 0.25 volumes of 80% 
sterilized glycerol and immediately kept at -80oC. 
 
3.2.3.12 Colony lift and Southern blotting 
 
3.2.3.12.1 Bacterial colony transfer 
   
     This methodology was chosen to define a clone of interest via hybridization experiments. 
The agar plates containing the subclone colonies were placed next to an open flame to 
minimize aerosol contamination. A nylon membrane was then carefully placed onto the agar 
surface and slightly pressed by using a sterile glass spatula. It is important to mark the 
orientation on the membrane itself and on the plate. 
 
     The membranes were then transferred into a Petri dish containing Whatman paper, 
covered with a small volume of denaturation solution, for 8 min. Two neutralization steps (8 
min each) followed in Petri dishes containing Whatman paper soaked in neutralization 
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solution. In the last step, the membrane was briefly submersed into a 2x SSC solution to 
remove the cell debris. The damp membrane was then crosslinked through either UV light 
for 2 min or heat exposure at 80°C for 2 h. 
 
3.2.3.12.2 Southern blotting 
 
     Southern blotting was used to analyze DNA from agarose gel. The transfer was performed 
as described in Sambrook/Fritsch/Maniatis laboratory manual. 
 
     Upon completion of electrophoresis, a gel picture was taken with a ruler to facilitate the 
size determination of hybridization signals afterwards. Before transfer, the upper corner of 
the gel was cut for orientation. The gel was flipped and placed on one layer of soaked 
Whatman paper on a glass plate. The Whatman paper reaches into a container filled with 20x 
SSC solution. A gel size nylon transfer membrane was put onto the gel and covered with two 
fitting and 20x SSC-soaked Whatman papers. A stack of fitting paper towels was put on top. 
Adding weights helps to evenly distribute pressure to the gel. The transfer was performed 
overnight.  
 
3.2.3.12.3 Radioactive Labeling of Nucleic Acids  
 
      Radioactive nucleotides were used to perform Random Primed Labeling or to label 
oligonucleotides  
 
Random Primed Labeling for colony lift 
     Random Primed Labeling was performed by incorporation of radioactive nucleotides 
using the RediprimeTM II kit provided by Amersham Pharmacia Biotech. In this kit, the 
concentration of dCTP is 20-fold lower the concentration of the other nucleotides to ensure 
the incorporation of radioactive α-32P dCTP into the newly synthesized DNA. 
 
     60 ng double stranded DNA were mixed with sterile H2O up to a final volume of 45 µl 
and then denatured for 5 min at 95°C. The denatured DNA was then transferred into the 
reaction vial provided in the kit. 5 µl α-32P dCTP was added and the solution was mixed, by 
pipetting it up and down about 10 times, followed by incubation at 37°C for 30 min. To 
remove remaining free nucleotides, the mix was loaded onto a prepared gel permeation 
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chromatography column (Microspin columns). Finally, the specific activity of the probe was 
measured in a scintillation counter.  
 
Labeling of oligonucleotides 
     In order to detect complementary DNA sequence (FGF-BP deletion mutants and FGFR1), 
e.g. on a blot, radioactively labeled oligonucleotides were used as probes. 
 
     The labeling reaction was performed in a volume of 20 µl containing 1 µl PNKinase 
(PN=polynucleotide), 2 µl 10x PNKinase buffer, 20 pmole oligonucleotide and 50 µCi γ-32P 
ATP. The enzyme was added last and the sample was incubated for 30 min at 37oC. 
 
3.2.3.12.4 Hybridization with labeled DNA  
 
     The membrane containing the crosslinked DNA was carefully rolled and inserted into a 
hybridization tube, the surface with the nucleic acids facing inwards. Approximately 10 ml 
prehybridization solution was added and the tube was incubated in a hybridization oven for at 
least two hours at 42°C. After the prehybridization, the radioactive probe was added and the 
membrane was incubated overnight under the same temperature conditions. 
 
3.2.3.12.5 Washing of membranes  
  
     Both membranes were washed in the same way. First the radioactive hybridization 
solution was transferred into a tube and stored for possible further use at -20oC. Then, the 
membranes were washed twice with ~15 ml 2x SSC/0.1% SDS for 15 min at 42°C. After 
discarding the washing solution, autoradiography of radioactive membranes was performed. 
 
3.2.3.12.6 Autoradiography of radioactive membranes  
 
     The membranes were taken out of their hybridization tubes and sealed into plastic foil. 
After checking the activity, the sealed membranes were put into a KODAK film cassette and 
exposed to Biomax MS films at -80°C for a time depending on the activity of the probe. In 
these studies exposure times ranged from 20 min to 2 days. 
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3.2.3.13 DNA Plasmid Purification  
 
      DNA plasmids were purified for purposes of analytical restriction digests, sequencing, 
cloning and generation of probes. The plasmid purification was achieved by using Qiagen 
QIAprep Mini-prep Kit for plasmid screening of transformed bacterial colonies and 
NUCLEOBOND Midi-prep Kit for purification of larger amounts of DNA for sequencing 
and generation of probes. 
 
3.2.3.13.1 Qiagen Mini-prep DNA plasmid isolation  
 
     5 ml LB medium containing 100 µg/ml ampicilline was inoculated with bacterial cells and 
incubated overnight at 37oC. The cultured cells were centrifuged at 3,000 x g for 10 min in 
order to form a bacterial cell pellet. The medium was aspirated and the pellet was 
resuspended in 250 µl buffer P1, containing RNase A, and transferred into a fresh tube. For 
alkaline cell lysis 250 µl buffer P2 was added and mixed with the solution by gently 
inverting the tube. The lysis reaction, which solubilizes the phospholipids and proteins of the 
cell membrane and denatures the chromosomal and plasmid DNA, was allowed to proceed 
for 5 min. Then, 350 µl buffer N3 was added for neutralization purposes. To avoid any 
localized precipitation, the solution was mixed immediately after the addition of buffer. The 
sample was centrifuged at 3,000 x g for 15 min with the cell debris and SDS precipitate 
forming a pellet. The supernatant, containing the plasmid DNA was then transferred to a 
QIAprep spin column and centrifuged at 3000 x g for 1 min. The silica-gel membrane 
ensures a selective absorption of plasmid DNA in high salt buffer. To wash the column salt 
contaminants, 750 µl buffer PE were added and the column was centrifuged for 1 min at 
3000 x g. To elute plasmid DNA, the column was placed on a clean microfuge tube and 50µl 
H2O were added in the center of the column. After waiting for 3 min the column was 
centrifuged at 3000g for 1 min. Due to the low salt concentration of the H2O, the plasmid 
DNA was eluted from the column and collected. The DNA yield was defined by 
spectrophotometry. 
 
3.2.3.13.2 NUCLEOBOND Midi-prep DNA plasmid isolation 
 
     The plasmid DNA purification principle using the NUCLEOBOND Midi-prep kit is 
similar to the process of the Qiagen Mini-prep. Bacterial cells were incubated in 250 ml LB  
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medium, containing 100 µg/ml ampicilline overnight at 37oC. To harvest the bacterial cells, 
the culture was centrifuged at 5,000 x g for 15 minutes. All traces of supernatant were 
removed and the bacterial cell pellet was resuspended in 4 ml buffer S1 containing RNase. 
The suspension was transferred into a fresh tube and 4 ml of buffer S2 was added. The 
solution was mixed and incubated at RT for 5 min. Next, 4 ml buffer S3 was added and 
immediately mixed with the solution. The sample was incubated on ice for 5 min and then 
centrifuged at 12,000 x g for 30 min at 4oC. Meanwhile, AX 100 columns were equilibrated 
by applying 2.4 ml buffer N2 onto the column and allowing it to elute by gravity flow. The 
supernatant from the centrifugation was immediately removed, applied to the equilibrated 
column and allowed to enter a resign by gravity flow. Subsequently, the column was washed 
twice with 5 ml buffer N3. Addition of 5 ml buffer N5 onto the column eluted the plasmid 
DNA. The DNA then was precipitated by adding 3.6 ml isopropanol. The sample was mixed 
and subsequently centrifuged at 15,000 x g for 30 min at 4oC. The supernatant was decanted 
and the DNA pellet was washed with 70% ethanol and centrifuged at 15,000 x g for 10 min. 
The supernatant was aspirated and the pellet was air-dried for 5-10 min. The plasmid DNA 
was dissolved in 50-100 µl H2O and the concentration was determined. 
  
 
3.2.3.14 DNA Sequencing 
 
     DNA sequencing was done by commercial sequencing (MWG Biotech, Ebersberg). 
 
3.2.3.15 Preparation of total RNA from SW-13 and COS-7 cells 
 
     RNAs from SW-13 and COS-7 cells were prepared by using peqGOLD TriFastTM reagent 
as described by the manufacturer (PEQLAB, Erlangen). After growth of cells in a culture 
flask to 80% confluency, the culture medium was discarded, and the cells were resuspended 
in 2 ml ice-cold peqGOLD TriFastTM and incubated at RT for 5 min. Afterwards, 200 µl 
chloroform/ml peqGOLD TriFastTM reagent was added, vials were vigorously mixed and 
centrifuged at 13,000 rpm for 10 min at 4°C. The organic phase including the protein-
containing interphase was discarded. Total RNA was precipitated by adding 0.5 ml 2-
propanol to the aqueous phase. After centrifugation at high speed for 30 min at 4°C, the 
pellet was washed twice with 70% ethanol. The dried pellet was resuspended in 30 µl DEPC-
treated ddH2O. 
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Diethylpyrocarbonate (DEPC) treatment of water 
     200 µl of DEPC was added to 100 ml of ddH2O, stirred vigorously to emulsify DEPC in 




      RT-PCR was performed with 2 µg denatured RNA using recombinant Transcriptor 
Reverse Transcriptase as described by the manufacturer (Roche, Mannheim, Germany). The 
cDNA product (2 µl) was amplified in a 50 µl final volume containing 5 µl 10x PCR buffer 
without Mg2+, 3 µl 25 mM MgCl2, 0.2 mM dNTPs, 10 pmol of each primer listed in table 4 
and 0.5 µl Taq polymerase for 35 cycles under the following conditions:  
 
3 min 94oC 
 
30 sec 94oC 
                      30 sec 52oC    (35 cycles) 
90 sec 72oC 
 
6 min 72oC 
 




Table 4: Primers for cDNA amplification 
 
FGF-BP deletion mutants 
Construct (cDNA) Forward primer Reverse primer 
FGF-BP FGF-BP_2_f FGF-BP_2_r 
BP-N-215 BP-N215_2_f BP-N215_2_r 
BP-N-150 BP-N150_2_f BP-N150_2_r 
BP-N-99 BP-N99_2_f BP-N99_2_r 
BP-C-91 FGF-BP_2_f FGF-BP_2_r 
BP-C-146 FGF-BP_2_f FGF-BP_2_r 
   
FGFR1  
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3.2.4 Confocal laser-scanning microscopy 
 
     Confocal imaging of COS-7 and SW-13 cells was performed with a confocal laser 
scanning inverted microscope LSM 510 META (Carl Zeiss GmbH, Germany). To analyze 
the cells by confocal microscopy, 80,000 cells were grown on glass slides for at least 24 h 
under standard conditions prior to the experiment. Transient transfections were performed as 
described above using 1-3 µg DNA. After 48 h, the medium was aspirated and slides were 
washed with PBS. The cells were either fixed as described above or analyzed directly by 
confocal microscopy using a Plan-Apochromat 63x/1.4 Oil lens. For detection of different 
fluorescent dyes used in this study, the appropriate microscope settings was used as indicated 
in table 5. 
 
Table 5: Microscopy configuration 
 
Fluorescent dyes Laser lines used for excitation Filters used for detection of 
the emmision 
Microscopy configuration for detection of a single fluorescent dye 
CFP 458 nm line of Argon laser 475 nm long pass filter 
YFP 514 nm line of Argon laser 530 nm long pass filter 
Alexa Flour 488 nm line of Argon laser 505 nm long pass filter 
Texas red 543 nm line of HeNe laser 560 nm long pass filter 
   
Microscopy configuration for parallel detection of CFP/YFP  
CFP 458 nm line of Argon laser BP 475–525 nm band pass filter
YFP 514 nm line of Argon laser BP 530–600 nm band pass filter
   
Microscopy configuration for parallel detection of CFP/Texas red 
CFP 458 nm line of Argon laser BP 475–525 nm band pass filter
Texas red 543 nm line of HeNe laser 560 nm long pass filter 
   
Microscopy configuration for parallel detection of YFP/Texas red 
YFP 514 nm line of Argon laser BP 530–600 nm band pass filter
Texas red 543 nm line of HeNe laser 560 nm long pass filter 
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4 RESULTS 
 
4.1 The fibroblast growth factor-binding protein (FGF-BP) in ovarian  
      carcinomas 
 
4.1.1 Characterization of the monoclonal anti-human FGF-BP antibody 
 
     The specificity and sensitivity of the FGF-BP antibody used in the immunohistochemical 
studies is very important in order to produce reliable results regarding the expression of FGF-
BP in nonmalignant and malignant ovarian tissues. First, this monoclonal antibody was 
characterized by Western blotting (Fig. 7 a). Recombinant FGF-BP with N-terminal and C-
terminal His6 tags was expressed as non-secreted protein in SF-9 insect cells using the BAC-
TO-BAC baculovirus expression system [130], and partially purified under denaturating 
conditions. Western blotting analysis using the monoclonal anti-human FGF-BP antibody 
revealed a single band of FGF-BP (~30 kDa) and showed very low background (Fig. 7 a). 
 
     To further analyze the usefulness of the anti-FGF-BP antibody in immunohistochemistry, 
stainings of prostate carcinoma sections with already established FGF-BP overexpression 
were performed. As negative control, the primary antibody was replaced by the dilution 
buffer (2% BSA in TBST, Fig. 7 b). In contrast to negative controls, which showed no 
immunopositivity, strong brown color was observed in the cytosol of glandular epithelial 
cells of prostate carcinoma tissues, confirming the specificity and sensitivity of the anti-






















Fig. 7 Determination of specificity and sensitivity of the monoclonal anti-human FGF-BP antibody by 
Western blotting and immunohistochemistry. 
A) Identification of a single band of recombinant FGF-BP by Western blotting using the monoclonal anti-
human FGF-BP antibody. B) Immunohistochemical analysis of prostate carcinomas tissues using anti-FGF-BP 
antibody. While negative controls (a) showed no brown signals, FGF-BP specific staining was strong in the 
cytoplasm of glandular epithelial cells of prostate carcinoma (b), confirming previous data on the expression of 
FGF-BP in prostate carcinomas [303]. These results demonstrate the sensitivity and specificity of the 
monoclonal anti-human FGF-BP antibody. 
 
 
4.1.2 FGF-BP overexpression in human ovarian carcinoma 
 
     Immunohistochemistry was used in the context of this thesis to examine the expression 
status of FGF-BP in 28 normal ovaries and 123 ovarian carcinomas by tissue microarrays. 
Informative tissue microarray (TMA) results were observed in 26 of 28 normal ovarian 
tissues and in 106 of 114 ovarian carcinomas. The lost samples were considered as non-
informative samples and not included in the current data compilation.  
 
      In the evaluation of FGF-BP IHC staining in different ovarian tissue samples, expression 
of FGF-BP in nonmalignant and malignant tissues was observed primarily as cytoplasmic 
immunopositivity (Fig. 8 e and f). Because the IHC conditions for all tissues in the TMA 
sections were identical, semiquantitative scoring criteria for IHC evaluation were used in 
which the staining intensities were evaluated from 0 to 4 (negative = 0, weak = 1, moderate = 
2, strong = 3, and very strong = 4). IHC results were recorded independently by two blinded 
investigators.  
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     The expression pattern of FGF-BP in epithelial cells from different ovarian tissues was 
heterogeneous, with different staining intensities. Because the FGF-BP expression in all 
normal ovarian tissues was negative (0) or weak (1) (Fig. 8 a and b), staining intensities 0-2 
were interpreted as normal expression of FGF-BP, whereas values 3-4 were interpreted as 
overexpression of this protein (Fig. 8 c and d). Using this rating, overexpression of FGF-BP 
was detected in 43 of 106 informative ovarian carcinomas (40%) (Table 6). In contrast, the 
normal ovarian tissues did not show overexpression of FGF-BP. 
 
Table 6: The expression of FGF-BP in normal ovaries and in ovarian carcinomas  
FGF-BP: No. of tissue samples (%) Tissue type No. of samples with 
informative results Normal expression Overexpression 
Normal ovary 26 26 (100%) 0 (0%) 
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Fig. 8 Expression of FGF-BP in ovarian tissues. 
A) The expression pattern of FGF-BP in different ovarian tissues was heterogeneous, with different staining 
intensities.  a and b represent the staining intensity of normal ovarian tissues, which was 0 (a) or 1 (b). In 
contrast, in ovarian carcinomas the FGF-BP IHC staining ranged from 1-4 and 40% of samples showed 
staining intensity 3 (c) or 4 (d). Positive expression of FGF-BP in nonmalignant (e) and malignant tissues (f) 
was observed primarily as a cytoplasmic pattern. B) Graphic presentation of the mean of staining intensities of 
normal and malignant ovarian tissues (Mean +/- SD). In ovarian carcinomas, the mean of staining intensities 
was ~3 fold higher compared to normal ovarian tissues. IHC results were obtained independently by two 
blinded investigators.  
 
 
4.2 Mechanism of FGF-BP action 
 
4.2.1 Subcellular distribution of FGF-BP in COS-7 and SKOV-3 cells 
 
     To gain insight into the cellular functions of FGF-BP, an expression vector for full length 
FGF-BP-CFP was constructed by fusing CFP to the C-terminus of FGF-BP (Fig. 9 a). For the 
analysis of the subcellular localization of this FGF-BP-CFP fusion protein in COS-7 and 
SKOV-3 cells by confocal microscopy, cells were grown on coverslips 24 h under standard 
conditions prior to the transient transfection with the FGF-BP-CFP expression vector. At 48 
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h post transfection, the medium was aspirated and substituted by phosphate buffered saline 
(PBS), and the cells were analyzed by confocal microscopy without fixation. Detection of the 
fluorescence of CFP showed that FGF-BP-CFP was diffusely localized in the cytoplasm in 
both cell lines. Interestingly, strong fluorescence in the Golgi region as well as in vesicular 
elements concentrated in the Golgi area was seen (Fig. 9 c). 
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Fig. 9 Subcellular localization of FGF-BP-CFP in COS-7 and SKOV-3 cells. 
A) Schematic diagram of CFP-tagged full length FGF-BP. FGF-BP-CFP was constructed by fusing CFP to the 
C-terminus of full length FGF-BP. Numbers listed above refer to amino acids. COS-7 cells were transiently 
transfected with FGF-CFP expression vector. After 48 h, the cells were either lysed and subjected to SDS-
PAGE and Western blot using anti-GFP antibodies (B) or analyzed by confocal microscopy (C). Western blot 
analysis demonstrated the expression of FGF-BP-CFP in transfected COS-7 cells (~52 kDa). Confocal 
microscopy analysis showed the cytoplasmic localization of FGF-BP-CFP, with strong fluoresence in Golgi 
area in both cell lines COS-7 and SKOV-3 (C).  
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4.2.2 FGF-BP colocalization with ERGIC in COS-7 cells 
 
     FGF-BP is a secretory protein since it contains a classical N-terminal signal peptide. The 
newly synthesized secretory proteins undergo folding and post-translational modification 
reactions before becoming competent to be transported out of the endoplasmic reticulum 
(ER) [304-306]. Transport along this pathway occurs via an intermediate compartment called 
ER-Golgi intermediate compartment (ERGIC). The observed fluorescence pattern of FGF-
BP-CFP in Golgi area suggested the presence of FGF-BP in the ERGIC. Therefore, the 
colocalization of FGF-BP-CFP with the ERGIC-specific protein was analyzed in COS-7 
cells. COS-7 cells were transiently transfected with FGF-BP-CFP expression vector and 
fixed at 48 h post transfection. By means of indirect immunoflouresence, the ERGIC marker  
 





          
Fig. 10 Colocalization of FGF-BP-CFP with ERGIC-53 in COS-7 cells. 
By indirect immunofluorescence, ERGIC was detected using mouse monoclonal anti-ERGIC antibodies in 
FGF-BP-CFP-expressing COS-7 cells. Texas red conjugated anti-mouse antibodies were used to visualize the 
primary antibody. The fluorescence of CFP (red) and Texas red (blue) was detected using the appropriate 
microscope configuration for parallel detection of CFP and Texas red. Confocal images of COS-7 cells 
expressing FGF-BP-CFP revealed colocalization of FGF-BP-CFP with ERGIC-53. The arrows indicate the 
colocalization of both proteins in the same cells. Note that there are FGF-BP-negative cells since COS-7 cells 
were transiently transfected with FGF-BP-CFP expression vector.  
 
Results                                                                          70  
protein ERGIC-53 was detected using mouse monoclonal anti-ERGIC and Texas Red-
conjugated anti-mouse antibodies. Double labeling of cells for FGF-BP and ERGIC-53 
showed colocalization of both proteins (Fig. 10). 
 
 
4.2.3 Translocation of FGF-BP into the nucleus upon Coexpression of FGF-BP with 
         FGF-2 
            
      FGF-2 is considered the best characterized binding partner for FGF-BP. To study the 
effects of the interaction of FGF-2 with FGF-BP on the subcellular distribution of both 
proteins in COS-7 cells, changes in their subcellular localization upon coexpression were 
examined. These experiments were carried out using the 18 kDa isoform of FGF-2. 
 
      In the first set of experiments, an expression vector for FGF-2-YFP was constructed by 
fusing YFP to the C-terminus of FGF-2. COS-7 cells were transiently transfected with the 
FGF-2-YFP expression vector and the fluorescence of YFP was detected after 48 h by 
confocal microscopy. Confocal images revealed a primarily nuclear localization of FGF-2 in 
COS-7 cells (Fig. 11 a). Fluorescence in the cytoplasm could be observed to some extent 
(Fig. 11 a). 
 
      Next, COS-7 cells were transiently cotransfected with FGF-BP-CFP and FGF-2 
expression vectors and analyzed by confocal laser scanning microscopy at 48 h post 
transfection. While cytoplasmic localization of FGF-BP as well as localization to ERGIC 
were observed in cells transfected only with the FGF-BP-CFP construct (Fig. 11 b), confocal 
microscopy revealed a nuclear localization of FGF-BP-CFP upon coexpression with non 
labeled FGF-2 (Fig. 11 c), indicating translocation of FGF-BP into the nucleus. 
 
Results                                                                          71  









                        
Fig. 11 Upon coexpression with nuclear FGF-2, cytoplasmic FGF-BP is localized in nucleus in COS-7  
cells. 
A) Nuclear localization of FGF-2-YFP fusion protein (green) in COS-7 cells was detected by confocal 
microscopy analysis. Very strong YFP fluorescence was detectable in the nucleoli.  YFP fluorescence in the 
cytoplasm was very weak compared to nucleus. B) Confocal images of COS-7 cells transfected only with FGF-
BP-CFP construct revealed cytoplasmic localization of FGF-BP (red) in COS-7 cells. C) Coexpression of FGF-
BP-CFP (red) with non labeled FGF-2 translocates FGF-BP into the nucleus in COS-7 cells. Localization of 
FGF-BP to ERGIC was not seen upon coexpression with FGF-2.  
 
 
4.2.4 Colocalization of FGF-BP with FGF-2 in the nucleus 
 
     The previous findings regarding the translocation of FGF-BP into the nucleus upon 
coexpression with FGF-2 indicated that FGF-BP probably interacts with FGF-2 in the 
nucleus. To examine the subcellular colocalization of FGF-2 and FGF-BP, COS-7 cells were 
transiently cotransfected with both constructs of fusion proteins (FGF-BP-CFP and FGF-2-
YFP) and analyzed by confocal laser scanning microscopy. 
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     In this analysis the adjustment and setting of microscopy configuration is very important 
in order to ensure complete separation of fluorescence of CFP and YFP during the 
simultaneous recording of both proteins. The microscopy configuration in the first set of 
images (Fig. 12 a) showed a complete separation of CFP and YFP fluorescence as seen by 
comparison of two cells which were either transfected with FGF-BP-CFP or with FGF-2-
YFP expression vectors. Furthermore, different subcellular localization of FGF-BP 
(cytoplasmic) and FGF-2 (nuclear) was seen in these cells. These settings of configuration 
were chosen as standard for all images taken for parallel detection of CFP and YFP in the 
experiments in this thesis.  
 
     As expected from the previous data of translocation of FGF-BP into the nucleus upon 
coexpression of FGF-2, colocalization of both proteins in the nucleus was demonstrated in 
cells coexpressing both fusion proteins (Fig. 12 b). 
                   
                    







Fig. 12 FGF-BP colocalizes with FGF-2 in the nucleus. 
COS-7 cells were transienly cotransfected with FGF-BP-CFP and FGF-2-YFP expression vectors. At 48 h post 
transfection, medium was aspirated and substituted by phosphate buffered saline (PBS) and the cells were 
analyzed by confocal microscopy without fixation. A) Control for the microscopy configuration for parallel 
detection of CFP (red) and YFP (green) fusion proteins. Complete separation of CFP and YFP fluorescence 
was achieved. B) Colocalization of FGF-BP (red) and FGF-2 (green) was seen in cells coexpressing FGF-BP-
CFP and FGF-2-YFP. Colocalization is indicated by the yellow color resulting from the overlay of red and 
green. 
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4.2.5 Subcellular distribution of FGF-BP and FGF-2 in SW-13 cells 
 
     The non-tumorigenic adrenal carcinoma cell line SW-13 expresses constitutively high 
levels of FGF-2 but no FGF-BP [88]. Due to these properties of SW-13 cells, several studies 
have been performed using this cell line to analyze the role of FGF-BP in the activation of 
FGF-2. In the context of this thesis, SW-13 cells were chosen to study the subcellular 
localization of FGF-BP as well as the effects of interaction of FGF-2 with FGF-BP on cell 
proliferation. 
 
      SW-13 cells were transiently transfected with the FGF-BP-CFP construct and were 
analyzed by confocal microscopy after 48 h. In contrast to COS-7 cells, FGF-BP was 
localized primarily in the nucleus of SW-13 cells (Fig. 13 a). Furthermore, localization of 
FGF-BP to ERGIC was not seen. 
 
     To address the question if the subcellular localization of endogenous FGF-2 is similar to 
the subcellular distribution of FGF-BP-CFP, immunofluorescence was performed to detect 
the endogenous FGF-2 in SW-13 cells. SW-13 cells were grown on coverslips for 24 h prior 
to fixation. Endogenous FGF-2 was detected using anti-FGF-2 antibodies and Alexa Fluor 
488-conjugated anti-rabbit antibodies. A mainly nuclear localization of endogenous FGF-2 
was observed with some additional cytoplasmic staining (Fig. 13 b). These results indicate 
that both proteins are colocalized in the nucleus.  
 




Overlay Phase contrastB) FGF-2 (Immunofluorescence) Alexa Fluor Channel
FGF-2     
 
Fig. 13 Subcellular localization of FGF-BP and FGF-2 in SW-13 cells. 
A) SW-13 cells were transfected with the FGF-BP-CFP expression vector. At 48 h post transfection, cells were 
analyzed by confocal microscopy without fixation. Confocal images revealed a nuclear localization of FGF-BP-
CFP (red) in SW-13 cells. B) Endogenous FGF-2 (green) localizes primarily to the nucleus in SW-13 cells as 
detected by immunofluorescence. 
 
 
4.2.6 Generation of C- and N-terminal truncations of FGF-BP 
 
     The data regarding the colocalization of FGF-BP and FGF-2 as well as the translocation 
of FGF-BP into the nucleus of COS-7 cells upon coexpression with FGF-2 led to the 
question of which segment(s) of FGF-BP are responsible for the interaction with FGF-2 and 
nuclear translocation. This analysis was performed through the generation of C- or N-
terminally truncated FGF-BP constructs as CFP-tagged proteins. This included the targeted 
disruption of certain disulfide bonds in the full length FGF-BP. The N-terminal signal 
sequence for secretion, however, was attached to all N-terminally truncated FGF-BP 
constructs (Fig. 14). 
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BP-N-99 (1 – 99)
FGF-BP  full length
(1 – 234)
BP-N-215 (1 – 215)
BP-N-150 (1 – 150)
BP-C-91 (91 – 234)
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Fig. 14 Schematic representation of the CFP-tagged full length as well as C- and N-terminally truncated 
FGF-BP constructs. 
Human full length FGF-BP is 234 residues long. 10 cysteine residues (represented by the symbol S), which are 
positionally conserved in human, mouse and bovine FGF-BP, form 5 disulfide bonds. The light grey color (left) 
represents the N-terminal signal peptide and the dark grey color (right) represents the CFP (239 amino acids), 
which is attached to all constructs. The strategy of the construction of C- and N-terminal truncations of FGF-
BP is based on the disruption of certain disulfide bonds of the full length FGF-BP. Numbers listed left in the 
figure refer to amino acids.   
  
 
4.2.7 Colocalization and interaction of various truncated FGF-BP constructs with FGF- 
         2 in COS-7 cells 
 
      In the first set of experiments, the subcellular localization of various CFP-tagged FGF-BP 
constructs in COS-7 cells was studied (Fig. 15 a). COS-7 cells were grown on coverslips and 
transfected after 24 h with expression vectors containing various truncated FGF-BP 
constructs. At 48 h post transfection, the subcellular localization of various mutants of FGF-
BP was analyzed by confocal microscopy. Similar to the subcellular localization of full 
length FGF-BP, all CFP-tagged FGF-BP constructs showed a primarily cytoplasmic 
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localization with a particularly strong fluorescence in Golgi area, indicating the localization 
of various mutants of FGF-BP to ERGIC (Fig. 15 a). 
 
      Next, the colocalization of various truncated FGF-BP mutants with FGF-2 in COS-7 cells 
was examined. COS-7 cells were cotransfected with FGF-2-YFP and various CFP-tagged 
FGF-BP constructs. After 48 h, the fluorescence of CFP and YFP fusion proteins was 
detected by confocal microscopy using the appropriate microscope settings for parallel 
detection of CFP and YFP fluorescence (Fig. 15 b). Upon coexpression with FGF-2, all C-
terminally truncated FGF-BP mutants still showed a nuclear colocalization with FGF-2 (Fig. 
15 b). In contrast, translocation of FGF-BP into the nucleus was not seen in the case of N-









Fig. 15 (next page) Nuclear colocalization and interaction of FGF-BP with FGF-2 is lost upon N-terminal 
truncations of FGF-BP. 
A) Subcellular localization of various CFP-tagged FGF-BP constructs (red) upon transfection of COS-7 cells 
with the corresponding FGF-BP-CFP expression vector. Confocal images revealed for all C- and N-terminally 
truncated FGF-BP mutants a cytoplasmic distribution similar to full length FGF-BP. B) Fluorescence of CFP 
(red) and YFP (green) as detected by confocal microscopy after cotransfection of COS-7 cells with FGF-2-YFP 
and various CFP-tagged mutants of FGF-BP expression vectors. Overlay of red and green color results in 
yellow indicating the colocalization of FGF-2 and C-terminally truncated FGF-BP mutants in nucleus of COS-
7 cells. BP-N-99 construct, which represents the smallest C-terminally truncated mutant of FGF-BP, showed 
upon coexpression with FGF-2 more CFP fluorescence in cytoplasm of COS-7 cells as compared to other C-
terminally truncated FGF-BP constructs, indicating reduced interaction with FGF-2 and decreased nuclear 
translocation. N-terminally truncated FGF-BP constructs (BP-C-91 and BP-C-146) did not show translocation 
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4.2.8 Colony formation of stably transfected SW-13 clones in soft agar 
 
     The adrenal carcinoma cell line SW-13 expresses high levels of FGF-2 and lacks 
expression of the FGF-BP. Furthermore, it has been demonstrated that the stable transfection 
of SW-13 cells with an FGF-BP expression vector or the addition of FGF-2 induces the 
colony formation in soft agar [88,307]. For this reason, the analysis of the biological 
significance of the interaction of various FGF-BP truncations with FGF-2 was performed 
using this cell line. First, constructs of C- and N-terminally truncated forms of FGF-BP 
without fusion partner were generated and cloned into pRC/CMV expression plasmids. SW-
13 cells were then stably transfected with these constructs or with the empty vector (CMV) 
as a control.  
 
      Soft agar assays were performed to study the anchorage-independent growth of these 
stably transfected SW-13 cell lines. As expected, full length FGF-BP-transfected SW-13 
cells grew more large colonies compared to the control cells stably transfected with the 
empty vector (CMV) (Fig. 16 lower panel). The similar tendency was also seen in SW-13 
clones stably transfected with C-terminally truncated FGF-BP constructs. In contrast, no 
induction of soft agar colony formation was observed in SW-13 cells stably transfected with 
constructs containing N-terminal truncations of FGF-BP.  
 
 





























































Fig. 16 FGF-BP-mediated stimulation of soft agar colony formation is lost upon the N-terminal truncation 
of FGF-BP. 
A) Stable expression of various C- and N-terminally truncated FGF-BP mutants in SW-13 cells as determined 
by RT-PCR and PCR-Southern hybridization (upper panel). Total RNA was extracted from cells. The presence 
of mRNA coding for various truncations of FGF-BP was determined by RT-PCR and PCR-Southern 
hybridization analysis with the specific primers described in Materials and Methods. The evaluation of the 
induction of colony formation of SW-13 transfectants in soft agar is shown in the lower panel. Colonies >50 µm 
were counted after 3 weeks. SW-13 cells transfected with full length or C-terminally truncated FGF-BP 
constructs grew more colonies >50 µm compared to control cells (CMV). No induction of soft agar colony 
formation was observed in SW-13 cells stably transfected with constructs containing N-terminal truncations of 




4.2.9 Effects of FGF-BP and truncated mutants on growth of COS-7 cells in soft agar 
 
     To further explore the biological effects of various truncations of FGF-BP in another cell 
line, COS-7 cells were stably transfected with expression plasmids containing C- and N-
terminally truncated FGF-BP constructs without fusion partner, and anchorage-independent 
growth assays were performed using these various mass transfected COS-7 cells. After 3 
weeks, colonies >50 µm were counted. Surprisingly, and in contrast to SW-13 cells, 
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anchorage-independent cell growth assays revealed an inhibitory effect of full length FGF-
BP on the growth of COS-7 cells in soft agar (Fig. 17, lower panel), resulting in a decreased 
colony formation compared to control cells. Formation of large colonies was observed in 
COS-7 cells stably transfected with C- and N-terminally truncated FGF-BP constructs, 
indicating that the loss of the C- and N-terminus of FGF-BP abolished the inhibitory effect of 

































































Fig. 17 C- and N-terminal truncations of FGF-BP abolish the inhibitory effects of FGF-BP on colony 
formation of COS-7 cells in soft agar.  
A) Determination of mRNA expression of various C- and N-terminally truncated FGF-BP mutants in stably 
transfected COS-7 cells by RT-PCR (upper panel). Total RNA was extracted from cells. The presence of mRNA 
coding for various truncations of FGF-BP was determined by RT-PCR with the specific primers described in 
Materials and Methods. Soft agar assays show the inhibitory effects of full length FGF-BP on growth of COS-7 
cells in soft agar (lower panel). Full length FGF-BP-transfected COS-7 cells grew small colonies compared to 
control cells transfected with empty vector (CMV). The FGF-BP-mediated inhibition of the growth of COS-7 
cells in soft agar was lost upon C- and N-terminal truncation of FGF-BP. Colony numbers of control cells 
(CMV) were set to 1.0.  B) Representative images of counted soft agar colonies. 
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4.2.10 Inhibition of stimulating effects of FGF-2 on cell growth by endogenously  
           expressed FGF-BP 
 
      For characterization of the biological activity of FGF-BP resulting from its interaction 
with FGF-2, effects of transient transfection of FGF-BP on soft agar colony formation of 
FGF-2-expressing COS-7 cells on cell growth in soft agar were studied.  
 
      First, it was examined if COS-7 cells express FGF receptors. RT-PCR was performed 
using mRNA from COS-7 cells or human hepatoblastoma cell line HepG2 (as a positive 
control [308]) in the presence of FGFR1-specific primers. A predicted 530-nucleotide 
fragment was determined by agarose gel electrophoresis in both cell lines, indicating the 
expression of FGFR1 mRNA in COS-7 cells (Fig. 18 a). This result was further confirmed by 
PCR-Southern hybridization analysis (Fig. 18 a).  
 
     In further experiments, an FGF-2 construct without fusion partner was generated and 
stably expressed in COS-7 cells. Control cells stably transfected with empty vector (CMV) 
and FGF-2 transfectants were transiently transfected with empty vector (CMV) or FGF-BP 
expression vectors. At 4 h post transfection, a soft agar assay was performed. After 3 weeks, 
colonies >50 µm were counted. Induction of colony formation in soft agar was shown in the 
stably FGF-2-transfected COS-7 cells, which were transiently transfected with CMV, 
compared to control transfectants (Fig. 18 b). In contrast to stably FGF-BP-transfected COS-
7 cells, which grew small colonies compared to control cells transfected with the empty 
vector as shown above (Fig. 17), transient transfection of COS-7 cells with FGF-BP 
expression vector had no effect on colony formation of COS-7 cells in soft agar. However, 
the transient expression of FGF-BP in FGF2-expressing COS-7 cells resulted in a decreased 
colony formation compared to (FGF-2/CMV) cells, indicating the reversal of the stimulatory 
activity of FGF-2 expression on colony formation in soft agar (Fig. 18 b). These results 
suggested an FGF-BP-mediated inhibition of the stimulating effects of FGF-2 on growth of 
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Fig. 18 FGF-BP-mediated inhibition of stimulating effects of FGF-2 on colony formation of COS-7 cells in 
soft agar. 
A) Determination of the expression of FGFR1 mRNA by RT-PCR and PCR-Southern hybridization. Total RNA 
was extracted from COS-7 and HepG2 cells (as a positive control) and RT-PCR was performed using specific 
primers described in Materials and Methods. The presence of 530-nucleotide fragment (upper panel), which is 
confirmed by PCR-Southern hybridization (lower panel), demonstrates the expression of FGFR1 in COS-7 
cells. B) Soft agar colony formation of FGF-2-expressing and control COS-7 cells. Cells were transiently 
transfected as indicated in the figure and at 4 h post transfection soft agar assays were performed. After 3 
weeks, colonies were counted. The number of colonies >50 µm of (FGF-2/CMV) cells was >2 fold higher than 
control cells (CMV/CMV), indicating the stimulating effects of FGF-2 on growth of COS-7 cells in soft agar. 
Transient transfection of stably CMV-transfected COS-78 cells with FGF-BP expression vector had no effect on 
induction of colony formation compared to control cells (CMV/CMV). In contrast, coexpression of FGF-BP 
with FGF-2 reversed the stimulatory effects of FGF-2 on colony formation of FGF-2-expressing COS-7 cells. 
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4.2.11 Effect of exogenous recombinant FGF-BP on FGF-2-mediated stimulation of 
           colony formation in soft agar 
 
      Previous results demonstrated the inhibitory effects of endogenously expressed FGF-BP 
on the colony formation of FGF-2-expressing COS-7 cells in soft agar. To test if the 
inhibitory effects can also be mediated by exogenously added FGF-BP, recombinant FGF-BP 
was used. This His-tagged recombinant protein was expressed as a non-secreted protein in 
SF-9 insect cells using BAC-TO-BAC baculovirus expression system [130] and purified 
under denaturating conditions. Gel electrophoresis with Coomassie staining, as well as 
Western blotting, revealed a single band (~30 kDa) only in infected SF-9 insect cells, 
demonstrating the expression of recombinant FGF-BP (Fig. 19 a). 
     
     To provide evidence that the recombinant purified FGF-BP can interact with FGF-2 and is 
biologically active, 0.2 µg recombinant FGF-2 or BSA (as a negative control) were dotted 
onto a nitrocellulose membrane and a Dot blot was performed as described in Materials and 
Methods. The Dot blot analysis showed only a signal, where FGF-2 was dotted onto the 
nitrocellulose membrane, indicating the binding of recombinant FGF-BP to FGF-2 (Fig. 19 
b). 
 
      In further experiments, soft agar assays were performed using FGF-2-expressing COS-7 
cells. COS-7 cells stably transfected with empty vector were used as a control. To analyze 
the effects of exogenously added recombinant FGF-BP on the colony formation induced by 
endogenously expressed or exogenously added FGF-2, recombinant FGF-BP and FGF-2 
were directly applied onto the solidified agar as indicated in the figure (Fig. 19 c) at final 
concentrations of 5.0 µg/ml and 1.0 ng/ml, respectively. As expected, colony formation was 
stimulated by the addition of FGF-2 to control cells, which was comparable to the induction 
of colony formation in FGF-2-expressing COS-7 cells (Fig. 19 c). While, addition of 
exogenous FGF-BP did not result in any effects on colony formation of control cells, it 
inhibited the FGF-2-induced colony formation in FGF-2-expressing COS-7 cells. These 












































































Fig. 19 Growth-inhibitory effects of exogenously added FGF-BP. 
A) Gel electrophoresis with Coomassie staining, as well as Western blotting, revealed a single band (~30 kDa) 
in eluates containing purified FGF-BP expressed in SF-9 insect cells. The control represents non infected SF-9 
insect cells, which were subjected to the same FGF-BP purification procedure. B) Detection of the binding of 
recombinant FGF-BP to FGF-2 by Dot blot analysis. 0.2 µg FGF-2 or BSA were dotted onto a nitrocellulose 
membrane and a Dot blot was performed as described in Materials and Methods using anti-FGF-BP antibody. 
C) Induction of colony formation in control and FGF-2-expressing COS-7 cells in soft agar upon exogenous 
addition of recombinant FGF-BP or FGF-2. 0.5 µg/ml recombinant FGF-BP or 0.1 ng/ml FGF-2 were added 
immediately onto the solidified agar as indicated in the figure. After 3 weeks, colonies >50 µm were counted. 
Exogenously added FGF-2 stimulated the colony formation of control cells, indicating the cell growth-inducing 
bioactivity of FGF-2. This effect was comparable to the effect of endogenously expressed FGF-2. Addition of 
FGF-BP abolished the effects on stimulation of colony formation in FGF-2-expressing COS-7 cells, indicating 
the dependence of the growth inhibitory effects of FGF-BP on its interaction with FGF-2. In contrast, FGF-BP 
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4.2.12 Cellular uptake of exogenous FGF-BP is dependent on the expression of and  
            interaction with FGF-2 
 
     The translocation of FGF-BP into the nucleus of COS-7 cells upon coexpression with 
FGF-2 (Fig. 11) as well as the inhibitory effects of FGF-BP on cell growth in soft agar 
mediated by exogenously added recombinant FGF-BP (Fig. 19), suggests the uptake of FGF-
BP into the cells after its secretion to exert its biological activity. Furthermore, nuclear 
colocalization of FGF-BP and FGF-2 (Fig. 12) indicates that the uptake of FGF-BP may be 
dependent on the interaction of FGF-BP with FGF-2.  
 
     To study the cellular uptake of FGF-BP in COS-7 cells und its dependence on the 
expression of FGF-2, COS-7 cells were transiently transfected with CMV (empty vector) or 
FGF-2 expression vector and at 48 h post transfection, incubated with (5,000 cpm/well) 
[125I]-labeled FGF-BP for 1 h. The cells were then fractionated by differential centrifugation 
as described in Materials and Methods. The nuclear and combined mitochondrial and 
microsomal fractions were measured in a γ-scintillation counter. Radioactivity of both 
fractions obtained from FGF-2-transfected cells was 2 fold higher than the control cells (Fig. 
20 a). 
 
     To confirm the dependence of the cellular uptake of exogenous FGF-BP on its interaction 
with FGF-2, COS-7 cells were transiently transfected with CMV or FGF-2-YFP expression 
vector and incubated with (3 µg/well) recombinant FGF-BP for 1 h and indirect 
immunofluorescence was performed using mouse monoclonal anti-FGF-BP antibodies. The 
primary antibody was visualized with Texas red-conjugated mouse antibodies and the cells 
were analyzed by confocal microscopy using the appropriate microscope settings for parallel 
detection of YFP and Texas red (Fig. 20 b). Texas red fluorescence was only detected in the 
nucleus of FGF-2-YFP-transfected COS-7 cells, which were incubated with the recombinant 
FGF-BP (Fig. 20 b). The nuclear colocalization of FGF-2 and exogenously added FGF-BP in 
these cells demonstrated the dependence of cellular uptake of FGF-BP on its interaction with 
FGF-2 and confirmed previous results regarding the subcellular localization of FGF-BP and 
FGF-2 obtained from the coexpression of both proteins. Texas red fluorescence was not 
detectable in the FGF-2-YFP-negative and FGF-2-YFP-transfected COS-7 cells incubated 
with recombinant FGF-BP or buffer E, respectively (Fig. 20 b). Background fluorescence 
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 Fig. 20 (next page) Dependence of cellular uptake of exogenous recombinant FGF-BP in COS-7 on the 
expression and interaction with FGF-2. 
A) Uptake of [125I]-labeled FGF-BP in COS-7 cells. COS-7 cells were transiently transfected with the CMV or 
the FGF-2 expression vector. At 48 h post transfection, (5,000 cpm/well) [125I]-FGF-BP was added to the cells. 
After washing with PBS, cells were fractioned by differential centrifugation as described in Material and 
Methods. Radioactivity of nuclear and combined mitochondrial and microsomal fractions obtained from FGF-
2-transfected cells was 2 fold higher than the radioactivity of fractions obtained from control cells transfected 
with the empty vector. B) Detection of the cellular uptake of exogenous FGF-BP in COS-7 cells transiently 
transfected with the CMV (a) or the FGF-2-YFP (b and c) expression plasmid by confocal immunofluorescence 
microscopy. COS-7 cells were grown on glass coverslips 24 h before transfection. At 48 h post transfection, 
cells were either incubated with 30 µl (~3 µg) recombinant FGF-BP diluted in 300 medium (a and c) or with 30 
µl buffer E (b) diluted in the same volume of medium for 1 h. The cells were then fixed and immunofluorescence 
was performed using monoclonal mouse anti-FGF-BP antibodies. For visualization of the primary antibody, a 
Texas red-labeled anti-mouse antibody was used. The fluorescence of YFP (green) and Texas red (red) was 
detected by adjustment of microscope configuration for parallel detection of YFP and Texas red. Texas red 
fluorescence was not detectable in the FGF-2-YFP-negative (a) and in the FGF-2-YFP-transfected (b) COS-7 
cells incubated with recombinant FGF-BP or buffer E, respectively. In contrast, confocal images revealed 
colocalization of FGF-BP with FGF-2 in FGF-2-YFP-transfected COS-7 cells (c) incubated with recombinant 
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4.3 Effects of riboyzme-mediated HER-2 downregulation on paclitaxel  
      sensitivity in SKOV-3 cells 
 
4.3.1 Effects of HER-2 phosphotyrosine kinase inhibitors D-69491 and D-70166 on  
         cell proliferation  
 
      Previous studies showed that treatment with the HER-2 inhibitory antibody trastuzumab 
(Herceptin), which downregulates HER-2 on the cell surface and is approved and well 
established for adjuvant therapy of different tumors, results in reduction of cell proliferation 
as well as markedly increased cellular paclitaxel resistance in human SKOV-3 ovarian cancer 
cells (see [243] for details).  
 
     To investigate the effects of HER-2 inhibition on proliferation of SKOV-3 cells by 
another different strategy, HER-2 phosphotyrosine kinase inhibitors D-69491 and D-70166 
(a gift from Baxter Oncology, Frankfurt/Main, Germany) were used. 
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Fig. 21 Reduction of proliferation of SKOV-3 cells by the newly developed HER-2 phosphotyrosine kinase 
inhibitors D-69491 and D-70166. 
Proliferation of SKOV-3 cells (closed circles) was >50 % inhibited upon addition of 1 µM D-69491 (open 
circles) or D-70166 (inverse triangles).  
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      SKOV-3 cells were cultivated for 7 days in the presence of 1 µM D-69491 or D-70166 
and cell numbers were assessed using a colorimetric assay based on the cleavage of the 
tetrazolium salt WST-1 by dehydrogenases in viable cells. Anchorage-dependent 
proliferation experiments revealed a >50 % reduction of cell proliferation upon addition of 1 
µM D-69491 or D-70166 (Fig. 21). 
 
4.3.2 Effects of HER-2 phosphotyrosine kinase inhibitors D-69491 and D-70166 on 
         Cellular paclitaxel resistance  
 
     Next, to study the effects of D-69491- and D-70166-mediated HER-2 inhibition on 
paclitaxel resistance in SKOV-3 cells, cells were treated with 1 µM D-69491or D-70166, or 
left untreated, 24 h prior to the addition of paclitaxel at the concentrations indicated (Fig. 22) 
and numbers of living cells were measured after 3-5 days. Dose-response curves revealed an 
increase in paclitaxel resistance upon pretreatment with D-69491 or D-70166 (Fig. 22). This 
effect was identical for both inhibitors with the IC50 of paclitaxel being shifted from ~5 nM 






































Fig. 22 Effects of the newly developed HER-2 phosphotyrosine kinase inhibitors D-69491 and D-70166 on 
paclitaxel resistance in SKOV-3 cells. 
Treatment of cells with 1 µM D-69491 (open circles) or D-70166 (inverse triangles) 24 h prior to the addition 
of paclitaxel reveals increased paclitaxel resistance upon HER-2 inhibition compared to untreated  cells (closed 
circles).  
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4.3.3 Ribozyme-mediated HER-2 depletion leads to reduced cell proliferation 
 
     To address a possible HER-2 dependence of proliferation and paclitaxel cytotoxicity in a 
third, more detailed approach, various stable isogenic SKOV-3 cell lines with ribozyme-
mediated reduction of HER-2 expression levels were used. In previous studies, SKOV-3 
ovarian carcinoma cells were stably transfected with the ribozyme expression vector RzB 
containing a ribozyme cloned into the pRc/CMV expression plasmid and designed to cleave 
1991 nucleotides downstream of the translation initiation site in the HER-2 mRNA. From the 
mass-transfected cells, clonal derivative cell lines with various degrees of HER-2 depletion 
were generated. The clones were termed RzB-3, RzB-7, RzB-8 and show 19.8 %, 50.0 % and 
12.5 % residual HER-2 protein levels, respectively, as determined by FACS analysis and 
Western blot [309]. 
 
     To study the effects of ribozyme-mediated HER-2 downregulation on cell growth, SKOV-
3 wildtype (with 100 % residual HER-2 expression level) and RzB-8 cells (with 12.5% 
residual HER-2 expression level) were cultivated for 5 days and cell numbers were assessed 
using a colorimetric assay. 
 


































                                 
Fig. 23 Ribozyme-mediated HER-2 downregulation leads to reduced proliferation of SKOV-3 cells. 
In proliferation assays, RzB-8 cells with 12.5% residual HER-2 expression level (open circles) showed a >50% 
decrease in proliferation compared to SKOV-3 wildtype cells (closed circles). 
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      Similar to the previous results based on tyrosine kinase inhibitors D-69491 and D-70166 
(Fig 21) and Herceptin (see [243] for details), ribozyme-mediated HER-2 downregulation led 
to reduction of cell growth. A >50% decreased of proliferation of RzB-8 cells on plastic 
compared to wildtype cells was observed (Fig. 23). 
 
4.3.4 Ribozyme-mediated HER-2 depletion leads to increased resistance towards 
         paclitaxel 
      
     Next, the effects of HER-2 expression levels on paclitaxel sensitivity in the different 
SKOV-3 cell lines wildtype, RzB-7, and RzB-8 were analyzed. Different SKOV-3 cell lines, 
i.e. wildtype, RzB-7, and RzB-8, were treated with paclitaxel at the concentrations indicated 
in the figure (Fig. 24) and numbers of living cells were measured after 3-5 days. In 
agreement with the previous results, ribozyme-mediated reduction of HER-2 expression 
significantly shifted the paclitaxel dose-response curves to the right with a maximum shift in 
the case of the RzB-8 cells (IC50 = 6.0 nM versus 0.9 nM in wildtype cells; Fig. 24, upper 
panel). 
 
4.3.5 Doxorubicin or cisplatin cytotoxicity is independent of HER-2 expression levels  
 
     To further investigate the effects of ribozyme-mediated HER-2 depletion in human 
SKOV-3 ovarian cancer cells on the resistance towards other anticancer drugs with different 
mechanisms of action, doxorubicin (topoisomerase II inhibitor) and cisplatin (intra-DNA 
strand cross-linker) cytotoxicities were analyzed in the clonal derivative cell line RzB-8  
compared to wildtype cells. 
 
      SKOV-3 cell lines with 100% (wildtype) and 12.5% (RzB-8) residual HER-2 expression 
levels were treated with doxorubicin and cisplatin at the concentrations indicated in the 
figure (Fig. 25) and numbers of living cells were determined after 3-5 days. In contrast to 
paclitaxel, cytotoxicities of doxorubicin or cisplatin were independent of cellular HER-2 
levels in SKOV-3 cells as indicated by very similar dose-response curves for wildtype and 








Cell line     HER-2         IC50
level (%)      (nM)
wt 100.0          0.9
RzB-7           50.0          2.0

















































Fig. 24 Effect of HER-2 expression levels on paclitaxel cytotoxicity in SKOV-3 ovarian carcinoma cells. 
SKOV-3 cell lines with different levels of residual HER-2 expression (see table) as determined by FACS 
analysis were analyzed for paclitaxel sensitivity. In proliferation assays, SKOV-3 wildtype cells were highly 
sensitive to paclitaxel treatment (upper panel, closed circles) while cell lines with decreased HER-2 expression 
levels displayed markedly reduced sensitivity (open circles and inverted triangles). Comparison of IC50 values 
(see table) revealed a direct correlation between HER-2 expression levels and paclitaxel sensitivity (‚HER-2 
gene dose effect‘, lower right).  
 
 
    
 









































Fig. 25 Doxorubicin and cisplatin cytotoxicity is independent of HER-2 expression levels.  
SKOV-3 wildtype cells (with 100 % residual HER-2 expression level) and RzB-8 (with 12.5% residual HER-2 
expression level) were treated with doxorubicin and cisplatin at the concentrations indicated. In proliferation 
assays, SKOV-3 cell lines wt and RzB-8 showed comparable sensitivities towards doxorubicin (left) and 
cisplatin (right).  
 
 
4.3.6 Paclitaxel cytotoxicity is dependent on serum concentration 
 
      In previous studies, a decreased proliferation rate of Herceptin-treated SKOV-3 cells 
compared to control cells was demonstrated (see [243] for details). It was also shown that D-
69491- and D-70166-treated cells (Fig. 21) as well as RzB-8 (Fig. 23) have a lower 
proliferation rate than control cells. Furthermore, a decreased paclitaxel sensitivity of SKOV-
3 cells pretreated with Herceptin or D-69491- and D-70166 as well as of RzB-8 was 
observed. In all three cases, it seems that the proliferation rate of the cells play a role in 
paclitaxel sensitivity. To address the correlation between the proliferation rate and paclitaxel 
sensitivity in SKOV-3 cells, dose-response curve under various serum concentrations was 
analyzed.  
 
      The paclitaxel cytotoxicity on SKOV-3 cells was dependent on the FCS concentration. A 
~20-fold or ~200-fold shift of the paclitaxel IC50 was observed in SKOV-3 wildtype cells 
upon the reduction of the FCS concentration from 10 % to 2 % or 0 %, respectively (Fig. 26). 
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Fig. 26 Paclitaxel cytotoxicity in SKOV-3 ovarian carcinoma cells is dependent on the serum concentration. 
Under different FCS concentrations, IC50 values of paclitaxel cytotoxicity on SKOV-3 wt cells varied. It shifted 
to ~20-fold (2 % FCS, inverted triangles) or ~200-fold (0 % FCS, circles) higher paclitaxel concentrations as 




4.3.7 Activation of MAP kinases is dependent on HER-2 expression levels but does not 
        change upon paclitaxel treatment 
 
     Because of the importance of mitogen-activated protein kinases (MAPKs) in signaling 
pathways as well as their implications in a wide array of physiological processes including 
cell growth, differentiation, and apoptosis, they were examined in the context of this thesis. 
The activation of the members of MAPK family (Erk1/Erk2, SAPK/JNK, p38) in SKOV-3 
ovarian carcinoma cells and the dependence of these effects on HER-2 levels as well as 
possible changes in response to paclitaxel treatment were analyzed by Western blotting. 
 
      SKOV-3 wildtype and RzB-8 cells, which show the highest and the lowest HER-2 
expressions levels, respectively, were cultivated for at least 24 h before the direct addition of 
paclitaxel and basal activity of all tested MAP kinases was detected by Western blotting 
already without paclitaxel treatment. While basal p42/44 activation was only ~70 % in RzB-8 
as compared to wildtype cells, the phosphorylation of p38 and of SAPK/JNK was ~1.8-fold 
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and ~5-fold higher in ribozyme-transfected cells, respectively (Fig. 27). However, paclitaxel 
treatment, even at high concentrations (not shown), did not result in statistically significant 
changes in p42/44, SAPK/JNK or p38 phosphorylation in SKOV-3 wildtype or ribozyme-



























































Fig. 27 Activation of MAP kinases is dependent on HER-2 expression levels but does not change upon 
Paclitaxel treatment.  
By Western blotting, SKOV-3 cell lines with 100 % (wt) and 12.5 % (RzB-8) residual HER-2 expression levels 
were assayed for phosphorylated (upper panels) p42/44, p38 and SAPK/JNK after 24 h treatment with 1 nM 
paclitaxel. The bands detected by the antibodies against the respective unphosphorylated proteins (lower 
panels) served as loading control. Bars (mean +/- SEM) show the changes in the ratios of 
phosphorylated/unphosphorylated proteins upon ribozyme-mediated HER-2 deprivation with wt = 1, and 
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4.3.8 Bcl-2 phosphorylation and hyperphosphorylation upon paclitaxel treatment is 
         independent of HER-2 expression levels 
 
      Recently, it was reported that one of the proteins that undergoes phosphorylation in 
paclitaxel treated cells is bcl-2, which is related to apoptosis [264,269,310,311]. In further 
experiments, changes in bcl-2 in response to paclitaxel treatment of different SKOV-3 cells 
were studied. Here, SKOV-3 wildtype cells and RzB-8 were treated with 1 nM paclitaxel for 
24 h, and phosphorylated and unphosphorylated bcl-2 protein in SKOV-3 wildtype and 
ribozyme-transfected cells was analyzed by Western blotting (Fig. 28). Paclitaxel treatment 
induced bcl-2 phosphorylation in both wildtype and RzB-8 cells, which was, however, 
independent of HER-2 expression levels (Fig. 28). 
 





































                                    
Fig. 28 Bcl-2 phosphorylation in SKOV-3 cells upon paclitaxel treatment is independent of HER-2 
expression levels.  
By Western blotting, SKOV-3 cell lines with 100 % (wt) and 12.5 % (RzB-8) residual HER-2 expression levels 
were assayed for bcl-2 after 24 h treatment with 1 nM paclitaxel. The two middle and upper bands represent the 
phosphorylated and hyperphosphorylated bcl-2. Bars (mean +/- SEM) represent ratios of 
phosphorylated/unphosphorylated (lower band) bcl-2 in arbitrary units since in untreated SKOV-3 wt cells the 
phosphorylated bcl-2 was below the limit of detection. The data represent at least three independent 
experiments. 
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4.3.9 Paclitaxel utilizes a caspase-independent pathway of induction of apoptosis  
 
      The caspase family of cysteine proteases play a key role in apoptosis and inflammation 
[312]. They are synthesized as inactive proenzymes that are processed in cells undergoing 
apoptosis by self-proteolysis and/or cleavage by another protease. The processed forms 
consist of large and small subunits which associate to form an active enzyme. The activation 
of caspase-3 and caspase-7, which represent effector caspases of two main pathways of 
induction of apoptosis, upon paclitaxel treatment and its dependence on HER-2 levels was 
examined. After 24 h treatment with 1 nM paclitaxel, procaspase-7 and -3 expression levels 
were assayed. Procaspase-7 levels were higher in HER-2-depleted cells compared to 
wildtype cells and no caspase-7 activation or changes in procaspase-7 levels upon paclitaxel 
treatment were observed (Fig. 29). Levels of procaspase-3 were similar in SKOV-3 wildtype 
and ribozyme-transfected cells and similar to caspase-7, no caspase-3 activation was seen 
(not shown).  
 








































































                                              
Fig. 29 Paclitaxel-mediated apoptosis is independent of caspase-7 and -3 in SKOV-3 cells.  
By Western blotting, SKOV-3 cell lines with 100 % (wt) and 12.5 % (RzB-8) residual HER-2 expression levels 
were assayed for procaspase-7 and procaspase-3 after 24 h treatment with 1 nM paclitaxel. Bars (mean +/- 
SEM) show the changes in the ratios of procaspase-7 or procaspase-3 (upper band)/loading control (lower 
band) upon ribozyme-mediated HER-2 deprivation with wt = 1, and represent at least three independent 
experiments. 
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4.4 Effects of riboyzme-mediated HER-2 downregulation on rViscumin  
      sensitivity in SKOV-3 cells and its underlying cellular events 
 
4.4.1 Ribozyme-mediated HER-2 depletion leads to increased resistance towards 
         rViscumin 
 
      Similar to the effects of Herceptin on paclitaxel sensitivity in SKOV-3 cells, it was 
observed that upon Herceptin treatment, the cellular rViscumin resistance was markedly 
increased in SKOV-3 ovarian carcinoma cells (see [313] for details). 
     
     To confirm that the effect of ribozyme-mediated HER-2 depletion on SKOV-3 sensitivity 
towards rViscumin is identical to the Herceptin effect, the sensitivity of SKOV-3 cell lines 
with various levels of residual HER-2 expression (wildtype, RzB-3, RzB-7, and RzB-8) 
towards rViscumin was examined in the context of this thesis. Different SKOV-3 cell lines 
were treated with rViscumin at the concentrations indicated (Fig. 30) and numbers of living 
cells were measured after 3-5 days. From dose response curves, IC50 values for different 
SKOV-3 cells were evaluated. Interestingly, a ribozyme-mediated >50 % reduction of HER-
2 expression significantly shifted the dose-response curves to the right (Fig. 30, left) with a 
maximum shift in the case of the RzB-8 cells (IC50 = 6.1 x 10-4 µg/ml). More strikingly, when 
comparing the different clonal cell lines with different residual HER-2 levels, a direct 
correlation between HER-2 expression levels and rViscumin sensitivity was observed: >50 % 
reduction of HER-2 expression led to decreased sensitivity of SKOV-3 ovarian carcinoma 
cells (Fig. 30, right and table). Hence, these experiments using HER-2 ribozyme-targeting 
confirm the data on the changes of rViscumin sensitivity upon Herceptin treatment. 
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Fig. 30 Effect of HER-2 expression levels on rViscumin cytotoxicity in SKOV-3 ovarian carcinoma cells. 
SKOV-3 cell lines with various levels of residual HER-2 expression were analyzed by growth assay in presence 
of rViscumin at concentrations indicated in the figure. SKOV-3 cells with high HER-2 expression levels (wt and 
RzB-7) were highly sensitive to rViscumin treatment (closed circles and open inverted triangles) while cell lines 
with >50 % decreased HER-2 expression levels (RzB-3 and RzB-8) displayed markedly reduced sensitivity 
(open circles and inverted triangles). Comparison of IC50 values (table, upper right) revealed a direct 
correlation between HER-2 expression levels and rViscumin sensitivity (‚HER-2 gene dose effect‘, lower right).  
 
 
4.4.2 rViscumin binding and uptake is independent of HER-2 levels  
 
      Binding of rViscumin to tumor cells as well as its cellular uptake is conferred through 
interactions of the B-chain of rViscumin with ‘viscumin receptor’ gangliosides of the 
neolacto series on the surface of tumor cells [288,289]. To address the question if the 
observed HER-2 dependence of rViscumin cytotoxicity is only a result of differential 
rViscumin binding and uptake, SKOV-3 wildtype and various stable isogenic SKOV-3 cell 
lines with ribozyme-mediated reduction of HER-2 expression levels were incubated with 
[125I]-labeled rViscumin, and at different time points the internalized [125I]-rViscumin was 
determined. The comparison between SKOV-3 wildtype and HER-2 depleted cells revealed 
no differences in [125I]-rViscumin binding and internalization over the whole time range 
indicating that this process is independent of cellular HER-2 levels (Fig. 31).  
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 Fig. 31 rViscumin binding and uptake is independent of HER-2 levels in SKOV-3 cells.  
SKOV-3 wildtype and HER-2 depleted cells were incubated with [125I]-labeled rViscumin and at different time 
points analyzed for internalized [125I]-rViscumin. rViscumin uptake was linear for at least 60 min and no 
differences in [125I]-rViscumin binding and internalization between the different cell lines were observed. SDS 
gel electrophoresis of cell lysates revealed a single radioactive band at the expected size confirming the 
integrity of the bound and internalized [125I]-rViscumin (inset). Control: equally treated well without cells.  
 
 
     To confirm the integrity of the bound and internalized [125I]-rViscumin, cell lysates were 
analysed by SDS gel electrophoresis and autoradiography revealed a single radioactive band 
at the expected size which was absent in equally treated wells without cells (Fig. 31, inset). 
Quantitation of the bands by densitometry after 30 min and 60 min again demonstrated the 
absence of differences between the cells, and the comparison between different time points 
confirmed for all four cell lines the equally linear uptake kinetics of [125I]-rViscumin. From 
these experiments, it was concluded that rViscumin binding and uptake is independent of 
HER-2 levels and therefore is not responsible for the observed HER-2 dependence of 
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4.4.3 Activation of members of the MAPK family upon rViscumin treatment under  
         serumfree conditions or in the presence of 10% FCS  
 
     To further elucidate the effects of rViscumin on molecular levels, the activation of the 
members of the mitogen-activated protein kinase (MAPK) family, Erk1/2, SAPK/JNK and 
p38 MAPK, upon rViscumin treatment was examined in SKOV-3 wildtype and RzB-8 cells 
grown under serumfree conditions or in the presence of 10% FCS. Cells were incubated 24 h 
with rViscumin at concentrations indicated in the figure (Fig. 32). In these experiments, 
differences between SKOV-3 wildtype and ribozyme-transfected cells were seen in the basal 
activation of all three signaling pathways as well as in the rViscumin-mediated response. 
Kinases Erk1/Erk2 in SKOV-3 wildtype cells grown in serum-containing media were 
activated by rViscumin in a dose-dependent manner (Fig. 32 a). In contrast, in HER-2-
depleted cells the basal level of Erk1/Erk2 phosphorylation was somewhat lower and no 
Erk1/Erk2 activation upon rViscumin treatment was observed even upon treatment with high 
doses of rViscumin (Fig. 32 a). Under serumfree conditions, in both cell lines basal levels of 
activated Erk1/Erk2 were similar and rViscumin-induced activation was stronger in SKOV-3 
wildtype cells as compared to ribozyme-transfected cells (Fig. 32 b). Since here and in other 
experiments toxic effects of rViscumin under serumfree conditions were observed already at 
5 ng/ml, no higher concentrations were used and decreased Erk1/Erk2 activation in wildtype 
cells treated with 5ng/ml rViscumin may be due to cell death. SAPK/JNK was activated by 
rViscumin in a dose-dependent manner in both wildtype and ribozyme-transfected SKOV-3 
cells grown in serum-contatining media. However, in wildtype cells levels of phosphorylated 
SAPK/JNK were always lower as compared to ribozyme-transfected cells (Fig. 32 c). Under 
serumfree conditions, rViscumin activated SAPK/JNK in a dose-dependent manner while 
SAPK/JNK phosphorylation in ribozyme-transfected cells reached maximum levels already 
at 1 ng/ml rViscumin and was again always higher than in wildtype cells (Fig. 32 d). Basal 
levels of activated SAPK/JNK without rViscumin treatment were below the limit of detection 
in both cell lines. Finally, for p38 activation results very comparable to SAPK/JNK were 
obtained (Fig. 32 e). In cells grown in the presence of serum, again an rViscumin dose-
dependent activation was observed in both cell lines with signals in wildtype cells always 
being below levels in ribozyme-transfected cells. Under serumfree conditions, in both cell 
lines basal levels of p38 were below the limit of detection and maximum p38 
phosphorylation was observed already at very low rViscumin concentrations with again 
ribozyme-transfected cells displaying higher activation (Fig. 32 f)             
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Fig. 32 rViscumin activates MAPK signaling pathways dependent on HER-2 expression levels and 
rViscumin concentrations.  
One representative set of data out of 3 - 6 independent experiments is shown. SKOV-3 wildtype (black bars) and 
ribozyme-transfected cells (RzB-8, grey bars) were treated for 24 h with rViscumin at the concentrations 
indicated under 10% FCS (left) or serumfree (right) conditions. Activation of p42/44 (Erk1/Erk2), SAPK/JNK 
and p38 was determined in Western blots using antibodies specific for phosphorylated proteins (upper panels). 
For loading control, Western blots were probed with antibodies recognizing the unphosphorylated proteins 
(lower panels). Bands were quantitated by densitometry and bar graphs represent the ratio upper/lower bands 
in arbitrary units. 
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4.4.4 rViscumin-mediated bcl-2 downregulation is dependent on HER-2 levels 
 
      To analyze the effects of rViscumin on molecules related to apoptosis, the changes of bcl-
2 upon rViscumin treatment of different SKOV-3 were examined by Western blotting. In 
contrast to paclitaxel, treatment with 10 ng/ml rViscumin did not lead to phosphorylation of 
bcl-2, but resulted in a marked, time-dependent down-regulation of the anti-apoptotic 
molecule bcl-2. Probably due to the limited sensitivity of the bcl-2 Western blot, this effect 
was not observed at 1 ng/ml rViscumin. In ribozyme-transfected cells, basal bcl-2 levels 
were comparable but upon rViscumin treatment the decrease was less profound (Fig. 33). 
 


























     
                                 
Fig. 33 rViscumin-mediated bcl-2 downregulation is dependent on HER-2 expression levels in SKOV-3 cells. 
One representative set of data out of 3 - 6 independent experiments is shown. SKOV-3 wildtype (black bars) and 
ribozyme-transfected cells (RzB-8, grey bars) were treated with 10 ng/ml rViscumin for the time points 
indicated in the figure. Expression of bcl-2 was determined by Western blotting using specific antibodies (upper 
panels) and normalized for equal loading (lower panels). Bands were quantitated by densitometry and bar 
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4.4.5 Caspase-3 and -7 are not involved in rViscumin-induced apoptosis  
 
     To further study the molecular basis of rViscumin-mediated induction of apoptosis in 
SKOV-3 cells, caspases-3 and -7 were chosen since their activation is the earliest cellular 
event to integrate the different apoptotic signals. SKOV-3 wildtype and RzB-8 cell lines were 
treated with 1 ng/ml rViscumin for the time intervals indicated in the figure (Fig. 34) and 
expression of procaspase-3 and -7 was determined by Western blotting. Treatment of SKOV-
3 wildtype cells with 10 ng/ml rViscumin did not result in the activation of caspase-7 or 
caspase-3 (not shown). While, procaspase-7 expression levels were higher in HER-2-
depleted cells compared to wildtype cells, levels of procaspase-3 were similar in SKOV-3 































































Fig. 34 rViscumin induces apoptosis independent of caspase-7 and -3 in SKOV-3 cells.  
One representative set of data out of 3 - 6 independent experiments is shown. SKOV-3 wildtype (black bars) and 
ribozyme-transfected cells (RzB-8, grey bars) were treated with 10 ng/ml rViscumin for the time points 
indicated. Expression of procaspase-7 and -3 was determined by Westeren blotting using specific antibodies 
(upper panels) and normalized for equal loading (lower panels). Bands were quantitated by densitometry and 
bar graphs represent the ratio upper/lower bands in arbitrary units.  
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5 DISCUSSION 
 
     The most lethal type of gynecological cancer in the Western world are ovarian carcinomas 
[295]. Most ovarian cancer patients present with advanced stage disease, and the overall 5-
year survival for these women is less than 30% [314,315]. Although new therapeutic 
approaches have been developed, these survival statistics have remained largely unchanged 
for many years. Clearly, there is a need for better understanding of the molecular 
pathogenesis of ovarian carcinoma in order to identify new biomarkers, which facilitate early 
detection, and new drug targets that will allow the development of more effective anti-cancer 
drugs. 
 
     The overexpression of a number of oncogenes and growth factors play important roles in 
the development of ovarian cancer. The main focus of this thesis lies on the analysis of the 
expression status and cellular functions of two gene products in ovarian carcinomas: the 
fibroblast growth factor-binding protein (FGF-BP) and human epidermal growth factor 
receptor-2 (HER-2). While no data are available on the expression status of FGF-BP in 
ovarian carcinomas, several studies have demonstrated that HER-2 is overexpressed in 
approximately 20-30% of ovarian carcinomas and that overexpression is significantly 
correlated with clinical outcome. 
 
     Previous studies have investigated the response to and expression of FGF-2 in a variety of 
ovarian cancer cell lines. An increase in cell proliferation and FGF-2 mRNA expression was 
observed in several cell lines in response to FGF-2 [316]. Levels of FGF-2 mRNA are also 
significantly higher in the ovarian tumors in patients with stage III and IV ovarian cancer 
when compared with normal ovaries [317]. Most recently, it was found that the entire FGF-2 
cell surface signaling apparatus (FGF-2, biologically active heparan sulphate, and FGFRs) is 
present in the ovarian cancer endothelium [318]. These data and other reports describing the 
activation of extracellular FGF-2 by FGF-BP in different cell lines [88,91], FGF-BP 
overexpression in some tumors [89,90] as well as the broad similarities in the localization of 
FGF-2 and FGF-BP in several tissues, e.g. during mouse embryo development [98] led to the 
analysis of the expression of FGF-BP in normal ovaries and in malignant epithelial 
carcinomas. 
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     In the context of this thesis, an immunohistochemical approach based on tissue 
microarrays stained with a monoclonal anti-human FGF-BP (anti-FGF-BP) antibody specific 
for human FGF-BP was used to determine the expression of FGF-BP in normal ovaries and 
ovarian carcinomas. The staining pattern of FGF-BP in all different ovarian tissues was 
heterogeneous, with different staining intensities. While the FGF-BP expression in normal 
ovarian tissues was negative (0) or weak (1), the FGF-BP IHC staining in ovarian carcinomas 
ranged from weak (1) to strong (4). This heterogeneity of FGF-BP staining in all different 
tissues required to set a cutoff in order to distinguish between normal and overexpression of 
FGF-BP. Hence, staining intensities 0-2 were interpreted as normal expression of FGF-BP, 
while values 3-4 were considered as overexpression. Although no tissues of normal ovaries 
showed the value 2, it was considered as normal expression of FGF-BP to produce reliable 
results regarding the overexpression of FGF-BP in ovarian carcinoma. Using this rating with 
interpretation of value 2 as normal FGF-BP expression, however, rather underestimates the 
percentage of FGF-BP-overexpressing ovarian carcinoma tissues. 
 
      Ovarian carcinoma is a morphologically and biologically heterogeneous disease, and this 
fact has likely contributed to difficulties in defining the molecular alterations associated with 
its development and progression. On the basis of morphological criteria, there are four major 
types of primary ovarian adenocarcinomas (serous, mucinous, endometrioid, and clear cell). 
Although various histological types of ovarian carcinoma presumably originate from the 
ovarian surface epithelium or related cell types such as endometriosis, some studies support 
the notion that these different histological types of ovarian carcinomas likely represent 
distinct disease entities (reviewed by [319,320]). In the TMA used in this thesis it was 
impossible to study the expression of FGF-BP in correlation to different subtypes of ovarian 
carcinomas since the majority of ovarian carcinoma tissues was indistinguishable regarding 
the histological type (data not shown). Furthermore, a putatively mixed histology with 
various subtypes of ovarian carcinoma in one tissue section was observed and data about 
tumor stage and grade were not available. Therefore, in this thesis the main focus was the 
comparison between the expression status of FGF-BP in normal ovarian tissues versus 
ovarian carcinoma tissues. 
 
      Generally, the data in this thesis provide evidence that FGF-BP is upregulated in ovarian 
carcinomas compared to normal ovarian tissues. This provides an excellent starting point for 
the further investigation of the expression status of FGF-BP in different histological subtypes 
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of ovarian carcinoma as well as the regulation of FGF-BP in different tumor stages of 
ovarian cancer.  
 
      Several previous studies described only the role of FGF-BP in the extracellular activation 
of FGF-2 and showed partly contradictory or incomplete data on the mechanism of action of 
FGF-BP. To gain further insight into the molecular mechanism of action of FGF-BP, its 
subcellular localization, cellular functions and effects resulting from the interaction of FGF-
BP with FGF-2 were studied in greater detail in this thesis by means of confocal laser 
scanning microscopy and soft agar assays. 
 
     The advantage of the green fluorescent protein and its spectral variants cyan (CFP) and 
yellow (YFP) lies in its ability to act as an N- or C-terminal protein tag. These fluorescent 
proteins as well as the fusion partner usually retain their functions, and depending on the 
nature of the fusion partner, GFP-related proteins can be directed specifically to different 
intracellular compartments. In this thesis, the advantage of this fusion with GFP and its 
related proteins was taken, which has been proven to be a useful tag for monitoring the 
subcellular distribution and trafficking of various proteins in living cells [321,322]. Hence, 
expression vectors for full length as well as various N- or C-terminally truncated FGF-BP 
mutants were constructed by fusing CFP to the C-terminus. It should be noted that the 
presence of the N-terminal signal peptide in all N-terminally truncated FGF-BP constructs 
was retained and guaranteed the analysis of the role of the N-terminal signal peptide in 
secretion and interaction of various mutants with FGF-2. Thus, the generation of misleading 
results due to the absence of this signal peptide in some truncated mutants was excluded.  
 
      FGF-BP is a soluble secreted protein with an N-terminal signal peptide [32] that 
promotes co- or post-translational import into the endoplasmic reticulum (ER) [323,324]. 
Once translocated into the lumen of the ER, secretory proteins are delivered to the cell 
surface by vesicular transport [325-329]. Transport along the pathway between the 
endoplasmic reticulum and the Golgi apparatus occurs via an intermediate compartment 
called ER-Golgi intermediate compartment (ERGIC). The type I transmembrane protein 
ERGIC-53 is ubiquitously expressed and constitutively cycles between ER and ER-Golgi 
intermediate compartment (ERGIC) [330]. In the ERGIC the protein segregates from 
anterograde-directed protein traffic and returns to the ER largely bypassing the Golgi 
apparatus [331]. The localization of ERGIC, which is described as the first post-ER 
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compartment in which anterograde (to the Golgi) and retrograde (to the ER) traffic separates, 
suggests protein sorting as a major function of ERGIC. In this thesis, it was shown for the 
first time that FGF-BP localizes primarily in cytoplasm and to ERGIC, indicating that FGF-
BP is secreted by a pathway employing ERGIC.  
 
     For the further analysis of the subcellular colocalization of FGF-BP constructs and FGF-2, 
and to study the biological significance of the interaction of various FGF-BP mutants with 
FGF-2, two cell lines were chosen: the normal cell line COS-7 and the adrenal carcinoma cell 
line SW-13. Due to the lack of FGF-BP expression in both cell lines (see Fig. 16 a and [88]), 
COS-7 and SW-13 cells appeared to be a good model to study the biological functions and 
relevance of the interaction of FGF-BP mutants with FGF-2.  
 
     One of the best characterized binding partners of FGF-BP is FGF-2. As described in 
greater detail in the introduction, five isoforms of FGF-2, with molecular weights of 18, 22, 
22.5, 24 and 34 kDa, have been identified, all derived from a single messenger RNA 
(reviewed in [66]). It has been reported that the 18 kDa FGF-2 is primarily a cytosolic 
protein without a signal sequence [68,332,333]. This protein is exported out of the cells by an 
unknown mechanism and stored in the ECM. In contrast, the high molecular weight (HMW) 
isoforms are predominantly located in the nucleus [68,334,335]. It has been shown that NH2-
terminal sequences are required for nuclei localization [66,336-338]. Based on these 
available data on the cytoplasmic localization of 18 kDa FGF-2 and on previous data 
regarding the activation of extracellular FGF-2 by FGF-BP as well as based on the observed 
cytoplasmic distribution of FGF-BP in SKOV-3 and COS-7 cells, 18 kDa FGF-2 was chosen 
to analyze the subcellular colocalization and interaction of FGF-BP constructs with FGF-2. 
 
     Surprisingly, the data in this thesis demonstrated that the expressed 18 kDa FGF-2 is 
primarily localized in the nucleus and clearly enriched in nuclei of COS-7 cells, while 
fluorescence of the fusion protein (FGF-2-YFP) in the cytoplasm was observed only to some 
minor extent. Since YFP does not contain any known nuclear localization sequence (NLS) 
and YFP or CFP alone demonstrates a faint nuclear and cytoplasmic fluorescence (not 
shown), the nuclear localization of the fusion protein represents a property of FGF-2 rather 
than a property of YFP. Recently and in agreement with these results, it was shown by 
confocal microscopy that the nucleus and the cytoplasm are positive for the 18 kDa FGF-2 
expressed as FGF-GFP fusion protein in CHO cells [339]. Furthermore, corneal endothelial 
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cells (CEC) accumulate the 18 kDa in the nucleus during the early stage of cell growth [340] 
and the expressed 18 kDa FGF-2 was directly translocated from the cytoplasmatic synthetic 
site to the nucleus [341]. Others reported that exogenous 18 kDa FGF-2 is internalized via 
high and low-affinity FGF receptors [342-344], and that it is translocated to the nucleus 
[345]. Taken together, the solely subcellular localization of 18 kDa FGF-2 in the cytoplasm 
and extracellular matrix (ECM) may not be accepted as a general rule.  
 
      Since the mechanism of release of the 18 kDa FGF-2 which lacks a signal peptide for 
secretion remains to be elucidated, it is unknown whether the 18 kDa FGF-2 is translocated 
after synthesis directly from cytoplasm to the nucleus or whether it is secreted first, 
internalized later and subsequently translocated to the nuclei. The nuclear localization of the 
18 kDa FGF-2 suggests that the intracellular 18 kDa FGF-2 can be targeted to the nucleus via 
NLS-independent pathways. Alternatively, the existence of another NLS in FGF-2 located 
within the 18 kDa FGF-2 may be responsible for the nuclear localization of 18 kDa FGF-2. 
The last suggestion may explain why the mutagenesis of individual putative nuclear 
localization domains in FGF-1 and FGF-2 has not always prevented nuclear localization 
[346,347].  
 
     Interestingly, upon coexpression with FGF-2 the cytoplasmic FGF-BP was translocated 
into the nucleus of COS-7 cells. In further experiments, the nuclear colocalization of FGF-2 
and FGF-BP was confirmed, suggesting an intracellular function of FGF-BP based on its 
interaction with 18 kDa FGF-2 in the nucleus. 
 
     To confirm the dependence of nuclear translocation of FGF-BP on FGF-2, the subcellular 
localization of FGF-BP was examined in SW-13 cells, which already express high levels of 
endogenous FGF-2.  FGF-BP was concentrated in the nucleus of SW-13 cells and showed a 
similar nuclear localization to FGF-2.  
 
     The data presented in this thesis on the translocation of FGF-BP into the nucleus as well 
as the dependence of the cellular uptake of exogenous [125I]-labeled FGF-BP on FGF-2 
suggest the uptake of secreted or exogenously added FGF-BP into the cells and its 
dependence on the interaction with FGF-2. This was confirmed by confocal microscopy of 
COS-7 cells, which were transiently transfected with an FGF-2-YFP expression vector and 
incubated with recombinant FGF-BP. These data indicated the internalization of FGF-BP, 
Discussion                                                                          110  
which may follow and depend on the binding of FGF-BP to FGF-2, by a pathway that allows 
its uptake into the cytoplasm and subsequent translocation to the nucleus. While, the 
observation of the uptake and nuclear localization of FGF-BP and their dependence on FGF-
2 suggest that both processes can occur in a ligand-dependent manner, it is unknown if FGF-
BP was internalized as a complex with FGF-2 and/or with other molecules and translocated 
in the nucleus. Furthermore, in the case of endogenous coexpression of FGF-BP and FGF-2 it 
cannot be excluded that FGF-BP interacts with FGF-2 in the cytoplasm prior to its secretion, 
and that it is only then translocated into the nucleus.  
 
     The colocalization data of FGF-BP with ERGIC suggest that the secreted FGF-BP is 
transported in a direction passing from the endoplasmic reticulum to the Golgi apparatus and 
then to the cell surface. Recently, it is becoming clear that proteins can move in the opposite 
direction in a process termed retrograde transport, eventually ending up in the cytoplasm (for 
reviews, see [348,349]. Although this pathway is poorly understood, it provides a possibility 
for the translocation of secreted FGF-BP from endoplasmic reticulum into the cytosol, where 
the interaction with FGF-2 may take place and may result in the translocation of FGF-BP 
into the nucleus.  
 
     Probably, the majority of intracellular molecules that interact with endogenous 18 kDa 
FGF-2 is still unkown. Recently, Bossard et al. [350] showed that a cytoplasmic protein 
called Translokin interacts specifically with the 18 kDa FGF-2 and is involved in the 
intracellular trafficking of the internalized growth factor. In addition, using the radiation 
inactivation method Prats et al. [351] reported that FGF-2 is present in the nucleus in two 
complexes: HMW FGF-2 in a complex of 320 kDa and 18 kDa FGF-2 in a complex of 130 
kDa. In agreement with these results, it was also shown that the various isoforms of FGF-2 
exist as relatively large protein complexes with one or more protein species, which was 
confirmed by immunoprecipitation assay [352]. These results indicate that intracellular FGF-
2 may associate with other molecules. The observed nuclear translocation of FGF-BP upon 
coexpression with FGF-2 as well as the nuclear colocalization of both proteins suggest that 
FGF-BP is one of the molecules that interact with intracellular FGF-2 and may play a role in 
the intracellular trafficking pathways of FGF-2 and hence in the modulation of its biological 
activity.   
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      Data on the FGF-binding site of FGF-BP are still lacking. Using various C- and N-
terminally truncated FGF-BP mutants, the segment(s) of FGF-BP, which are responsible for 
the interaction with FGF-2 and the nuclear translocation, were explored. Confocal 
microscopy revealed that the nuclear colocalization and interaction of FGF-BP with FGF-2 is 
lost upon the N-terminal truncation of FGF-BP. These data demonstrated for the first time 
the importance of the N-terminal segment of FGF-BP in the interaction with FGF-2.  
 
     Anchorage-independent growth assay correlates strongly with tumorigenicity and 
invasiveness in several cell types, e.g. small-cell lung carcinoma [353]. For this reason soft 
agar assays were performed using SW-13 and COS-7 cells stably transfected with various 
FGF-BP constructs to analyze the biological significance of the interaction of full length and 
various truncated FGF-BP mutants with FGF-2. As expected, stimulating effects of full 
length FGF-BP on the colony formation of SW-13 cells were observed. The similar effects 
have been demonstrated in previous studies [88,93]. Furthermore, through the blocking of 
colony formation of FGF-BP-transfected SW-13 cells by a specific antibody against FGF-2 it 
was demonstrated that the tumorgenic potential of FGF-BP is FGF-2-dependent [88]. These 
previous studies provide indirect evidence that FGF-BP can stimulate tumor growth by 
releasing and activating endogenous FGF-2 from the extracellular matrix (ECM). Based on 
the confocal microscopy data regarding the nuclear localization of FGF-BP in SW-13 cells, 
an intracellular mechanism of the stimulating function of FGF-BP based on its interaction 
with nuclear FGF-2 cannot be excluded. This suggestion is supported by the loss of FGF-BP-
mediated colony formation of SW-13 cells upon stable transfection with N-terminal 
truncated FGF-BP constructs (BP-C-91 and BP-C-146), which in confocal microscopy did 
not show nuclear colocalization and interaction with FGF-2.  
 
      Previously, it was shown that the recombinant FGF-BP displays bioactivity in terms of 
induction of tumor cell proliferation. Upon exogenous addition of recombinant FGF-BP, a 
dose-dependent stimulation of colony formation of SW-13 cells in soft agar was seen [130]. 
Based on the fact that two different neutralizing anti-FGF-2 antibodies added to the cells in 
soft agar reversed the stimulating effect of FGF-BP it was suggested that the recombinant 
FGF-BP is highly unlikely internalized by the cells and the mechanism of FGF-BP action 
seems to be confined to the extracellular matrix. The data of nuclear localization of FGF-BP 
in SW-13 cells as well as the cellular uptake of [125I]-labeled FGF-BP in SW-13 (data not 
shown) or in COS-7 cells suggest another mechanism of FGF-BP-action relying on the 
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internalization of FGF-BP and subsequent cellular stimulation through intracellular 
mechanism(s) seems possible. Furthermore, the inhibition of stimulating effects of FGF-BP 
on colony formation of SW-13 cells in soft agar after exogenous addition of two different 
neutralizing anti-FGF-2 antibodies indicate that the internalization of FGF-BP seems to be 
dependent on the interaction with FGF-2 in the extracellular matrix.  
 
     To explore the biological functions of FGF-BP and various mutants, COS-7 cells were 
used as another model system in this thesis. Surprisingly, inhibitory rather than stimulating 
effects were shown in soft agar assays with COS-7 cells stably transfected with full length 
FGF-BP. In agreement with this, Chen et al. [133] showed that FGF-BP at high medium 
concentrations inhibits DNA synthesis and cell growth in mouse fibroblast 3T3 cells. Based 
on the previously described data on the role of FGF-BP-binding to FGF-1 and FGF-2 in 
inhibiting their biological activities, they suggested that the inhibitory effects are probably 
due to the formation of FGF-BP/FGF complexes leading to the reduction of free FGF-1 and 
FGF-2 concentrations hence leading to insufficient stimulation of DNA synthesis and cell 
growth in these cells. These data and the results of this thesis regarding the cytoplasmic 
localization of FGF-BP in COS-7 cells indicate that FGF-BP may play specific physiological 
roles in addition to its function as extracellular carrier protein. 
 
     The FGF-BP-mediated inhibition of the growth of COS-7 cells in soft agar was lost upon 
C- and N-terminal truncations of FGF-BP, indicating that the complete sequence of full 
length FGF-BP is required to exert its inhibitory function. Furthermore, it is noteworthy that 
the inhibitory effects were not seen by the transient transfection with an FGF-BP expression 
vector or by exogenous addition of FGF-BP on COS-7 wild-type cells in soft agar. This 
difference in the effects could be explained by the short time and level of FGF-BP expression 
in transient transfection or by decreased stability in case of exogenous addition of FGF-BP, 
which is probably not sufficient to inhibit the cell growth in soft agar as seen in the stable 
transfection with the FGF-BP expression vector. 
 
     To examine the consequences of the nuclear interaction of FGF-BP and FGF-2 on the cell 
proliferation of COS-7 cells, the expression of the FGFR1 receptor as well as the stimulating 
effects of FGF-2 in COS-7 wild type cells were analyzed. COS-7 cells are FGFR1 positive as 
determined by RT-PCR and PCR-Southern blotting and stimulation of cell proliferation of 
COS-7 cells by endogenously expressed or exogenously added FGF-2 in soft agar was also 
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demonstrated. Upon coexpression of FGF-BP, the stimulation of colony formation of COS-7 
cells induced by FGF-2 was inhibited. Similar effects were obtained upon exogenous 
addition of recombinant FGF-BP that can bind to FGF-2 as evidenced by Dot blotting. It is 
noteworthy that the necessary concentrations of exogenously added FGF-BP to reverse the 
stimulating effects of FGF-2 were comparably high (5 µg/ml). This can be explained by the 
several steps included in the process of uptake of FGF-BP after its interaction with secreted 
FGF-2: 1) diffusion of FGF-BP to FGF-2 immobilized in the extracellular matrix (ECM), 2) 
binding of FGF-BP with FGF-2 before/after the interaction of FGF-2 with its receptor, 3) 
internalization of FGF-BP alone or as a complex with FGF-2 and/or other molecules, 4) 
translocation into the nucleus. Another possibility is that the FGF-BP used in these 
experiments was purified under strongly denaturing conditions, which may lead to partially 
inactive preparations. 
 
     Studies in ovarian neoplasms reported that HER-2 oncogene is overexpressed in 
approximately 20-30% of ovarian carcinomas [188,189,354-356] and found that HER-2-gene 
amplification, as determined by Southern blotting, and HER-2 overexpression, as determined 
by immunohistochemistry (IHC) significantly correlated with clinical outcome. Recently, it 
has been shown that tumor cell lines established in vitro from ovarian carcinoma, as well as 
ovarian carcinoma cells harvested from ascites fluid, frequently express the HER-2 protein 
on their surface, suggesting that cells expressing this protein have a selective growth 
advantage over HER-2-negative cells [188,357,358].     
 
    Although treatment of ovarian cancer has improved over recent years with the 
introduction of taxane-based chemotherapy, it is still a difficult clinical situation, since the 
majority of patients will relapse and the disease in the majority of these patients remains 
incurable. Clearly, there is a need for alternative chemotherapeutics with higher tumor cell 
specificity and lower side effects which preferably display cytotoxicity through mechanisms 
different from current cytostatic drugs. While there are clinical and experimental data 
indicating a role of HER-2 overexpression in tumor cell sensitivity to chemotherapy, results 
are conflicting as to whether elevated HER-2 levels lead to increased resistance or higher 
sensitivity of tumors, especially in ovarian carcinomas and in ovarian carcinoma cell lines, 
where HER-2 overexpression has been found in considerable percentages. Interestingly, 
highly drug-specific HER-2 effects have been previously described. It was found that 
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paclitaxel cytotoxicity, but not of other chemotherapeutics like cisplatin, vinblastine or 
doxorubicin is dependent on HER-2 levels in SKOV-3 ovarian carcinoma cells [210]. 
 
     Human SKOV-3 ovarian cancer cells overexpress HER-2 and express HER-1 but only 
very low levels of HER-3 and HER-4 [359]. Thus, they were chosen in the context of this 
thesis to analyze the HER-2 effects on paclitaxel and rViscumin cytotoxicity aside from the 
complex signaling network of other HER receptors. For this purpose, different and 
independent strategies were thereby used, including treatment with the HER-2 inhibitory 
antibody trastuzumab (Herceptin), phosphotyrosine kinase inhibitors, and downregulation of 
HER-2 expression by ribozyme-targeting. Finally, the underlying effects of the observed 
correlation between ribozyme-mediated HER-2 downregulation and paclitaxel and 
rViscumin sensitivity on cellular and molecular levels were analyzed. 
 
     Interestingly, in previous studies, the treatment with a HER-2 inhibitory humanized 
antibody (Herceptin), leads to increased paclitaxel resistance in SKOV-3 ovarian carcinoma 
cells. These results are in agreement with report that described the differentially expressed 
genes associated with paclitaxel resistance using cDNA array technology [211] and with 
other earlier studies [210]. On the other hand, there are other studies demonstrating the 
opposite observations e.g. HER-2 overexpressing breast cancer cells are more resistant than 
other cells towards certain chemotherapeutic agents inluding paclitaxel ([360] for review) 
and show the contrary to the observation of E1A-medited paclitaxel sensitization in HER-2-
overexpressing SKOV-3.ip1 cells [209].  
 
     In the context of this thesis, two newly developed low molecular weight inhibitors of HER 
tyrosine kinase activity, D-69491 and D-70166, were used to confirm the previous results 
obtained by Herceptin treatment of SKOV-3 ovarian carcinoma cells. Previously, it was 
shown that D-69491 and D-70166 inhibit HER-2 phosphorylation almost completely or 
completely at concentrations above 10µM [243] by acting through intracellular inhibition of 
HER-2-mediated signal transduction as seen before in A431 epidermoid carcinoma cells for 
HER-1 [361]. In agreement with previous results based on Herceptin, D-69491 and D-70166 
reduced the proliferation of SKOV-3 cells >50% upon addition of 1 µM, although the 
mechanism of action being completely unrelated to Herceptin. In the experiments, where the 
effects of D-69491 and D-70166 on proliferation and paclitaxel sensitivity were examined, 
the concentration of serum in medium was reduced to 0 - 2 %, since the solubility of both 
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HER tyrosine kinase inhibitor seems to be somewhat lower in 10 % FCS containing medium 
(unpublished data). 
      
     Since a >50% reduction of anchorage-dependent cell proliferation was observed upon 
addition of 1µM D-69491 or D-70166, this concentration was chosen to study the effects of 
these HER tyrosine kinase inhibitors on paclitaxel sensitivity in SKOV-3 cells. By 
examination of paclitaxel sensitivity after treatment of SKOV-3 cells with D-69491 and D-
70166, the similar tendency of increased resistance of cells towards paclitaxel, as seen before 
by Herceptin treatment, was observed. It should be mentioned that although SKOV-3 cells 
mainly express HER-2 and only much lower (HER-1) or very low (HER-3, HER-4) levels of 
the other HER receptors [359], effects through inhibition of receptors different from HER-2 
cannot be completely ruled out [361].  
 
     To address in more detail the underlying effects of the inverse correlation between HER-2 
expression levels and paclitaxel resistance on molecular levels as well as to exclude the 
possibility of interferences resulting from the inhibition of different HER receptors by D-
69491 and D-70166 kinase inhibitors, stable isogenic SKOV-3 cell lines with ribozyme-
mediated reduction of HER-2 expression levels were used. Selection of different clones with 
various levels of residual HER-2 expression excluded clonal artifacts non-related to HER-2 
expression and allowed to establish a 'HER-2 gene dose effect' of paclitaxel sensitivity. 
Hence, by using three independent strategies to transiently or constitutively inhibit HER-2-
mediated signal transduction, the HER-2 dependence of paclitaxel cytotoxicity in SKOV-3 
cells was demonstrated.  
 
     It is notably that by comparison of the paclitaxel IC50 values, which resulted from 
different experiments in this thesis as well as in previous studies [362], IC50 values increase 
with lower serum concentrations (this point is discussed in detail below) or reduced time of 
cells being exposed to the drug. Nevertheless, the effect of increased resistance upon HER-2 
inhibition was observed under each condition independently of incubation times or serum 
concentrations.  
 
     Targeting of HER-2 expression levels or signal transduction by Herceptin was previously 
shown to decrease proliferation of SKOV-3 cells (see [243] for details). Similarly, HER-2 
ribozyme-targeting and tyrosine kinase inhibitors reduced the proliferation of SKOV-3 cells. 
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Treatment of SKOV-3 cells with Herceptin or tyrosine kinase inhibitors prior to the addition 
of paclitaxel as well as HER-2 downregulation by ribozyme-targeting render the cells more 
resistant to paclitaxel. These results indicate that reduced proliferation may be the underlying 
cellular effect that determines the increased paclitaxel resistance of SKOV-3 cells. This could 
merely be because cells take a longer time to reach mitosis, where the lethal event upon 
paclitaxel treatment occurs. The active paclitaxel might be metabolized in this time and 
therefore the slower growing cells may be subjected to a lower effective dose by the time 
they reach mitosis. The correlation between proliferation rate and sensitivity towards 
paclitaxel is further supported by the fact that serum-starving conditions attenuate paclitaxel-
induced cell death in this cell system as well. On the other hand, doxorubicin or cisplatin 
cytotoxicities are independent of HER-2 levels as shown here and previously [210] 
demonstrating that HER-2 targeting does not result in a general increase in resistance 
towards all drugs only due to reduced cell proliferation. Taken together, these data indicate 
that HER-2 has an effect on cell cycle progression and proliferation which determines the 
cytotoxicity of paclitaxel, but not of doxorubicin or cisplatin.  
 
     Extracellular signals are transduced into the cell by a complex network of signaling 
pathways. Specificity of the cellular response is determined by an equilibrium existing 
between distinct pathways which in turn is dependent on the duration and strength of a 
signal. Previous data have shown that paclitaxel can activate several MAPK pathways, 
associated with Erk1/2, p38, and SAPK/JNK kinases [262,363-366]. These pathways are 
implicated in different, often opposite, cellular effects such as proliferation, differentiation, 
stress response, and apoptosis. To further explore the consequences of HER-2 
downregulation on molecular levels, especially with regard to paclitaxel sensitivity in 
SKOV-3 ovarian carcinoma cells, the activation of members of the mitogen-activated protein 
kinase (MAPK) familiy was examined. In Western blot experiments, basal (i.e. without 
paclitaxel treatment) levels of active MAP kinases indicated a decreased p42/p44 
phosphorylation as well as increased levels of phosphorylated SAPK/JNK and p38 upon 
HER-2 depletion. This reduced p42/p44 activation is in agreement with the decreased 
proliferation rate, which was observed in ribozyme-transfected cells with reduced HER-2 
expression. The higher phosphorylation of SAPK/JNK, which is activated by a variety of 
(environmental) stress factors, in ribozyme-transfected cells may result from the impairment 
of the cells upon HER-2 depletion. This is also reflected by the increased basal apoptosis 
rate, as seen previously [243]. Interactions between the MAPK pathways seem to be cell 
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specific. Although the involvement of p38 and SAPK/JNK kinases in promoting cell death 
and Erk1/Erk2 in proliferation has been demonstrated in many cell types, in some cells the 
opposite picture has been reported. For instance, in B lymphocytes p38 is required for 
proliferation and not for apoptosis [367], while in leukemic cells Erk1/Erk2 kinases rather 
than p38 have been reported to potentiate apoptosis [368].  
 
     In contrast to previous data of paclitaxel-mediated activation of members of MAPK 
family, which seems to be cell specific, no significant activation/deactivation of these kinases 
was observed in SKOV-3 cells upon paclitaxel treatment and the differences in basal levels 
cannot fully explain the HER-2 dependence of SKOV-3 paclitaxel sensitivity. 
 
     Both caspase-3 and caspase-7, which represent effector caspases of two main pathways of 
induction of apoptosis, are known to be activated in paclitaxel-induced apoptosis [369,370]; 
therefore, the relationship between caspase activities and HER-2 expression levels as well as 
paclitaxel-induced apoptosis in different SKOV-3 cells were examined in the context of this 
thesis. Caspases-3 and caspase-7 independently of HER-2 levels were not activated in 
SKOV-3 cells upon paclitaxel treatment, indicating that paclitaxel may utilize a caspase-
independent pathway of induction of apoptosis in SKOV-3 ovarian carcinoma cells. 
Conflicting data have been published as to whether paclitaxel induces caspase-3 in SKOV-3 
cells [209,371]. The discrepancy between the data of caspase-3 activation in this thesis as 
well as previous data [371] on the one hand and the earlier observation [209] on the other 
hand could be explained by the use of the HER-2-overexpressing subtype SKOV-3.ip1 in the 
latter study rather than the wildtype cells or by approach of repressing the HER-2 promoter 
via the adenovirus type 5 E1A gene. Indeed, IC50 values of paclitaxel estimated from Uneo et 
al. [209] are ~4 – 5 fold higher as compared to the data in this thesis and, since other studies 
in different cell lines have shown E1A-mediated enhanced sensitivity to other cytostatic 
agents being independent of HER-2 expression levels [372,373], it is possible that E1A-
mediated paclitaxel sensitization relies on a mechanism unrelated to HER-2. 
  
      Interaction among p53, the cyclin-dependent kinase inhibitors p21 and p16, and pRb has 
been shown to be crucial in cell cycle progression and apoptosis. p21Cip1 encodes a 21 kDa 
protein and was discovered as a Cdk inhibitor [374] as well as a wild type p53-inducable 
gene [375]. In breast cancer cells overexpression of HER-2 upregulates p21Cip1 leading to 
inhibition of paclitaxel-mediated activation of p34cdc2 and of subsequent apoptosis [197]. 
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SKOV-3 cells, however, do not express widtype p53 protein [362]. Therefore, p21Cip1 was 
not studied. 
 
     Furthermore, bcl-2, which blocks or delays apoptosis in many cell systems and exerts its 
antiapoptotic effect mainly through stabilization of mitochondrial membranes was studied. 
Previously, in different cancer types paclitaxel was shown to either diminish bcl-2 
transcription or to modify bcl-2 via phosphorylation [376,377], hereby inactivating bcl-2 and 
inducing apoptosis ([264] for review). In Western blotting experiments, paclitaxel time-
dependently induced the phosphorylation of the antiapoptotic protein bcl-2, which likely 
reflects the inactivation of bcl-2 and the onset of apoptosis. However, bcl-2 phosphorylation 
and hyperphosphorylation in SKOV-3 cells was independent of HER-2 expression levels. 
 
     The molecular network for the evolving paclitaxel resistance in SKOV-3 ovarian cancer 
cells seems to be complex as recently suggested in the same cell line [378]. In summary, a 
HER-2 dose dependence of SKOV-3 paclitaxel resistance was established in this thesis and 
cell proliferation was identified as an underlying cellular event.  
 
     rViscumin is a recombinantly expressed mistletoe lectin heterodimer which shows a 
completely different mechanism of action as compared to other cytotoxic compounds. To 
analyze the role of HER-2 expression in cellular chemoresistance towards this novel anti-
cancer drug, a strategy similar to paclitaxel was employed.   
 
     Initially, by ribozyme-targeting, a dramatic alteration of sensitivity to rViscumin in the 
HER-2-depleted cells was found. Moreover, by comparing cell lines with different residual 
HER-2 levels, a direct correlation between HER-2 levels and cellular sensitivity towards 
rViscumin in SKOV-3 cells was established. These results are in agreement with previous 
results based on Herceptin [313]. Interestingly, these findings are comparable to data on the 
sensitivity of SKOV-3 cells towards paclitaxel, although both drugs display cytotoxicity 
through completely different mechanisms (rViscumin: inhibition of translation; Paclitaxel: 
cell cycle arrest). 
 
     It has been described that the interaction of the rViscumin B-chain with ‘viscumin 
receptor’ gangliosides of the neolacto series on the surface of tumor cells is responsible for 
cellular rViscumin uptake in the cells, which is necessary for rViscumin to exert its effects 
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[288]. Using [125I]-labeled rViscumin, it was demonstrated that rViscumin uptake is 
independent of cellular HER-2 expression levels. Moreover, a linear rViscumin uptake over a 
time range of at least 60 min in all clonal derivative cells of SKOV-3, which was 
comparable, was observed. These data firmly rule out that HER-2 ribozyme-mediated 
alterations in rViscumin binding and/or uptake are responsible for the observed HER-2 
dependence of rViscumin cytotoxicity in SKOV-3 cells and clearly points towards 
intracellular mechanisms. 
  
     To explore the effects of rViscumin on molecular levels und their dependence on HER-2 
expression levels, MAPK-dependent signal transduction pathways were investigated. In this 
thesis, it was shown for the first time that rViscumin activates members of the MAPK family 
and that this activation follows a complex pattern which is dependent on cellular HER-2 
expression levels and on the rViscumin concentration. As seen before, without rViscumin 
treatment, the observed differences between wildtype and HER-2-ribozyme-transfected cells 
may be due to impaired activation by growth factors (p42/p44) and increased stress response 
(SAPK/JNK, p38) upon HER-2 depletion. Upon rViscumin treatment, however, the precise 
roles of the activated kinases remain somewhat obscure. It seems likely that activation of 
different MAP kinases by rViscumin treatment may be an attempt of the cells to maintain 
cellular homeostasis prior to and/or independent of apoptosis as hypothesized earlier for 
paclitaxel-treated cells [379]. 
 
     In further experiments, the changes in bcl-2 were studied. Bcl-2 was time-dependently 
downregulated in SKOV-3 wildtype cells upon rViscumin treatment. Interestingly, in HER-2 
depleted cells bcl-2 levels remained significantly higher after rViscumin treatment as 
compared to the wildtype cells, which may account for the low rViscumin sensitivity in 
ribozyme-transfected cells compared to wildtype cells.  
 
     Finally, to further study the molecular basis of rViscumin-mediated induction of apoptosis 
in SKOV-3 cells, procaspases-3 and -7 and their changes upon rViscumin treatment were 
analyzed. While basal procaspase-7 expression was ~2-fold higher in SKOV-3 cells upon 
HER-2 depletion, no activation of caspases-3 or -7 was observed after rViscumin treatment. 
In contrast, activation of caspases-3, -8, and -9 after treatment with different mistletoe lectins 
has been described in leukemic cell lines [380,381]. These earlier studies were mostly done 
in blood cells and employed various natural mistletoe preparations rather than the pure 
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recombinant protein, which could explain the lack in caspase activation upon rViscumin 
treatment. However, Hostanska et al. [287] have shown in a mouse tumor cell system that the 
rViscumin-mediated induction of apoptosis is independent of p53 and leads to caspase-3 
activation [287]. Regarding the role of p53, SKOV-3 cells do not express wildtype p53, 
however, no caspase-3 activation was observed in these cells. Also, the results in this thesis 
indicate that in SKOV-3 cells rViscumin-mediated induction of apoptosis is independent of 
the activation of caspases-3, -7, as well as caspases-8, -9, or -10.  
 
       In conclusion, the inverse correlation between HER-2 expression and rViscumin-
mediated bcl-2 downregulation may well account for the HER-2 dependence of cellular 
rViscumin sensitivity and determination of HER-2 expression levels in tumor cells as well as 
the further clarification of the mechanistic details of rViscumin-induced activation of 
downstream signalling pathways which may involve known or yet unknown modulators of 
MAPKs may open new avenues to better predict the efficacy of the new chemotherapeutic 
rViscumin. 
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6 SUMMARY 
 
      Ovarian cancer is one of the most widespread and lethal gynecological malignancies with 
so far limited treatment options. A better understanding of the genetic changes in ovarian 
pathogenesis is of critical importance. In this thesis, two gene products were studied: the 
fibroblast growth factor-binding protein (FGF-BP) and the human epidermal growth factor 
receptor-2 (HER-2).  
 
      FGF-BP is a heparin-binding protein which interacts with FGFs releasing them from the 
extracellular matrix and hence playing a significant role in extracellular FGF bioactivation. 
In this work, the immunohistochemical analysis of tissue microarrays (TMAs) revealed for 
the first time FGF-BP overexpression in 40% of invasive ovarian carcinomas. Since none of 
the normal ovarian tissues showed similar FGF-BP immunopositivity, these data suggest that 
FGF-BP overexpression may represent an acquired malignant phenotypic feature of ovarian 
carcinoma.  
 
     To further explore the molecular mechanism of FGF-BP action, confocal microscopy was 
employed. Dependent on the cell line, FGF-BP was either localized in the cytoplasm and 
released through a classic secretion pathway employing ERGIC or, despite a classical signal 
peptide, showed a nuclear localization. Interestingly, upon coexpression with nuclear FGF-2, 
cytoplasmic FGF-BP was translocated and colocalized with FGF-2 in the nucleus. 
Additionally, the dependence of the cellular uptake of exogenous FGF-BP on the expression 
of and interaction with FGF-2 was demonstrated. Various truncated FGF-BP mutant 
constructs showed that extensive truncations at the C-terminal end of FGF-BP had no effect 
on the subcellular localization and FGF-2 interaction, while upon N-terminal truncations 
nuclear colocalization and interaction of FGF-BP with FGF-2 was lost. Proliferation assays 
provided evidence that biological effects of FGF-BP depend on the cell line. While in SW-13 
adrenal carcinoma cells the stable transfection of FGF-BP induced cell proliferation, 
inhibitory activity of FGF-BP in COS-7 cells was demonstrated. Moreover, FGF-BP-
mediated stimulation of colony formation in soft agar was lost upon N-terminal truncations 
of FGF-BP in SW-13 cells, whereas C- or N-terminal truncations abolished the inhibitory 
effect of FGF-BP on COS-7 cell proliferation. The induction of cell proliferation resulting 
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from the expression of FGF-2 in COS-7 cells, which also express FGF receptors, was lost 
upon endogenous expression or exogenous addition of FGF-BP. 
 
      Hence, in addition to its already published extracellular role, FGF-BP exerts intracellular, 
nuclear functions. More specifically, dependent on the cell line FGF-BP displays inhibitory 
or stimulating activities upon interaction with FGF-2 in the nucleus.  
 
      HER-2 belongs to the epidermal growth factor (EGF) receptor family and plays an 
important role in human tumors. However, clinical and experimental data indicating effects 
of HER-2 overexpression on tumor cell sensitivity towards chemotherapy are conflicting as 
to whether elevated HER-2 levels lead to increased resistance or higher sensitivity of tumors. 
This is particularly true for ovarian carcinomas and ovarian carcinoma cell lines, where 
HER-2 overexpression has been found in considerable percentages. In this work, the role of 
HER-2 expression and signaling levels pertaining to paclitaxel and rViscumin 
chemoresistance were explored. 
 
     Treatment of SKOV-3 cells with two newly developed low molecular weight inhibitors of 
HER-2 tyrosine kinase activity resulted in a decrease in the cellular paclitaxel sensitivity. 
These data confirmed previous data regarding treatment with the HER-2 inhibitory antibody 
trastuzumab (Herceptin), which is well established in tumor therapy. Using various isogenic 
SKOV-3 cell lines with ribozyme-mediated stable reduction of HER-2 expression levels, a 
‘HER-2 gene dose effect’ of paclitaxel cytotoxicity was established, while doxorubicin and 
cisplatin cytotoxicity remained unchanged. To elucidate the underlying mechanisms of this 
effect, paclitaxel- or HER-2-mediated alterations in phosphorylation of MAP kinase p42/44, 
stress-activated protein kinase/Jun-terminal kinase (SAPK/JNK), and p38, and effects on the 
activation of caspase-3, caspase-7, and bcl-2 were analyzed. Activation of MAP kinases was 
dependent on HER-2 expression levels but did not change upon paclitaxel treatment. 
Paclitaxel-induced bcl-2 phosphorylation and hyperphosphorylation was independent of 
HER-2 expression levels. Finally, it was shown that paclitaxel utilizes a caspase-independent 
pathway of induction of apoptosis in SKOV-3 ovarian carcinoma cells. 
 
     The selective depletion of HER-2 by ribozyme-targeting also decreased the cellular 
sensitivity of SKOV-3 cells towards the recombinant cytostatic mistletoe rViscumin, 
establishing a ‘HER-2 gene dose’ dependence of rViscumin cytotoxicity, which is not 
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mediated by altered cellular rViscumin binding/internalization. The analysis of the 
underlying molecular effects of rViscumin treatment demonstrated that members of the 
MAPK family, p42/44, SAPK/JNK, and p38 are activated in a HER-2 and rViscumin 
concentration-dependent manner. While no rViscumin-mediated activation of caspase-3 and 
caspase-7 were observed, HER-2-dependent downregulation of the anti-apoptotic molecule 
bcl-2 was demonstrated. 
 
      In conclusion, by focusing on two cancer-relevant genes, this work establishes FGF-BP 
as a new potential target molecule in ovarian cancer therapy and explores its intracellular 
mechanism of action. Furthermore, this thesis provides new insights into the role of HER-2 
in ovarian cancer sensitivity towards cytostatic drugs like paclitaxel or rViscumin which may 
allow to better assess the efficacy of both drugs in a clinical setting. 




      Ovarialkarzinome gehören zu den weitverbreitetsten und lebensgefährlichsten 
gynäkologischen Tumoren mit bislang begrenzten Behandlungsmöglichkeiten. Ein besseres 
Verständnis der genetischen Änderungen in der Pathogenese des Ovarialkarzinoms ist von 
entscheidender Bedeutung. Im Rahmen dieser Doktorarbeit wurden  zwei Genprodukte 
analysiert: das Fibroblasten-Wachstumsfaktor-bindende Protein (FGF-BP) und der 
epidermale Wachstumsfaktor-Rezeptor-2 (HER-2). 
 
      FGF-BP ist ein Heparin-bindendes Protein, das mit FGFs wechselwirkt, sie von der 
extrazellulären Matrix freisetzt und folglich eine bedeutende Rolle in der extrazellulären 
FGF-Bioaktivität spielt. In dieser Doktorarbeit wurde mittels immunhistochemischer 
Untersuchungen an Tissue Microarrays (TMAs) erstmals gezeigt, dass FGF-BP in 40% aller 
Ovarialkarzinome überexprimiert ist. Da keines der normalen Ovarialgewebe eine 
vergleichbar starke immunhistochemische Färbung zeigte, deuten diese Daten an, dass die 
Überexpression von FGF-BP eine bösartige phänotypische Eigenschaft des Ovarialkarzinoms 
darstellen kann. 
 
     Um die molekularen Mechanismen der FGF-BP-Wirkung weiter zu untersuchen, wurde 
konfokale Mikroskopie eingesetzt. Abhängig von der Zellinie war FGF-BP entweder im 
Zytoplasma lokalisiert und wurde durch einen klassischen Sekretionsweg über ERGIC 
sekretiert, oder es wurde, trotz eines klassischen Signalpeptides, eine nukleäre Lokalisation 
gefunden. Bei der Koexpression mit nukleärem FGF-2 wurde interessanterweise das 
zytoplasmatische FGF-BP in den Zellkern transloziert und eine nukleäre Kolokalisation von 
FGF-BP und FGF-2 beobachtet. Zusätzlich wurde die Abhängigkeit der zellulären Aufnahme 
von exogenem FGF-BP von der Expression und Interaktion mit FGF-2 demonstriert. 
Verschiedene Verkürzungsmutanten des FGF-BP zeigten, dass Verkürzungen am C-
terminalen Ende keinen Effekt auf die subzelluläre Lokalisation und FGF-2-Wechselwirkung 
haben, während bei N-terminalen Verkürzungsmutanten die nukleäre Kolokalisation und 
Interaktion des FGF-BP mit FGF-2 nicht mehr auftrat. In Proliferationsassays wurde 
beobachtet, dass die biologischen Effekte von FGF-BP von der jeweiligen Zellinie abhängen. 
Während in SW-13-Nebennierenkarzinom-Zellen die konstitutive Expression des FGF-BP 
Zellproliferation induzierte, wurde in COS-7 Zellen ein Proliferations-hemmender Effekt 
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demonstriert. Außerdem unterblieb in Soft Agar-Assays bei N-terminalen 
Verkürzungsmutanten in SW-13-Zellen die FGF-BP-vermittelte Stimulation der 
Kolonienbildung, während bei C- und N-terminalen Verkürzungsmutanten in COS-7-Zellen 
der hemmende Effekt des FGF-BP auf die Zellproliferation aufgehoben wurde. Die durch 
FGF-2 vermittelte Induktion des Zellwachstums in den FGF-Rezeptor-positiven COS-7-
Zellen wurde durch endogene Expression oder exogene Zugabe des FGF-BP inhibiert. 
 
      Zusätzlich zu seiner bereits beschriebenen extrazellulären Rolle entfaltet FGF-BP somit 
auch intrazelluläre, nukleäre Funktionen. Insbesondere zeigt FGF-BP, abhängig von der 
jeweiligen Zellinie, hemmende oder stimulierende Aktivitäten, die offensichtlich auf der 
Wechselwirkung mit FGF-2 im Zellkern beruhen. 
 
     HER-2 gehört zur Familie der epidermalen Wachstumsfaktor-Rezeptoren und spielt eine 
wichtige Rolle in menschlichen Tumoren. Die klinischen und experimentellen Daten 
bezüglich der Effekte der HER-2-Überexpression auf die zelluläre Sensitivität von Tumoren 
gegenüber Chemotherapie sind jedoch widersprüchlich, insbesondere, ob eine erhöhte HER-
2-Expression zu einer höheren Resistenz oder einer erhöhten Sensitivität von Tumoren führt. 
Dies gilt besonders für Ovarialkarzinome und Ovarialkarzinom-Zellinien, in denen HER-2-
Überexpression zu einem hohen Prozentsatz gefunden wird. Im Rahmen dieser Arbeit wurde 
die Rolle der HER-2-Expression und HER-2-vermittelten Signaltransduktion in der 
zellulären Resistenz gegenüber Paclitaxel und rViscumin untersucht. 
 
     Die Behandlung von SKOV-3-Zellen mit zwei neu entwickelten niedermolekularen HER-
2-Tyrosinkinase-Inhibitoren führte zu erhöhter zellulärer Resistenz gegenüber Paclitaxel. 
Diese Daten bestätigten vorherige Ergebnisse bezüglich der Behandlung mit Anti-HER-2 
Antikörpern (Herceptin), die in der Tumortherapie etabliert sind. Anhand verschiedener 
SKOV-3-Zellinien mit ribozymbedingt verminderter HER-2-Expression wurde ein „HER-2-
Gen-Dosis-Effekt“ etabliert, während Doxorubicin- und Cisplatin-Zytotoxitäten unverändert 
blieben. Zur näheren molekularen Charakterisierung der zugrundeliegenden Mechanismen 
dieses Effektes wurden Paclitaxel- oder HER-2-vermittelte Veränderungen in der 
Phosphorylierung der MAP-Kinasen p42/p44, der stress-activated protein kinase/Jun-
terminal kinase SAPK/JNK und der p38 MAP-Kinase, sowie des Effekts auf die Aktivierung 
von Caspase-3 und Caspase-7 und bcl-2 analysiert. Die Aktivierung der MAP-Kinasen war 
abhängig von der HER-2-Expressions, aber änderte sich nicht unter Paclitaxel-Behandlung. 
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Eine beobachtete Paclitaxel-induzierte bcl-2-Phosphorylierung und -Hyperphosphorylierung 
war HER-2-unabhängig. Schließlich wurde gezeigt, dass Paclitaxel in SKOV-3 Zellen über 
einen Caspase-unabhängigen Weg Apoptose induziert.  
 
     Die selektive HER-2-Reduktion durch Ribozyme-Targeting führte in SKOV-3-Zellen 
auch zur Verminderung der Sensitivität gegenüber dem rekombinanten zytostatischen 
Mistellektin rViscumin. Wiederum wurde eine „HER-2-Gen-Dosis“-abhängige Sensitivität 
der Zellen gegenüber rViscumin beobachtet, die nicht durch eine geänderte zelluläre 
rViscumin-Bindung oder -Internalisierung vermittelt wird. Die Analyse der 
zugrundeliegenden molekularen Effekte zeigte, dass die Mitglieder der MAPK-Familie 
p42/p44, SAPK/JNK und p38 in HER-2- und rViscumin-konzentrationsabhängiger Weise 
aktiviert werden. Während keine rViscumin-vermittelte Aktivierung der Caspasen-3 und -7 
beobachtet wurde, zeigte sich eine HER-2-abhängige Herunterregulation des 
antiapoptotischen Moleküls bcl-2. 
 
     Zusammenfassend konzentriert sich diese Arbeit auf zwei Krebs-relevante Gene. FGF-BP 
wird als neues mögliches Zielmolekül in Ovarialkarzinom-Therapie etabliert und bezüglich 
seiner intrazellulären Wirkmechanismen analysiert. Die hier vorgestellten Untersuchungen 
zeigen ferner neue Daten zur Rolle der HER-2-Expression bezüglich der Sensitivität von 
Ovarialkarzinomen gegenüber Zytostatika wie Paclitaxel oder rViscumin, was für die 
Bewertung der Wirksamkeit dieser Chemotherapeutika in der klinischen Verwendung 
relevant sein könnte.  
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8 ABBREVIATIONS 
 
aFGF (FGF-1) acidic fibroblast growth factor  
APS ammonium peroxodisulfate 
bFGF (FGF-2) basic fibroblast growth factor 
BSA bovine serum albumin 
cDNA complementary DNA  
CFP cyan fluorescent protein 
cpm counts per minute 
DAB diaminobenzidine tetrahydochloride 
ddH2O bidestilled H2o 
DEPC diethylpyrocarbonate 
DMBA dimethyl benz (a) anthracene 
DMSO dimethyl sulfoxide 
ECL enhanced chemiluminescence 
ECM extracellular matrix 
EDTA ethylenediamine tetraacetic acid 
EGF epidermal growth factor 
ELISA enzyme-linked immunosorbent assay 
ERGIC enoplasmic reticulum-Golgi intermediate compartment 
Erk extracellular signal-regulated kinase  
FBS fetal bovine serum 
FGF-BP fibroblast growth factor-bindingprotein 
FGFRs fibroblast growth factor receptors 
FGFs fibroblast growth factors 
HER human epidermal growth factor receptor 
HER-2 human epidermal growth factor receptor-2 
HLGAGs heparan-like glycosaminoglycans 
HMW high molecular weight 
HSPGs heparan sulphate proteoglycans 
IC50 inhibitory concentration 50% 
IHC immunohistochemistry 
IMDM Iscove’s Modified Eagle’s Medium 
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kb kilo base 
kDa kilo dalton 
LB Luria-Bertani 
MAPK mitogen-activated protein kinase 
ML I mistletoe lectin I 
Ni-NTA nickel-nitrilotriacetic acid 
NLS nuclear localizing sequence 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PKC protein kinase C 
PTB phosphotyrosine binding domain 
PTK protein tyrosine kinases 
RIPs ribosome-inactivating proteins 
RT-PCR reverse transcription-polymerase chain reaction 
SAP Shrimp alkaline phosphatase 
SCC squamous cell carcinoma 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SSC sodium chloride-sodium citrate 
TAE tris-acetate-EDTA 
TBST tris-buffered saline tween 
TEMED tetramethylethylendiamine 
TKIs tyrosine kinase inhibitors 
TMA tissue microarrays 
TPA 12-O-tetradecanoylphorbol-13-acetate 
tRA all-trans retinoic acid 
Tris-HCl tris(hydroxymethyl)aminomethane hydrochloride 
U  unit 
UV  ultraviolet 
VEGF vascular endothelial growth factor 
YFP yellow fluorescent protein 
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